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Glycoengineering is a technology that could improve protein therapeutics. While protein 
glycosylation in general enhances solubility and stability, and reduces aggregation, 
immunogenicity and proteolysis, specific kinds of glycosylation may also be critical. For 
example, capping of glycans with N-acetylneuraminic acid (Neu5Ac) maximises circulatory 
half-life in humans. Moreover, some glycans directly participate in molecular recognition and 
other aspects of glycoprotein function. 
Glycoproteins produced by non-human mammalian cells carry glycans capped by N-glycolyl-
neuraminic acid rather than Neu5Ac. Yet production in human cell lines is costly and slow, 
requires specialist facilities, produces low yields and is subject to additional regulations. 
Hence there is a case for glycoengineering alternative expression systems capable of rapid, 
low-cost, high-yield glycoprotein production. This report focuses on the glycoengineering of 
Pichia pastoris, a yeast, to produce recombinant human glycoprotein factor H (FH) bearing 
human-like glycans. 
FH is a potent down-regulator of the complement system.  Mutations and SNPs in FH result 
in autoimmune diseases such as atypical haemolytic ureamic syndrome and age-related 
macular degeneration (AMD). Recombinant FH is an enticing therapeutic candidate for 
treating AMD, but high doses are required since FH is abundant (200-300 mg l-1) in normal 
human serum. Human FH (155 kDa), with eight sites of N-linked glycosylation and 40 
disulphides, is a challenging target for recombinant production. Yet FH was previously 
expressed to 10s of milligrams in P. pastoris. 
In this study, methods were established to confirm that human plasma-derived (h)FH carries 
predominantly N-linked diantennary disialylated complex-type glycans, with monosialylated 
diantennary structures and triantennary structures in fucosylated and non-fucosylated 
forms, contributing to glycan heterogeneity. Functional comparison of native hFH, 
enzymatically desialylated (DeSia-) hFH and deglycosylated recombinant P. pastoris-
produced (DeGly-r)FH showed that DeSia-hFH had the lowest affinity for complement 
protein C3b, its key target. Moreover, DeSia-hFH binds C3d, an opsonic C3b-breakdown 
product, whereas native hFH does not. DeSia-hFH had an improved ability to accelerate 
decay of the C3 convertase (an enzyme that cleaves C3 to C3b) compared to native hFH, but 
neither was as good as DeGly-rFH in this respect. In contrast, DeGly-rFH had reduced cofactor 
activity (for factor I-mediated degradation of C3b) compared to native hFH whereas DeSia-
hFH did not have reduced cofactor activity. These data suggest that sialylation of FH glycans 
may play a role in stabilising a conformation of circulating FH that is not fully effective, 
consistent with specificity for self-surfaces and resistance to bacterial hijack. 
Aiming eventually to produce human-like glycosylated FH in glycoengineered P. pastoris, the 
SuperMan 5 strain served as a starting point. While conventional strains of P. pastoris put 
hypermannosylated N-linked glycans on proteins, glycans on SuperMan 5-produced FH were 
shown to contain just five mannose (Man) residues. In further glycoengineering, and 
following unsuccessful efforts to use inABLE technology for this purpose, commercially 
available (GlycoSwitch) vectors were used to introduce genes encoding the 
glycosyltransferase enzymes N-acetylglucosamine (GlcNAc) transferase I (GnTI) and 
galactose (Gal) transferase. These catalysed the formation of a hybrid-type glycan containing 
an N-acetyllactosamine (Gal-β(1,4)-GlcNAc (LacNAc)) antennae on a five-mannose glycan. 
Then two more GlycoSwitch plasmids, containing genes encoding α-Mannosidase II (ManII) 
and GnTII, were introduced into P. pastoris to catalyse the formation of a second LacNAc 
antennae. MALDI-TOF analysis found the glycosylation of this strain to be heterogeneous, 
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containing the humanised diantennary digalactosyl glycan as well as other endogenous yeast 
glycans. This strain was designated SuperGal. Large-scale expression of rFH with terminally 
galactosylated complex-type glycans (Gal-rFH) in SuperGal yielded 100s of milligrams of 
purified Gal-rFH. Yeast-type glycans were enzymatically removed from rFH and the 
remaining complex-type humanised glycans were sialylated with a recombinant bacterial 
α(2,6)-sialyltransferase from Photobacterium sp. expressed in E.coli. 
Purified sialylated (Sia-) and non-sialylated (Gal-) rFH expressed in SuperGal were 
functionally characterised in vitro using SPR-based assays. In C3b-binding assays Sia-rFH had 
lower affinity compared to Gal-rFH. Both bound with lower affinity than DeGly-rFH. A similar 
pattern of binding affinity was seen for C3d. In C3 convertase decay-acceleration assays, all 
rFH glycoforms performed equally well and had greater activity than hFH. Conversely, Sia- 
and Gal-rFH were shown to perform equally as well as hFH in CA assays, while all three 
versions outperformed DeGly-rFH. However, in vivo complement activity assay carried out in 
a FH-knockout mouse model showed that humanisation of the glycosylation of rFH did not 
significantly improve activity compared to DeGly-rFH. In addition, analysis of the circulatory 
half-life of rFH showed that humanisation did not improve half-life.  
Further engineering steps will be required to increase the complex-type glycan site 
occupancy on rFH with a view to improving circulatory half-life and efficacy. However, this 
study represents a significant step forward in developing a therapeutically useful source of 
































Genes encode proteins and proteins carry out the intra- and extracellular functions for life. 
Some proteins, especially those that occupy the extracellular environment (e.g. in the 
blood), are decorated with sugar chains called glycans. Glycans confer several advantages 
to proteins in the extracellular environment including protection and signal recognition – 
e.g. signalling to the immune system that the glycosylated protein is safe. 
An immune pathway regulatory protein called factor H (FH) protects self-surfaces from 
auto-immune attack. However, mutations in the gene which encodes FH can lead to 
autoimmune disease which could result in blindness and kidney defects. A potential 
therapy for patients with a deficiency in FH is providing them with a source of functional 
FH. 
 
Using genetic engineering it is possible to produce high quantities of human proteins in 
micro-organisms such as yeasts. The main disadvantage to using yeast to produce human 
proteins with glycans is that yeast attach the wrong kind of glycan to proteins. The glycans 
on yeast derived human FH would signal to the human immune system that the protein is 
not safe, resulting in the proteins destruction. 
 
This study first focused on characterising the glycans on human FH purified from human 
blood to answer the questions what do the glycans look like and what role do they have in 
the function of human FH? Then, this study focused on changing the glycosylation pathway 
of yeast to humanise the glycans attached to FH. Finally, the function of yeast produced FH 
with human glycans was characterised in binding studies and in FH deficient mice to 
answer the question: Does yeast produced FH with human glycans function the same as 
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Figure G.1: Structures of the most prevalent glycans in this study. Graphic structures (non-reducing terminus top, reducing 
terminus bottom) and short hand notation (written non-reducing terminus left to reducing terminus right) are represented.   
Figure G2: Figure of the different glycoforms of factor H (FH) produced in this study. Graphic representation of A) human 
(h)FH before and after (DeSia-hFH) enzymatic desialylation with α(2-3,6,8)-neuraminidase. B) recombinant (r)FH expressed in 
commercially available glycoengineered Pichia pastoris strain SuperMan 5 before and after (DeGly-rFH) enzymatic 
deglycosylation with endoglycosidase (Endo) Hf. C) rFH expressed in P. pastoris strain SuperGal, glycoengineered to produce 
humanised diantennary galactose terminal glycans, before and after (Gal-rFH) enzymatic deglycosylation with Endo Hf. Endo 






















































Figure G3: Figure of the P. pastoris expression shuttle vector plasmids used in this study. A) Commercially available 
GlycoSwitch plasmids which, when used to transform P. pastoris strain SuperMan 5, encode enzymes for the biosynthesis 
of humanised diantennary complex-type galactose terminal glycans in P. pastoris. B) P. pastoris expression shuttle vector 
plasmid generated in this study using the proprietary inABLE DNA assembly technique. This plasmid (pPpGalHy) contains 
multiple genes on one plasmid that encode enzymes for the biosynthesis of an intermediate hybrid-type galactose 



















































Figure G4: Figure of the commercially available P. pastoris expression shuttle vector plasmids pPICZα. In a previous study, 
Dr. Heather Kerr cloned the human CFH gene sequence into the multiple cloning site (MCS) and subsequently 
transformed the expression plasmid into P. pastoris strain SuperMan 5. This FH expressing SuperMan 5 strain was 
subsequently used in this study to modify the glycosylation pathway. 
Figure G5: Figure of the commercially available pET24 E. coli expression plasmid modified, in this study, by cloning a 
bacterial Photobacterium sp. α(2,6)-sialyltransferase gene sequence (tPH-6STco) in frame with a His6-tag DNA sequence. 
The plasmid was transformed into E. coli expression strain BL2, the encoded enzyme PH-6ST was expression and purified 



























1.1 N-linked Glycosylation 
 
Glycans are short, usually branched, chains of monosaccharides covalently conjugated to 
each other by glycosidic linkages. One terminus of a glycan is called the reducing end; this is 
the part of the glycan conjugated to either protein or lipid. The reducing end is so named 
because, when liberated from the protein or lipid conjugate, the terminal monosaccharide 
is a hemiacetal and thus can be reduced (by, for example, Tollen’s reagent). At the other 
terminus of the glycan is the non-reducing end, so called because the oxygen attached to 
C1 (C2 in the case of sialic acid) (fig. 1.1) forms part of the glycosidic linkage with the 





















Figure 1.1: A) Linear Fischer projection and B) Haworth projection of galactose. Carbons are labelled from the first 
carbon in the backbone starting nearest the carbonyl carbon. In B) α- and β-anomers are identified from the position 
of the anomeric centre (C1) relative to the anomeric reference atom (C5) – for example, in α-galactose the C1 
hydroxyl group is trans relative to the C5 carbon CH2OH group. Conversely, in β-galactose the C1 OH is cis to the C5 
CH2OH group. C) Haworth projection of the disaccharide β(1,4)-N-acetyllactosamine. The convention is to write from 
left to right the non-reducing terminus to the reducing terminus, so called because the reducing terminus has a 
hemiacetal group that can be reduced. The glycosidic linkage is β(1,4) because it forms between the C1 carbon of 





The convention for writing glycans is from non-reducing end to reducing end, the 
equivalent of 5’ to 3’ for nucleic acids, or N-terminus to C-terminus for polypeptides. In 
addition, each carbon in the monosaccharide ring structure is numbered. For example, in a 
linear Fischer projection of galactose (fig. 1.1 A) the carbonyl group is placed at the top of 
the chain and C1 is the first carbon at the top of the chain. 
The anomericity of a monosaccharide and the carbon number are key factors for assigning 
glycosidic linkages. The convention for writing glycosidic linkages is based on the two 
carbons engaged in the linkage; the anomericity is written first followed by the carbon 
number of the non-reducing end, then a comma followed by the carbon number of the 
preceding monosaccharide. For example, figure 1.1 C shows galactose with a β(1,4)-
glycosidic linkage with N-acetylglucosamine, Galactose-β(1,4)-N-acetylglucosamine. 
Galactose (Gal) is at the non-reducing terminus and in the β anomeric configuration, N-
acetylglucosamine (GlcNAc) is at the reducing terminus and the two are linked via the C1 
carbon of Gal to the C4 carbon of GlcNAc. 
 
1.1.1 N-linked glycan biosynthesis: The early processing steps are conserved in all 
eukaryotes 
 
As far back as the 1950s it was identified that asparagine was the N-linked glycan 
attachment site on glycosylated proteins (Cunningham et al., 1957 and, Johansen et al, 
1958). In the 1960s, N-acetylglucosamine was identified as the first monosaccharide linking 
the glycan to asparagine (Johansen et al., 1961 and, Nuenke and Cunningham, 1961). The 
glycan is pre-synthesised on a lipid anchor before en bloc transfer onto asparagine (fig. 1.2) 
(Chapman et al., 1979 and, Lehle, 1980). The enzymes involved in glycan biosynthesis were 
discovered from studies of Saccharomyces cerevisiae ALG (altered in glycosylation) genes 










The substrates for glycosyltransferase enzymes are nucleotide sugars and these are 
synthesised in the nucleus or cytoplasm. The negative charge of nucleotide sugars prevents 
passive diffusion into the ER and golgi, where they are required for the bulk of glycan 
biosynthesis. Therefore, as well as nucleotide synthetases, glycosylation is reliant upon 
nucleotide sugar transporters. These are transmembrane antiporters that couple import of 
nucleotide sugars into the ER and golgi against export of nucleoside monophosphate 
products of glycosyltransferase (Caffaro and Hirshberg, 2006).  
In all eukaryotes, N-linked glycans are initially biosynthesised on a lipid-like membrane 
anchor, called dolichol phosphate (Dol-P), on the cytoplasmic face of the endoplasmic 
reticulum (ER) (fig. 1.2). Glycan biosynthesis is initiated by the transfer of phosphorylated 
GlcNAc from uridinyl-phosphate-GlcNAc to Dol-P to form dolichol pyrophosphate GlcNAc 
(Dol-P-P-GlcNAc). A second GlcNAc is covalently attached via a β(1,4)-glycosidic bond to the 
GlcNAc of Dol-P-P-GlcNAc to form the chitobiose disaccharide core common to all N-linked 
glycans (fig. 1.3). The chitobiose core is further extended by the sequential addition of 
three mannose (Man) residues to form the trimannosyl core, Man3GlcNAc2-P-P-Dol. The 
trimannosyl-core is extended further by the covalent addition of six Man residues and 
Figure 1.2: Synthesis of the precursor glycan on dolichol phosphate (red square) and transfer onto asparagine in 
the sequence Asn-X-Ser/Thr (where X is any amino acid except proline) of the nascent polypeptide chain in the 




three glucose (Glc) residues, to form Glc3Man9GlcNAc2-P-P-Dol, and during this process the 
dolichol linked precursor glycan is flipped into the ER lumen. 
The multi-subunit protein complex oligosaccharyltransferase (OST) catalyses the cleavage 
of the GlcNAc-P bond and transfer of the precursor glycan en bloc to the γ-amido group of 
an asparagine residue in the glycosylation consensus sequence Asn-X-Ser/Thr, where X is 
any amino acid except proline, of a nascent polypeptide chain as it is being translated into 
the ER lumen. Trimming, re-addition followed by re-trimming of the three terminal Glc 
residues by α-glucosidases is an important quality-control check point for monitoring 
correct folding of glycoproteins in the ER. The glycan is trimmed further in the ER by α-












1.1.2 N-linked glycan biosynthesis: The late processing steps are responsible for N-linked 
glycan diversity 
 
In all eukaryotes, the initial stages of glycosylation in the ER are conserved. The 
glycosylation pathways of different eukaryotes diverge upon entering the Golgi apparatus. 
In mammals, the Man8GlcNAc2 glycan that leaves the ER has three Man residues removed, 
by a golgi resident ManI, to form Man5GlcNAc2. This is the key intermediate for the 
production of hybrid- and complex-type glycans (fig. 1.4).  
 
 
Figure 1.3: Core glycan structure common to all N-linked glycans. The chitobiose core is composed of two covalently 
bonded GlcNAc connected by a β(1,4)-glycosidic linkage. Extension of the chitobiose core by three mannoses create 
the trimannosyl core. Myriad glycosyltransferases catalyse the incorporation and extension of the trimannosyl core to 






A medial-golgi resident enzyme, GlcNAc transferase I (GnTI) catalyses the transfer of 
GlcNAc onto the α(1,3)-Man (fig. 1.3) of the trimannosyl core of Man5GlcNAc2. The 
resulting GlcNAc1Man5GlcNAc2 is the precursor for hybrid-type glycans and is converted to 
a complex-type glycan by removal of two Man residues to expose the trimannosyl core 
α(1,6)-Man (fig. 1.3), by a trans-golgi resident ManII, to form GlcNAc1Man3GlcNAc2. GnTII 
then catalyses the transfer of GlcNAc onto the exposed trimannosyl core α(1,6)-Man to 
form the complex-type glycan, GlcNAc2Man3GlcNAc2.  
In the trans-golgi, galactosylation and sialylation by galactosyltransferases (GalT) and 
sialyltransferases (SiaT), respectively, further extend the antennae to form hybrid-type and 
diantennary complex-type terminally sialylated glycans, Sia1Gal1GlcNAc1Man5GlcNAc2 and 
Sia2Gal2GlcNAc2Man3GlcNAc2, respectively (fig. 1.4).  
In mammals, the most common N-linked glycan is complex-type. As well as the diantennary 
glycan described above, additional glycan-processing enzymes can facilitate the addition of 
one or two more antennae to form tri- or tetra-antennary glycans, and fucosyltransferases 
can add α(1,6)-fucose to the asparagine linked GlcNAc in the glycan chitobiose core (fig. 
1.4).  
In yeast, however, N-linked glycans are mannosylated. A golgi-resident 
mannosyltransferase, encoded by the yeast gene OCH1, catalyses the addition of a single 
Man to the Man8GlcNAc2 glycan that leaves the ER. The Man9GlcNAc2 product is the 
substrate for further mannosylation, by myriad golgi resident mannosyltransferases, 
yielding, in Pichia pastoris (Komagataella pastoris), high-mannose glycans containing 9-15 
mannose and, in S.cerevisiae, hypermannosylated glycans of up to 50 mannose residues 
(fig. 1.5). 
Figure 1.4: N-linked glycans are composed of three major types: high mannose-, hybrid- and complex-type. The high 
mannose-type glycan can be written in text, from non-reducing to reducing terminus, as MannGlcNAc2, hybrid-type as 





In insects, processing of N-linked glycans removes all but the trimannosyl core mannose to 
yield paucimannose glycans which can be either α(1,3)- or α(1,6)-fucosylated (fig. 1.4). 
As well as producing high-mannose and paucimannose glycans, plants can also produce 
galactose terminal hybrid- and complex-type glycans with α(1,3)-fucosylation and the 






1.1.3 Glycosylation has intrinsic and extrinsic functions 
 
The function of glycosylation is twofold. Firstly, glycans confer properties on protein 
conjugates that are irrespective of the type of glycan, these are termed intrinsic functions. 
As already mentioned, in the ER addition of glucose to, and removal of glucose from, the 
nascent glycoprotein is key to the calnexin/calreticulin protein-folding quality-control 
checkpoint (Hebert et al., 1996). Other intrinsic effects of glycosylation include enhanced 
protein solubility, thermal stability, avoidance of aggregation, avoidance of cross-linking and 
resistance to proteolysis (Oh-eda et al., 1990, Delorme et al., 1992, Wang et al., 1996, 
Duarte-Vázquez et al., 2003). 
Figure 1.5: Glycan diversity in different groups of eukaryotes. The trimannosyl core is common to all N-linked glycans 
and extension of this basic structure leads to the wealth of diversity in N-linked glycan structures. n any number 




In a study comparing five glycoproteins from a range of organisms, from yeast to mammals, 
with either N- or O-linked glycosylation, the total glycan content rather than the specific 
type of glycosylation conferred thermal stability and resistance to aggregation (Wang et al., 
1996). Therefore, it is likely that these intrinsic effects, especially enhanced protein stability 
and improved survival were the main evolutionary drive for glycosylating proteins, 
particularly those that occupy the harsh vacuole or extracellular environments. 
 
In addition to the intrinsic effects, glycosylation serves extrinsic effects. In mammals, the 
many processing enzymes and the non-template driven, spatio-temporal nature of glycan 
biosynthesis results in substantial glycan heterogeneity and complexity. The fact that this 
complexity is evolutionarily maintained, and that glycans are predominantly present on the 
surface of cells and in the extracellular environment, points to key functions for glycans. 
These are now thought to include information encoding and signalling. This idea is 
supported by the fact that several congenital disorders of N-linked glycosylation exist 
(Jaekan, 2011). These are caused not by a lack of glycosylation, but by an inability to 
process complex-type glycans. Indeed, complex-type glycan structures are important for 
lymphocyte-endothelial attachment and rolling (Imai et al., 1991 and, Somers et al., 2000), 
cell-cell interaction and signalling (Crocker, 2002), endocytosis and immunity (Ashwell and 
Harford, 1982, Schwartz, 1984, Fukuda et al., 1989 and, Taylor and Drickamer, 1993).  
 
It is this immunity aspect of the extrinsic glycan function, especially accelerated clearance 
of therapeutic glycoproteins bearing aberrant glycans, together with the intrinsic functions, 
that is most relevant to the biopharmaceutical industry. The intrinsic effects of glycans 
allow for longer storage of proteins and at higher concentrations than non-glycosylated 
proteins. However, therapeutic glycoproteins bearing aberrant glycans are cleared rapidly 
from circulation. Therefore, glycoproteins present a unique challenge to the 
biopharmaceutical industry. Simply removing the glycans from therapeutically useful 
glycoproteins is not effective at enhancing efficacy. For example, studies on erythropoietin 
(EPO) which has three N-linked glycosylation sites, show that the in vitro activity is 
increased upon deglycosylation but the in vivo activity is decreased (Delorme et al., 1992). 





An additional challenge to the biotherapeutic industry is recombinant production of 
therapeutically useful glycoproteins in expression systems. As was seen in the case of EPO, 
proteins lacking human-like terminally sialylated glycans are generally cleared rapidly. 
There are two primary routes of glycoprotein clearance in humans, both of which target 
aberrant, non-sialylated glycans. First, the asialoglycoprotein receptor, which is located on 
the extracellular face of hepatocytes, binds to terminally galactosylated glycans on 
glycoproteins, i.e.  glycans that have lost sialic acid, and facilitates their endocytosis 
(Ashwell and Harford, 1982, Schwartz, 1984 and, Fukuda et al., 1989). 
The second mechanism of clearance is via recognition by mannose-binding lectins. These 
are either membrane-associated to macrophage and hepatic endothelial cells and facilitate 
endocytosis (Taylor and Drickamer, 1993) or, in the case of collectins and ficolins, free in 
sera where they activate complement in response to targeted aberrant glycosylation (Ikeda 
et al., 1987). In both instances, the mannose-binding lectin binds to glycoconjugates with 
terminal GlcNAc and Man residues. This serves as an important innate immune response 
against pathogenic organisms, such as the parasitic yeast Candida albicans, bearing 
abnormal terminal monosaccharides (Ezekowitz et al., 1990). 
  
1.1.4 Mammalian glycosylation and sialic acids 
 
An important aspect of mammalian glycosylation is the capping of complex-type glycans 
with sialic acid. Sialic acids are a particularly diverse family of monosaccharides, comprising 
a common backbone with various functional groups and the ability to form multiple 
different glycosidic linkages. Sialic acids warrant a more in-depth discussion because of 
their physiological importance and the pharmacokinetic benefits that sialic acids bestow 
upon biotherapeutic proteins. 
 
First discovered on salivary mucins (Greek Sialos), sialic acids are a group of nine-carbon 
backbone monosaccharides (fig. 1.6) predominantly found at the terminus of N- and O-
glycans, glycosphingolipids and some GPI-anchors, on proteins and cell surfaces. 
The sialic acids are diverse. As well as having α/β anomericity, the fifth carbon (C5) group 
can be N-acetylated (N-acetylneuraminic acid, Neu5Ac) or hydroxylated (2-keto-3-
deoxynononic acid, Kdn). The C5 N-acetyl group can also be hydroxylated to yield N-
glycolylneuraminic acid (Neu5Gc), a monosaccharide that humans have lost the ability to 
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biosynthesise. Additionally, the C5 amino group may not be acetylated, which gives 
neuraminic acid (Neu). 
 
Based on these four core sialic acids further diversification occurs. Each of the backbone 
carbon hydroxyl-groups and the C1 carboxyl group may be modified, while there are 
multiple possibilities for glycosidic linkages. Nonetheless, the most common sialic acid is 
Neu5Ac. The most common linkage formed by this sialic acid involves its α-2 position in 







High levels of sialic acids are present on glycoproteins, in the glycocalyx and on matrix-
associated proteins such as mucins. The concentration of sialic acids within the glycocalyx 
of a single B-cell has been estimated to be over 100 mM (Collins et al., 2004). 
The negative charge on sialic acids sets this monosaccharide apart from the other, neutral, 
monosaccharides which make up complex-type N-linked glycans. This negative charge is an 
important contributor to the biophysical landscape of biological systems, for example the 
negative charge on the surface of human erythrocytes prevents unwanted cell-cell 
interactions in blood circulation and sialylation enhances mucin viscosity (Raju and 
Davidson, 1994). 
Thus, the density of sialic acids has a significant biophysical effect on the molecules and 
cells to which the sialic acids are conjugated and is an important factor in the circulatory 
life-time of glycoproteins (Fukuda et al., 1989 and, Yang et al., 1992), immunogenicity 
(Fenouillet et al., 1986), receptor interaction (Sumer-Bayraktar et al., 2011) and, 




Figure 1.6: Haworth projection of the molecular architecture common to all sialic acids. This structure is depicted in 
α-anomeric configuration, where the C2 hydroxyl group sites below (axial) the plane of the heterocyclic pyranose ring 
structure. In the β-anomer the C2 hydroxyl group is equatorial. The R groups listed form the four core sialic acids of 






1.2.1 Three complement activation pathways converge on the formation of C3b 
 
Complement is one of the oldest evolutionary components of the immune system, bridging 
the gap between innate and adaptive immunity (Dunkelberger and Song, 2010). 
Complement is, therefore, one of the first lines of defence against pathogens. 
 
Composed of over 40 proteins, present in the blood or on membrane surfaces, activation of 
complement causes a sequential enzymatic activation cascade that leads to the generation 
of proinflammatory anaphylatoxins, opsonisation of surfaces (i.e. tagging them for 
phagocytosis) and cell lysis by assembly of the pore-forming membrane-attack complex 
(Dunkelberger and Song, 2010). 
 
There are three pathways of activation of complement (fig. 1.7). All three pathways involve 
formation of a complex that cleaves the key complement protein C3 to C3b, as described 
Figure 1.7: Overview of the complement process. The three complement-activation pathways converge on the formation 
of the opsonin C3b which, when in complex with Bb, forms a powerful self-amplification loop to generate more 
molecules of C3b. Opsonisation of surfaces by C3b and downstream complement cascades facilitated by the formation of 
C3 convertase complexes, C3bBb and C4bC2a, lead to phagocytosis, inflammation and, eventually, cell lysis. Complement 
pathways of activation are coloured red (alternative pathway) and blue (classical and lectin pathways),  the downstream 
complement pathway is coloured purple and the downstream effects of complement activation are boxed in green. 
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below. The classical pathway (CP) and the lectin pathway (LP), are activated by pathogen- 
or danger-recognition molecules.  
 
The CP is activated in response to immunoglobulin (Ig) G and IgM binding to pathogens or 
non-self antigens. In this process, the multimeric complement C1 complex binds, via C1 
component C1q, to the Fc portion of IgG clusters or IgM bound to antigen, which causes a 
conformational change and activation of the serine protease C1r. C1r cleaves and activates 
another serine protease component of C1, C1s. Activated C1s catalyses the hydrolysis of 
the fluid-phase protein molecules C4 and C2 to form the complex C4bC2a. This complex is 
called the CP and LP C3-convertase as it cleaves the abundant fluid-phase protein C3 to 
form C3a, an anaphylatoxin, and C3b. 
The LP leads to formation of the same C3-convertase i.e. C4bC2a. It does so in response to 
glycosylation patterns present on yeast, bacteria, parasites and viruses. These glycosylation 
patterns are recognised by the mannose-binding lectin and ficolins which then trigger 
mannose-binding lectin-associated protein (MASP) 2 (Wallis et al., 2007) to cleave C4 and 
C2, resulting, as in the CP, in C3-covertase (C4b2a) complex formation and thus production 
of C3a and C3b. 
The third pathway, the alternative pathway (AP), differs from the lectin and classical 
pathway in that it does not require pattern recognition molecules for activation. In a 












Figure 1.8: Schematic diagram of the conversion of C3 to C3b. Proteolytic cleavage of C3a from C3b results in a 
repositioning of the TED domain of C3b, thus exposing the previously buried reactive thioester for attachment of 





C3(H2O) undergoes a structural rearrangement (Chen et al., 2016) whereby the TED domain 
rotates and migrates to reveal a binding site for factor B.  In this context factor B is a 
substrate for factor D, which cleaves away the Ba fragment leaving C3bBb. The remaining 
Bb fragment has protease activity for C3 and this complex (C3(H2O)Bb) is called the initiating 
C3 convertase. It generates C3b (177 kDa) and the anaphylatoxin, C3a. C3b has a similar 
conformation and shape to C3(H2O) but formation of C3b exposes a previously buried 
reactive thioester (fig. 1.8) (Janssen et al., 2006). Nucleophilic attack of the newly exposed 
thioester by surface associated hydroxyl groups allows attachment of C3b, to these 
surfaces (Sahu, et al., 1994 and, Nagar et al., 1998).  C3b, like C3(H2O) is a platform for factor 
B cleavage and the product, C3bBb is called the AP C3 convertase. This stokes an 
amplification process in which, unless regulated, a positive-feedback loop produces a large 
number of C3b molecules very rapidly.  These, produced in their millions, can rapidly coat 
any surfaces that have nucleophilic groups, tagging these for phagocytosis. 
 Thus, all three pathways converge on formation of C3b.  Regulation of C3b production, and 
in particular, the positive feedback loop that generates large amounts of C3b, is critical on 
self surfaces. 
 
1.2.2 Factor H deactivates complement in fluid phase and on self-surfaces 
 
The AP is always “on” (i.e. in tick over mode) and C3b, that can participate in a positive 
feedback loop, binds to nearly any surface - including self surfaces.  Clearly there is a 
constant danger of C3b overproduction and collateral damage to host tissue. To ensure this 
process is kept under tight control, multiple membrane-associated and fluid-phase 
regulators of complement exist to maintain the homeostatic balance between fast, 
efficient pathogen destruction and the prevention of autologous complement-mediated 
attack.   
 
The soluble glycoprotein factor H (FH) is a key regulator of complement activation. FH is 
encoded by the CFH1 gene located in the Regulator of Complement Activation gene cluster 
on the long arm of chromosome 1, 1q32 (Weis, et al., 1987 and, Rodríquez De Córdoba, et 
al., 1999). FH is a large 1,213-amino acid, 155-kDa glycoprotein composed of a single 
polypeptide chain folded into 20 complement control protein (CCP) domains arranged like 
“beads on a string” (Ripoche et al., 1988 and, Vik et al., 1988). The structure of FH CCPs has 
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been extensively characterised (Perkins et al., 1988, Barlow et al., 1991, Barlow et al., 1992, 
Barlow et al., 1993, Makou et al., 2012 and, Morgan et al., 2012), each CCP forms a 
globular structure containing two pairs of disulphide bonds, thus full-length FH contains 40 
disulphide bonds. 
FH has eight sites of N-linked glycosylation; CCPs 9, 12, 13, 14, 17 and 18 contain one 
glycosylation site each and the two remaining sites are both located on CCP 15 (fig. 1.9). 
Fenaille et al. (2007a) have shown that the glycans on human FH are exclusively complex-
type, and the majority of them feature identical diantennary disialylated structures, 
Sia2Gal2GlcNAc2Man3GlcNAc2, collectively accounting for 67.4% of total glycan content.  
Monosialylated diantennary (9.2%), Sia1Gal2GlcNAc2Man3GlcNAc2, and trisialylated 
triantennary (3.9%), Sia3Gal3GlcNAc3Man3GlcNAc2, structures are also present. These three 
structures are additionally present in a fucosylated form (8.9%, 2.0% and 4%, respectively). 









FH is expressed predominantly in the liver, but also locally in the eye (Skerka et al., 2007 
and, Scholl et al., 2008), circulates in blood plasma at a concentration of 200 – 300 
milligrams per litre (Hakobyan, et al., 2008 and, Sofat et al., 2013) and regulates 
complement at the level of C3b (Weiler et al., 1976) both in fluid-phase and on self-
surfaces. FH regulates complement in three ways. First, FH competes with FB for binding to 
C3b, preventing the formation of the potent C3bBb, C3-convertase complex, thus 
attenuating C3b self-amplification. Second, FH can bind to the labile C3bBb complex and 
accelerate the rate of dissociation of this complex by a factor of about 50.  This is FH’s 
decay-acceleration activity (DAA). Thirdly, FH is a cofactor for the serine protease factor I 
Figure 1.9: Schematic of FH. CCPs are labelled 1 – 20 from N-terminus to C-terminus. CCPs 1-4 (dark blue) are 
responsible for C3b binding, cofactor activity (CA) and decay acceleration activity (DAA). CCPs 19-20 are also 
capable of binding to C3b and, in addition, polyanions. Polyanion binding CCPs (coloured yellow) are responsible 
for discriminating self from non-self surfaces. Glycosylation sites are marked by dark blue triangles. The image 




(FI) for cleavage of C3b; this is FH’s cofactor activity (CA). Binding of FH to C3b enables the 
recruitment of FI which catalyses the first step in the degradation of C3b, conversion to 
iC3b. Continual degradation steps eventually leave just the TED domain of C3b (called C3d) 
on self-surfaces. 
 
The N-terminal CCPs 1-4 of FH have been shown to bind to C3b (fig. 1.10) and are primarily 
responsible for CA and DAA of FH (Gordon et al., 1995, Kuhn and Zipfel, 1996, Hocking et 
al., 2008, Schmidt et al., 2008 and Pechtl, et al., 2011). The crystal structure of N-terminal 
CCPs 1-4 in complex with C3b shows that CCPs 1-4 bind C3b along the length of C3b at a 
site overlapping with the Bb interaction site on C3b and CCPs 1-2 directly occlude the Bb 
binding site on C3b (fig. 1.10 C). This suggests that DAA of FH is mediated exclusively by 
these CCPs via a combination of competition between, and electrostatic repulsion of, Bb in 
the C3 convertase complex (Wu et al., 2009). Crystal structures of C3b in complex with FI 
and “mini-FH”, composed of CCPs 1-4 and CCPs 19-20 joined by a short linker, show that FI 
binds to FH across CCPs 2-3 (fig. 1.10 B) and re-orientates the C-terminal domain of C3b to 
allow FI access to the first, of a potential three, scissile bonds (Xue et al., 2017). Thus, CA of 
FH facilitates the docking of FI to C3b and results in the disruption of the FB binding site via 
cleavage of two to three scissile bonds in C3b. 
 
The C-terminal CCPs 19-20 bind tightly to C3b and C3d but do not participate directly in CA 
and DAA (Ferreira et al., 2006, Schmidt et al., 2008, Ferreira et al., 2009 and Lehtinen et al., 
2009). CCPs 19-20 have been shown to interact with C3b in the TED domain (fig. 1.10 A) 
and this binding site is located near to, but distinct from, the interaction site in the TED 
domain of the N-terminal CCP 4 (Morgan et al., 2011 and, Kajander et al., 2011). Mutations 
in CCPs 19-20 do not affect FH-mediated complement regulation in the fluid phase, but 
these mutations hinder FH-mediated complement regulation on self-surfaces (Ferreira et 
al., 2006). Thus, key to the function of FH is the ability of the molecule to recognise self 
from non-self. This allows FH to attenuate complement activation on self-surfaces (not on 
foreign surfaces) and this is crucial for surfaces that do not already possess membrane-
associated complement regulators.  
 
Self-surfaces are decorated in negatively charged polyanions, e.g. glycosaminoglycans 
(GAGs) and sialic acids, and FH has been shown to interact with these structures via at least 
two sites located on CCP 7 (Blackmore et al., 1996 and Giannakis et al., 2003) and CCP 20 
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(Blackmore et al., 1998). Other putative binding sites have been reported (Pangburn et al., 
1991; Ormsby et al., 2006), however, these may not be of physiological relevance (Schmidt 
et al., 2008). Polyanions may engage CCPs 7 and 19-20 by electrostatic interactions. Blaum 
et al., (2015), using a crystal structure of FH CCPs 19-20 in complex with C3d (TED domain 
of C3b) and an α(2,3)-Neu5Ac linked trisaccharride, showed that the carboxyl-group of 
Neu5Ac formed a salt bridge with the FH arginine 1215 side chain.  
 
Although the complete structure of FH has not yet been characterised, piecing together 
collections of small angle X-ray scattering (SAXS), analytical ultracentrifugation and nuclear 
magnetic resonance data of stretches of CCP modules and crystal structures of CCPs 1-4 
and 19-20 in complex with C3b indicted that FH appears to adopt a bent back structure 
when in complex with C3b (Aslam and Perkins, 2001 and, Morgan et al., 2011), enabling 
Figure 1.10: Potential model for the engagement of FH, FI and Bb with C3b. A) Superimposed X-ray 
crystallography-derived structures of C3b:FH1-4 and C3b:FH19-20, with SAXS envelope for CCPs 1-5 overlaid and 
juxtaposed with NMR derived structures of CCPs 6-8 and SAXS derived envelopes of CCPs 8-15 and 15-19. Image 
adapted with permission from Morgan et al., 2011. B) Contact regions of FI with C3b in complex with FI, figure 
taken and adapted with permission from Xue, et al. (2017). C) Overlay of the FH and Bb binding sites on C3b, the 
red region indicates where FH and Bb overlap, figure taken and adapted with permission from Wu et al. (2009). D) 
Schematic diagram of C3b on a pathogenic, non-self surface. FH does not bind to C3b on non-self surfaces that 
lack polyanions such as GAGs, the dotted outline represents where FH would bind to C3b. E) Schematic diagram 
of the interaction of FH with C3b on a self-surface. On self-surfaces polyanionic structures mark these surfaces as 
self and stabilise FH interaction with C3b enabling complement regulation. On self-surfaces already protected 
from complement activation by FH binding, FH may remain anchored to C3d via CCPs 19-20 and search out other, 




simultaneous interaction of the N-terminal CCPs 1-4 and C-terminal CCPs 19-20 (fig. 1.10 
A).  
In addition, FH has been shown to have enhanced affinity for C3b and C3d and enhanced 
DAA in the presence of a bacterial FH-binding protein PspCN (Herbert, et al., 2015). Cross-
linking mass spectrometry data show that PspCN cross-links with FH at CCPs 9-10 and that, 
in the absence of PspCN, FH preferentially adopts two conformations: in the first 
conformation CCPs 4 and 5-7 form cross-links with CCPs 19-20, however, in the second 
conformation these CCPs do not form cross-links and the cross-links that do form occur 
between immediately adjacent CCPs, e.g. CCP 3 with 4, 4 with 5, 5 with 6, etc (Herbert et 
al., 2015). This indicates that FH can have either a compact conformation or a more 
extended conformation. However, in the presence of PspCN, the conformational 
preference of FH is shifted toward the first, more compact conformation. This, together 
with the enhanced C3b and C3d affinity and DAA of FH in the presence of PspCN, indicates 
that the compact conformation of FH is more active. This led Herbert et al., (2015) to 
reason that circulating FH in vivo also adopts compact and elongated conformations and 
that the active compact conformation is stabilised in the presence of self-surfaces by 
simultaneous interaction of CCPs 1-4 and 19-20 with C3b and CCPs 7 and 20 with self-

















Figure 1.11: Schematic diagram showing the interconversion of FH from the latent, extended conformation (upper) 
to the compact, more active conformation (middle). Cross-linked sites in the compact structure of FH are marked 
by blue lines. CCPs 19-20 are shown to cross-link with CCPs 4 and 6-7 holding the two C3b binding domains in close 
proximity to one another. On self surfaces (bottom right) Herbert et al. (2017) reason that CCPs 7 and 20 
interaction with self-surface polyanionic markers (labelled here as GAG) stabilise the compact, more active 
conformation of FH facilitating complement regulation on self-surfaces. The image was taken and adapted with 




1.2.3 Diseases associated with factor H 
 
Given the central role of FH in regulating complement activation, it is unsurprising that 
mutations and single nucleotide polymorphisms (SNPs) in FH lead to autoimmune diseases.  
Mutations that result in impaired ability to secrete FH into the circulation have been 
described in humans and animals (Ault et al., 1997, Sánchez-Corral et al., 2000, Hegasy et 
al., 2003). Most cases of the rare kidney disorder, membranoproliferative 
glomerulonephritis-type II (MPGNII) or “dense deposit disease” are caused by a lack of FH 
in circulation. This leads to uncontrolled fluid-phase complement activation resulting in 
depletion of plasma C3 and other complement components (Thompson and Winterborn, 
1981 and, Ault et al., 1997) and deposition of C3b on the basement membrane of the 
glomerulus causing wall thickening and fibrosis (Licht et al., 2007). In support of a link 
between FH deficiency and MPGNII, mice deficient in cfh (cfh-/-) have uncontrolled C3 
activation and spontaneously develop MPGNII. Subsequent deletion of the mouse gene 
encoding FB abolishes the cfh-/- phenotype (Pickering et al., 2002). Development of MPGNII 
in early life has severe repercussions; children have a poor prognosis and often develop 
late-stage renal disease. The median survival time of children with MPGNII is less than nine 
years (Schwertz et al., 1996).  
 
FH is also linked to another rare kidney disorder, the heritable disease atypical haemolytic 
uraemic syndrome (aHUS). aHUS is characterised by haemolytic anaemia, 
thrombocytopaenia and acute renal failure (Ferreira et al., 2006). The recessive form of the 
disease is strongly associated with mutations clustering in the C-terminal region of FH, 
particularly in CCP 20 (Rodríguez De Córdoba et al., 2004). Functional analysis of common 
mutations associated with aHUS in the C-terminal domains of FH show an impaired ability 
to bind to C3b and polyanionic self-markers (Pangburn, 2002, Ferreira et al., 2009 and, 
Lehtinen et al., 2009). In addition, transgenic mice modified to express a version of FH 
lacking the C-terminal five CCPs spontaneously developed aHUS but were still able to 
regulate complement in plasma (Pickering et al., 2007). This led to the premise that aHUS-
causing FH mutants are able to regulate complement in fluid phase, preserving levels of C3 
in plasma, but C3b amplification is poorly regulated on self-surfaces due to a reduced 
ability of the mutant FH to bind either or both of polyanions and self-surface associated 




Age-related macular degeneration (AMD) is the leading cause of blindness in the developed 
world (Klein et al., 2002).  Early-stage AMD predominantly affects rod-mediated dark 
adaptation (Owsley et al., 2015), but in its later stages AMD is characterised by a central 
scotoma and loss of vision (Toomey et al., 2017). A hallmark of AMD is the presence of 
numerous soft drusen, yellow deposits containing oxidised proteins and lipids as well as FH.  
The “dry” form of AMD features retinal pigment epithelial (RPE) atrophy (Toomey et al., 
2017). The “wet” form is neovascular and vision loss is caused by the formation of 
abnormal blood vessels of choriocapillaries in the Bruch’s membrane of the retina (Toomey 
et al., 2017). 
 
FH has been strongly linked with the onset of AMD. Four separate studies found a tyrosine-
to-histidine allelic variant at amino acid 402 that in homozygotes increases the risk of 
developing AMD over sevenfold.  The Y402H variant is the cause of ~43% of cases in older 
adults with AMD (Edwards et al., 2005, Hageman et al., 2005, Haines et al., 2005 and, Klein 
et al., 2005). The Y402H polymorphism occurs in the polyanion-binding CCP 7 of FH.  The 
Y402H variant was thought to have a reduced affinity for self-surface polyanions, reducing 
the efficiency of FH recruitment to the RPE and other layers in the Bruch’s membrane. 
Studies on truncated recombinant fragments of FH, CCPs 6-8, support this hypothesis and 
show that the H402 variant has a reduced ability to bind to the polyanion heparin in vitro 
and ex vivo (Clark et al. 2006, Clark et al., 2010 and, Clark et al., 2013). However, these 
results have not been validated with full-length FH (Ormsby et al., 2008 and, Kelly et al., 
2010). 
 
1.2.4 Potential biotherapeutics for the treatment of factor H-linked disease 
 
Molecular replacement strategies offer a possible route to treat diseases caused by a 
deficiency of active FH. In support of this, plasma infusions containing functional FH have 
been shown to be effective in restoring partial complement regulation in mice (Paixão-
Cavalcante et al., 2009 and, Fakhouri et al., 2010), pigs (Høgåsen et al., 1995) and humans 
(Appel et al., 2005, Licht et al., 2005 and, Licht et al., 2006). However, the need for high 
circulating concentrations of FH, and its relatively short half-life of approximately six days 
(Licht et al., 2005), mean that regular plasma infusions would be required. In addition, the 
risk of infection associated with plasma transfusion means there is a strong case for using 




“Mini-FH” molecules composed of the functional N- and C-terminal domains of full-length 
FH have shown therapeutic promise in in vitro and ex vivo assays (Hebecker et al., 2013, 
Schmidt et al., 2013 and, Nichols et al., 2015). However, of the three “mini-FH” molecules 
described to date, just one (Nichols et al., 2015) has been assessed in vivo. Nichols et al. 
(2015) describe the recombinant expression, in a Chinese hamster ovary (CHO) cell line, of 
a “mini-FH” with a molecular weight of 59 kDa and consisting of the N-terminal CCPs 1-5 
and C-terminal CCPs 18-20 of FH joined together by a short, twelve glycine polypeptide 
linker. This protein was thus designed to be significantly smaller than FH (and easier to 
produce) but to retain its key regulatory and C3b-binding domains. “Mini-FH” had 
comparable CA and DAA compared to full-length FH, in vitro and ex vivo, however, in vivo 
“mini-FH” had a reduced effectiveness at restoring complement regulation in cfh-/- mice 
and it was completely cleared from circulation in just six hours. Conversely, in “mini-FH”-
treated animals, C3 deposition in the glomerulus was reduced, suggestive of protection 
from complement on self-surfaces, however, the effect of self-surface protection by “mini-
FH” in comparison with full-length FH was not tested over longer periods 
The short half-life of “mini-FH” and the inability to regulate complement in fluid phase 
prevents use of “mini-FH” as an effective replacement therapy for diseases caused by FH 
deficiency. 
 
Alternative approaches to the development of FH-replacement therapies have focused on 
recombinant production of full-length FH (Sharma and Pangburn, 1994, Sánchez-Corral et 
al., 2002, Schmidt et al., 2011, Büttner-Mainik et al., 2011 and, Michelfelder et al., 2017). 
However, with protein yields of 20 micrograms per gram of dry-cell weight in the moss 
Physcomitrella patens (Büttner-Mainik et al., 2011), 1 milligram per litre of P. patens cell 
culture (Michelfelder et al., 2017), 2 milligrams per litre of COS7 cell culture (Sánchez-
Corral et al., 2002) and 5 milligrams per litre of Sf9 cell culture (Sharma and Pangburn, 
1994) only Schmidt et al. (2011) report yields of recombinant FH (>10 milligrams per litre P. 
pastoris cell culture) high enough to have potential for production on the scale required for 
therapeutics.  
 
Importantly, the glycosylation profile of mammalian cell- derived recombinant FH has not 
been characterised (Sánchez-Corral et al., 2002). Other cells used for recombinant FH 
production cannot glycosylate with mammalian complex-type glycosylation (Sharma and 
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Pangburn, 1994, Sánchez-Corral et al., 2002, Schmidt et al., 2011, and, Büttner-Mainik et 
al., 2011).  
 
Therefore, there remains a pressing need to produce therapeutically useful quantities of 
recombinant FH with human glycosylation. This calls for a comparison of the expression 
systems available for production of N-linked glycoproteins, with a specific focus on FH and 
the need for high yields. 
 
1.3 Glycoprotein-production systems 
 
Agalsidase alpha and beta, epoetin alpha and beta, follitropin alpha and beta, lutropin 
alpha, transforming growth factor-β1, antithrombin, thyrotropin alpha, lenograstim, 
sargramostim, interleukin-3, prourokinase, lymphotoxin, coagulation factor VIIa, VIII and IX 
are just some of the therapeutic proteins whose stability and efficacy have been improved 
by glycosylation (Solá and Griebenow, 2010).  
 
Below, various glycoprotein-production systems are explored with an emphasis on the type 
of glycan produced and consideration of any additional glycoengineering requirements in 
the context of human recombinant factor H production. 
 
1.3.1 Bacteria, Plants, and Insects 
 
Escherichia coli offers several advantages for heterologous expression of recombinant 
proteins. It is cheap, grows readily on a variety of media and lends itself to genetic 
manipulate. Indeed, the first US Food and Drug Administration (FDA) approved 
recombinant biotherapeutic, human insulin, was recombinantly produced in E. coli. But, 
unlike FH, insulin is not a glycoprotein. The lack of N-linked glycosylation machinery in E. 
coli and poor disulphide bond formation are major constraints for the use of E. coli as an 
expression system for recombinant glycoproteins.  
 
The discovery of a bacterial homologue of a subunit of OST, called pglB, in Campylobacter 
jejuni (Szymanski et al., 1999, Szymanski et al., 2002 and, Nita-Lazar et al., 2005) and the 
successful recombinant expression of this protein in E. coli (Feldman et al., 2005) raised 
hopes for an approach to humanise glycoprotein production based on glycoengineered E. 
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coli. To date, however, efforts to produce fully humanised glycosylation (Valderrama-
Rincon et al., 2012) in E. coli, and to improve glycosylation site efficiency, (Ding et al., 2017) 
have met with limited success. In addition, although disulphide bond-forming strains of E. 
coli have been developed, such as SHuffle (Lobstein et al., 2012) and Origami, the 
inefficiency of disulphide bond formation in these strains coupled with the high disulphide 
bond requirement of FH, which contains forty disulphide bonds, severely limits the use of E. 
coli for production of recombinant human FH with humanised glycosylation. 
 
Advances have been achieved in glycoengineering of insect cells to produce humanised 
glycosylation (Jarvis and Finn, 1996, Hollister et al., 1998) with terminal sialylation (Jarvis et 
al., 2001) and exclusion of the highly immunogenic α(1,3)-fucose from glycans (Mabashi-
Asazuma et al., 2013). However, insect cells are slow growing and often produce low 
protein yields, which limits the applicability of this system for production of therapeutically 
useful quantities of FH, especially considering the high concentration of FH in blood 
plasma. 
 
Like insect cells, plant cells offer a non-microbial recombinant glycoprotein production 
option. The moss Physcomitrella patens is attractive in this respect as it is well 
characterised, it can be cultured in simple media and is fully differentiated and, therefore, 
genetically stable (Decker et al., 2014). Plants can glycosylate proteins with mammalian-like 
diantennary terminally digalactosylated complex-type glycans, Gal2GlcNAc2Man3GlcNAc2, 
but the galactose forms a β(1,3)-glycosidic linkage with GlcNAc, which differs from the 
human Gal-β(1,4)-GlcNAc glycosidic linkage. Like insects, plants incorporate the 
immunogenic α(1,3)-fucose as well as the immunogenic β(1,2)-xylose monosaccharide and 
efforts have focused on removal of these antigenic epitopes in glycoengineered Arabidopsis 
thaliana (Strasser et al., 2004) and moss (Koprivova et al., 2004). 
 
In support of the potential of glycoengineered moss strains for biotherapeutic glycoprotein 
production Michelfelder et al. (2017) successfully expressed full-length human FH in P. 
patens glycoengineered to supress fucosyl- and xylosylation and to produce and attach to 
proteins the diantennary GlcNAc-terminal glycan, GlcNAc2Man3GlcNAc2. However, a multi-
step purification procedure, lack of protein purity, relatively low yields (1 milligram per litre 
cell culture), and the likelihood of accelerated clearance from blood circulation due to the 
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presence of GlcNAc terminal glycans, limits the biotherapeutic applicability of this source of 
recombinant human FH. 
 
1.3.2 Mammalian cells 
 
Mammalian expression systems are the dominant method for production of recombinant 
therapeutic glycoproteins. Of these CHO cells are the most frequently utilised. For example, 
in 2015 and 2016 over half of the FDA-approved new biologics were CHO cell-derived 
recombinant proteins (Lalonde and Durocher, 2017). 
 
The major advantage of using mammalian expression systems for recombinant 
glycoprotein production is the commonality in mammalian and human glycosylation – both 
are capable of producing complex-type, terminally sialylated glycans. However, mammalian 
systems produce the immunogenic glycan epitopes Neu5Gc and galactose-α(1,3)-galactose 
(Bosques et al., 2010 and, Ghaderi et al., 2010), and CHO cells specifically are incapable of 
generating α(2,6)-sialylation and α(1,3)-fucosylation (Patnaik and Stanley, 2006). These 
factors result in glycoengineering, either in vivo or in vitro downstream in the manufacture 
process, being a key requirement for optimising the pharmacokinetic properties of 
glycoprotein therapeutics expressed in CHO cells. In addition to this, CHO cells, being 
immortalised cells, have low long-term genetic stability often resulting in impaired process 
yields (Bailey et al., 2012). 
Human expression systems are increasingly used to produce therapeutic glycoproteins. 
Since they are also immortalised cell lines they face similar limitations in terms of genetic 
stability as other mammalian systems. In addition to this, human cell lines, when cultured 
on animal-derived media, can incorporate Neu5Gc on glycoproteins (Bardor et al., 2004) 
and the cell surface which, when used for transplantation procedures, represented the first 




FH circulates in blood plasma at 200 – 300 µg/mL and, therefore, high yields of 
recombinant protein are likely required to meet the needs of therapeutic use in humans. 
Matthews et al. (2017) estimate that, for the same number of cells, CHO cells would occupy 
75% of a bioreactors volume whereas microbial cells would occupy just 10% of the 
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bioreactor volume. In addition to this, microbrial eukaryotes have faster growth times 
leading to more rapid strain engineering as well as higher volumetric productivity 
(Matthews et al., 2017). 
Yeast offers a compromise between the human-like glycosylation of mammalian expression 
systems and the fast growth rates and ease of genetic manipulation of prokaryotic systems. 
To add to this FH has been expressed in the methylotrophic yeast P. pastoris, to 
therapeutically useful 10s-of-milligram quantities in the Barlow group (Schmidt et al., 
2011). In addition, fully humanised glycosylation of both N- and O-linked glycosylation in 
this species has been reported (Hamilton et al., 2006 and, Hamilton et al., 2013). 
Considering this, the yeast P. pastoris offers the potential to produce recombinant human 
FH with humanised glycosylation whilst also meeting the high demands on yield of 
therapeutic use in large numbers of human patients. 
 
1.4 Pichia pastoris and glycoengineering 
 
Pichia pastoris has grown in popularity for heterologous protein production and is used 
widely in the biotechnology and biopharmaceutical industries. An advantage of P. pastoris 
is its ability to grow to high cell densities, over 130 grams of dry cell weight per litre has 
been achieved in continuous culture (Cereghino and Cregg, 2000), on simple chemically 
defined media. Moreover, its doubling time is short compared to mammalian cells. 
Importantly for our purposes, it can efficiently perform post-translational modifications 
such as N-linked glycosylation and disulphide bond formation.  
 
A significant contributor to the usefulness of this strain is the tightly regulated and very 
strong inducible AOX1 promoter (Cregg et al., 1985). P. pastoris is a methyltrophic yeast 
meaning that it is capable of growing on media containing methanol as the sole carbon 
source. The enzyme responsible for initiating methanol metabolism is alcohol oxidase 
(AOX), which has been shown to constitute 33% of the total soluble protein content of cells 
cultured in methanol (Couderc and Baratti, 1980). There are two genes that encode AOX in 
P. pastoris, AOX1 and AOX2. These differ in strength of expression. AOX1 expresses more 




The AOX1 promoter (AOX1p) was first used for recombinant protein expression by Tschopp 
et al., (1987) and has become the most commonly used promoter for expression of 
recombinant proteins in P. pastoris. The promoter is strongly repressed in the presence of 
glucose, glycerol and ethanol (Inan and Meagher, 2001), but fully active in the presence of 
methanol when these other carbon sources have been depleted. This allows for a two-
stage cell culture. In the first stage, growth is carried out on non-methanol media which 
allows cells to reach high cell density. In the second stage, non-methanol carbon sources 
are depleted and replaced with methanol allowing for high-level expression of 
heterologous protein without compromising growth of the cell culture.  As a little-used 
alternative to AOX1p, the glycercaldehyde-3-phosphate promoter (GAPp) is a constitutive 
promoter that can achieve high-level expression comparable to the inducible AOX1p 
(Waterham et al., 1997).  
 
These two promoters have enabled the establishment of P. pastoris as a powerful 
recombinant protein expression platform. For example, Werten et al. (1999) reported the 
production of 14.8 grams per litre of cell culture of mouse gelatin under the control of the 
AOX1p and Mallem et al. (2014) report the production of 10 grams per litre of cell culture 
of human serum albumin. 
 
The Barlow group has capitalised on the advantageous protein-production characteristics 
of P. pastoris in order to achieve high yields of recombinant, disulphide-rich CCP modular 
segments of the protein FH (Schmidt et al., 2008, Schmidt et al., 2010, Makou et al., 2012) 
and full-length FH to 10s of milligram quantities (Schmidt et al., 2011, Herbert et al., 2015 
and, Kerr et al., 2017). 
In these studies (Schmidt et al., 2011, Herbert et al., 2015 and, Kerr et al., 2017), the CFH 
gene was cloned into the P. pastoris expression plasmid pPICZα downstream of the AOX1p, 
to enable tightly controlled inducible expression, and placed in frame with a gene sequence 
encoding the S. cerevisiae α-secretion signal, for secretion of FH into the culture media. The 
plasmid was linearised at a site in the AOX1p by restriction endonuclease digestion and 
introduced into P. pastoris by electroporation. Linearisation of the plasmid facilitated 
single-site homologous recombination between the AOX1p sequence in the plasmid and 
the homologous AOX1p site in the genome of P. pastoris thus, generating a genome 
integrated expression plasmid – this is standard procedure for heterologous protein 
expression in P. pastoris. All strains of P. pastoris used in the current study were 
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constructed, previously, to express recombinant human FH in this way. The focus of the 
current study was to engineer the glycosylation pathway of P. pastoris that could already 
express recombinant FH. 
 
1.4.1 Glycoengineering of P. pastoris: galactose-terminal glycans 
 
Initial attempts to glycoengineer yeast started in S. cerevisiae with the discovery of the 
mannosyl transferase-encoding gene OCH1. This gene was found to be responsible for 
catalysing the formation of the first step in the hypermannosylation process of yeast glycan 
synthesis. Knockout of och1 prevented further glycosylation of the Man8GlcNAc2 glycan 
that leaves the ER (Nakayama et al., 1992) (fig. 1.12). 
 
Chiba et al. (1998) developed this further, by transforming S. cerevisiae Δoch1 and Δmnn1, 
a gene responsible for outer glycan mannosylation (Shindo et al., 1993), with an α(1,2)-
mannosidase I from Aspergillus saitoi fused with the ER-retention signal peptide sequence 
HDEL (Pelham, 1988) at the C-terminus. Expression of ManI in the double-knockout strain 
of S. cerevisiae produced the high-mannose glycan Man5GlcNAc2, as intended. However, 
the efficiency was low – approximately 20% of the heterogenous glycoprofile of 








Callewaert et al. (2001) identified that the glycoprofile of proteins expressed in P. pastoris 
contain Man8GlcNAc2 glycans and therefore hypothesised that the OCH1 homologue in P. 
pastoris is less active than OCH1 in S. cerevisiae. In addition, Callewaert et al. (2001) also 
noted that, unlike with S. cerevisiae, P. pastoris does not produce the hyper-immunogenic 
outer chain terminal α(1,3)-mannose. Callewaert et al. (2001) identified that these factors 
would make P. pastoris a more suitable host for glycoengineering attempts than S. 
cerevisiae. Callewaert et al. (2001) expressed HDEL-tagged ManI from Trichoderma reesei in 
P. pastoris and found variable results when co-expressed with recombinant glycoproteins. 
The glycoprofile of trans-sialidase co-expressed in the P. pastoris ManI strain produced 
glycans predominantly of the intended five-mannose type, Man5GlcNAc2 (fig. 1.12). 
However, co-expression of influenza A haemagglutinin produced a glycoprofile containing 
Man9GlcNAc2 as the smallest glycan. 
 
Choi et al. (2003) were able to greatly improve the efficiency of production of the target 
five-mannose, Man5GlcNAc2 glycan, the chassis for hybrid- and complex-type glycan 
Figure 1.12: Comparison of the glycosylation pathway in yeast and humans. The initial stages of glycosylation are 
conserved in the ER lumen where a pre-synthesised high-mannose glycan is transferred onto an asparagine in the 
sequence Asn-X-Ser/Thr (where X is any amino acid except proline) of the nascent polypeptide. The glycan that 
leaves the ER consists of eight mannose units and two N-acetylglucosamine units (Man8GlcNAc2). In the golgi of 
yeast the gene product of OCH1, a mannosyltransferase, catalyses the transfer of a single mannose onto the 
eight-mannose glycan to form Man9GlcNAc2. This is the substrate for further mannosylation. In humans, 
however, the eight-mannose glycan that leaves the ER is cut back by mannosidase I to a five-mannose glycan, 
Man5GlcNAc2, and this is then extended by the sequential action of multiple monosaccharide transferases to 
produce complex-type glycans terminating in sialic acid, Sia2Gal2GlcNAc2Man3GlcNAc2. For simplicity only 
diantennary complex-type glycans are shown here, however, one to two additional antennae can be generated 





formation, by utilising the Δoch1 deletion together with expression of the Caenorhabditis 
elegans ManI enzyme. This strain was able to produce the Man5GlcNAc2 structure with high 
efficiency, >75% (Choi et al., 2003). Choi et al. (2003) then took this a step further.  They 
expressed H. sapiens GnTI, fused with a yeast golgi localisation domain, together with a 
UDP-GlcNAc transporter from Kluyveromyces lactis, which transports the GnTI substrate, 
UDP-GlcNAc, across the golgi membrane from the cytoplasm in which it is synthesised, to 
generate GlcNAc1Man5GlcNAc2. Although yields were low, this was the first-time hybrid-
type glycosylation was reported in yeasts. 
 
Using a combinatorial library approach, Hamilton et al. (2003) were the first to report the 
production of a complex-type glycan in yeast. Building upon the strain engineered by Choi 
et al. (2003), Hamilton et al. (2003) sequentially introduced Drosophila melanogaster 
ManII, responsible for converting GlcNAc1Man5GlcNAc2 to GlcNAc1Man3GlcNAc2, followed 
by Rattus norvegicus GnTII which converted the hybrid-type glycan GlcNAc1Man3GlcNAc2 
into the complex-type glycan GlcNAc2Man3GlcNAc2. In both instances, the catalytic domains 
of the two introduced enzymes ManII and GnTII were fused to S. cerevisiae Mnn2 golgi 
transmembrane localisation domains. 
 
In a parallel approach, Vervecken et al. (2004) developed a strain of P. pastoris expressing a 
hybrid-type glycan terminating in galactose, Gal1GlcNAc1Man5GlcNAc2. The key features of 
this study were two-fold. Firstly, Vervecken et al. (2004) were able to create the Δoch1 
strain by simple single homologous recombination between a truncated och1 gene on an 
expression plasmid and the endogenous OCH1 site in the genome. This achievement 
simplified the otherwise laborious task of Δoch1 deletion used previously (Nakayama et al., 
1992, Nakanishi-Shindo et al., 1993 and, Choi et al., 2003) and allowed for the ManI gene to 
be integrated simultaneously with Δoch1 deletion by including the ManI gene on the same 
plasmid as the truncated och1 sequence. This represented the first instance of galactose 
incorporation into glycans biosynthesised in vivo in yeast. 
 
In yet another parallel approach, Bobrowicz et al. (2004) were able to generate a complex-
type glycan terminating in galactose, Gal2GlcNAc2Man3GlcNAc2, in P. pastoris. This study 
differed from previous studies in two ways. First, unlike previous studies that focused on 
engineering glycosylation in the golgi lumen, this study aimed to block the glycosylation 
pathway at an earlier stage, before OCH1, when the glycan is biosynthesised on the 
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dolichol linker. Bobrowicz et al. (2004) deleted Δalg3 which prevented extension of the 
dolichol-linked Man5GlcNAc2-P-P-Dol glycan. This glycan could then be transferred onto the 
nascent glycoprotein in the ER. Second, building on the work of Choi et al. (2003) and 
Hamilton et al. (2003), Bobrowicz et al. (2004) were able to generate the galactose-
terminal complex-type glycan, Gal2GlcNAc2Man3GlcNAc2, by expressing a fusion protein 
construct of the catalytic domains of Schizosaccharomyces pombe UDP-galactose 4-
epimerase and H. sapiens β(1,4)-galactosyltransferase, in a process inspired by Chen et al. 
(2000), to the S. cerevisiae Mnn2 golgi membrane-localisation domain. This construct 
allows for the simultaneous production of a pool of UDP-galactose substrate, generated by 
epimerisation of UDP-galactose, and transfer of galactose from this substrate onto the 
nascent GlcNAc2Man3GlcNAc2 glycan. 
 
1.4.2 Glycoengineering of P. pastoris: sialic acid terminal glycans 
 
The final, and arguably the most important, step in humanising the glycosylation pathway 
of P. pastoris was realised by Hamilton et al. (2006) who accomplished the impressive feat 
of introducing five exogenous genes involved in the biosynthesis of CMP-sialic acid, 
transport of CMP-sialic acid into the golgi and transfer of sialic acid onto the nascent glycan 
to form the fully humanised diantennary terminally sialylated glycan 
Sia2Gal2GlcNAc2Man3GlcNAc2 with sialic acid in an α(2,6) linkage (fig. 1.13). Hamilton et al. 
(2006) were also able to consolidate the sialic acid biosynthesis pathway onto a single 
expression plasmid and, by using a combinatorial library optimisation approach, were able 
to achieve 90.5% disialylated and 7.9% monosialylated diantennary complex-type glycans 












1.4.3 P. pastoris glycoengineering technology: GlycoSwitch vs GlycoFi 
 
Jacobs et al. (2009) combined the previous works (Callewaert et al., 2001, Hamilton et al. 
2003, Bobrowicz et al., 2004 and, Vervecken et al., 2004) to generate the licensable 
GlycoSwitch technology. 
 
GlycoSwitch consists of a single starting strain of P. pastoris, called SuperMan 5, that has 
been engineered to contain Δoch1 and T. reesei ManI, in a process similar to that described 
in Vervecken et al. (2004), as well as four vector plasmids encoding H. sapiens GnTI, D. 
melanogaster ManII, R. norvegicus GnTII and the S. pombe UDP-glucose 4-epimerase/ H. 
sapiens GalT fusion construct described by Bobrowicz et al. (2004). 
 
Introduction of this technology into SuperMan 5 yields a humanised galactose terminal 
diantennary complex-type glycan, Gal2GlcNAc2Man3GlcNAc2. Jacobs et al. (2009) report 
that the doubling time of the glycoengineered strain, also expressing recombinant mouse 
interleukin-10, is almost doubled compared to a wild-type strain, 2.4 hours compared to 
4.6 hours, respectively. Although this is a significant increase in doubling time and, 
therefore, could negatively affect protein production yields, it is still less than the 20 – 24 
hour doubling time of CHO cell lines expressing recombinant proteins (Sunstrom et al., 
2000). Thus, demonstrating that glycoengineered P. pastoris still retains an advantageous 
growth rate compared to CHO cells. Therefore, given that P. pastoris is a well-established 
Figure 1.13: Schematic diagram of the steps required to sialylate galactose-terminal complex-type glycans in 
yeast golgi. The pathway is initiated by conversion of uridine diphosphate (UDP)-GlcNAc to N-
acetylmannosamine-6-phosphate (ManNAc-6-P) by UDP-N-acetylglucosamine-2-epimerase/N-
acetylmannosamine kinase (GNE). ManNAc-6-P is converted to sialylate-9-phosphate by N-acetylneuraminate-9-
phosphate synthase (SPS) and then to sialic acid by sialylate-9-phosphate phosphatase (SPP). CMP-sialic acid 
synthase (CSS) catalyses the charging of sialic acid with cytidine monophosphate (CMP) the CMP-sialic acid 
product is transported into the golgi lumen from the cytoplasm by CMP-sialic acid transporter (CST). The 




system used for high-level production of full-length human recombinant FH (Schmidt et al., 
2011, Herbert et al., 2015 and Kerr et al., 2017), it seems that the GlycoSwitch technology 
offers an attractive route for the production of potentially therapeutic human recombinant 
FH with humanised glycosylation. 
 
The in vivo sialylation technology developed by Hamilton et al. (2006) as part of GlycoFi Inc. 
was sold to Merck-Serono in 2008 (Roumeliotis, 2008). This technology relies upon the 
GlycoSwitch technology to achieve terminal galactosylated complex-type glycans in vivo 
and then builds upon this glycan species by the addition of sialic acid. However, Merck-
Serono’s ownership of this technology, and their restricted offerings of licenses for its use, 
has hampered the academic research community in applying this technology for the 
production of recombinant glycoproteins with humanised glycosylation in P. pastoris.  This 
does not preclude the replication of this technology in vivo for research purposes.  An 
alternative is to purchase a license for GlycoSwitch to humanise the glycosylation as far as 
terminal galactose in vivo followed by enzyme-catalysed sialylation of recombinant 
humanised glycoproteins in vitro.  
 
The current study focused on implementing the GlycoSwitch technology to develop a 
galactose-terminal glycan in vivo. Once this was achieved the next step was an attempt to 
implement in vivo sialylation, modelling the method on the GlycoFi technology. Ancillary to 
this, in vitro sialylation of purified recombinant FH carrying terminally galactosylated 
glycans was performed with a recombinant sialyltransferase. 
 
1.5 Glycobiology toolkit 
 
Glycans are a diverse group of carbohydrate molecules. As yet, no single method exists for 
complete characterisation of glycans and therefore a repertoire of techniques must be 
employed in order to acquire information on the type of glycosylation (N- or O-linked, high-
mannose, hybrid- or complex-type), the monosaccharide composition, the nature of the 
glycosidic linkages, etc. Detailed below are the key techniques used in this study for the 
analysis and characterisation of glycans. 
 




Glycosidases are a group of enzymes that catalyse the hydrolysis of O-glycosidic bonds. This 
group can be divided into two categories: 1) glycosidases that cleave glycosidic bonds at 
the terminus of a polysaccharide chain – exoglycosidases – and 2) those that cleave 
glycosidic bonds from within a polysaccharide chain – endoglycosidases. 
 
The enzymes most frequently used as tools in glycobiology, Endoglycosidase H (endo H) 
and Peptide-N-glycosidase F (PNGase F), cleave different types of bond and have different 
substrate specificities. Endo H is an endoglycosidase that cleaves the glycosidic linkage 
between the two GlcNAc of the chitobiose core of N-linked glycans (fig. 1.14). In contrast, 
PNGase F cleaves the glycopeptide linkage between the reducing terminal chitobiose core 
GlcNAc and the N-linked asparagine residue on the polypeptide chain; in other words, 
PNGase F is an amidase but, like endo H, it liberates N-linked glycans from glycoproteins 
(fig. 1.13). 
 
PNGase F can cleave all major types of N-linked glycan (Tretter et al., 1991), except for 
those with an α-1,3-fucose linked to the chitobiose core. 
Conversely, Endo H has a narrower substrate specificity in that it can cleave only high-



























Figure 1.14: Schematic diagram showing the substrate specificities of the endoglycosidases Endoglycosidase H (endo 
H) and Peptide-N-glycosidase F (PNGase F) toward high-mannose (left) and complex-type (right) glycans. Also shown 
are the glycan-binding specificities of the lectins Erythrina cristagalli (ECL, blue crescent), Sambucus nigra (SNA, red 
indented triangle) and, Concanavalin A (Con A, purple triangles joined point to point). ASN – asparagine residue linked 
to N-linked glycan at the reducing terminus. The α-linked mannose of the trimannosyl-core are labelled (however, 





1.5.2 Lectins – carbohydrate binding proteins 
 
Lectins are a group of carbohydrate-binding proteins that exhibit extraordinary specificity 
for their intended target. For example, Sambucus nigra lectin (SNA) will bind preferentially 
to N-acetylneuraminic acid (Neu5Ac) in an α(2,6)-glycosidic linkage with galactose (Gal) 
compared to Neu5Ac α(2,3)-Gal. SNA can weakly bind to free Gal but not to free Neu5Ac 
(Shibuya et al., 1987), indicating that the glycosidic linkage is an essential part of SNA 
recognition. 
 
In this thesis, three lectins were used for western blot and ELISA to detect specific glycan 
moieties. The lectins used were (fig. 1.14):   
(i) SNA (see above). 
(ii) Erythrina cristagalli lectin (ECL) – binds strongly to the disaccharide N-
acetyllactosamine (LacNAc) (Iglesias et al., 1982) (providing it is not sialylated) 
that is a key component of the antennae of most complex mammalian glycans 
(Debray et al., 1986), therefore ECL binds epitopes on the terminus of the 
glycan.  
(iii) Concanavalin A (ConA) – binds to α-mannose (as well as α-glucose) (Goldstein 
et al., 1973) when it is situated within the trimannosyl-core common to all N-
linked glycans. Additionally, Goldstein et al., (1973) found that ConA can bind 
to its epitope regardless of whether it is at the glycan terminus or buried within 
the glycan chain. 
 
Throughout this study, ConA was used to detect for the presence of a glycan, irrespective 
of the glycan type (e.g. high-mannose, complex-type, etc). SNA was used to detect for the 
presence of sialic acid (specifically Neu5Ac). Finally, ECL was used to detect the presence of 
LacNAc. In general, lectins have served as an important part of the glycan-analysis toolkit to 







1.5.3 BlotGlyco glycan purification and MALDI-TOF mass spectrometry 
 
A significant obstacle in whole glycan characterisation is that a lengthy purification 
processes must be employed to achieve the clean, highly pure glycan samples required for 
glycan analysis (Pilobello and Mahal, 2007). Sialic acids present an additional limitation in 
whole-glycan characterisation due to the presence of the C1 COO- group. This group 
contributes to the inherent instability of the sialic acid α-glycosidic linkage, often resulting 
in loss of sialic acid during the harsh ionisation conditions used in matrix-assisted laser-
desorption ionisation (MALDI) and, even, during electrospray ionisation (ESI). In addition to 
this, both positive and negative ions form, resulting in splitting of mass signals. Moreover, 
partial alkali salt formation can interfere with the mass spectrum profile, often leading to 
complex spectra that are difficult to decipher (Powell and Harvey, 1996). The negatively 
charged sialic acids also interfere with analysis by high performance liquid chromatography 
(HPLC). The distinct chemistry of sialic acids, compared to the other neutral 
monosaccharides that make up complex-type glycans, often results in the requirement for 
multiple HPLC steps. 
 
BlotGlyco is a hydrazide-functionalised solid-support resin technology platform that 
overcomes these limitations in whole-glycan characterisation (fig. 1.15). BlotGlyco 
covalently fixes glycans with a free reducing terminus to the hydrazide-support resin by 
facilitating, under mild acidic conditions, the formation of a Schiff base hydrozone bond 
between the carbonyl oxygen of the reducing terminal monosaccharide and the hydrazide 
group (fig. 1.15 B). This process is highly specific for glycans and, because the reducing 
terminus is common to all free glycans, is non-discriminatory (Furukawa et al., 2008).  
Glycans can then be simultaneously released and tagged by transamination, substituting 
the resin for an appropriate tag via an oxime or hydrozone bond. 
 
The procedure to purify and tag glycans for analysis takes six hours, compared to 2-3 days 
for standard procedures, and in addition, the functionalised resin has a very high hydrazide 
density of ~460 µmol/mL (Furukawa et al., 2008). Therefore, whole-glycome analysis can 








In addition to this, BlotGlyco utilises a solid-phase esterification procedure for methyl 
esterification of sialic acid COO-, forming the neutral group COOCH3. This process 
eliminates the need for use of toxic, halogenated solvents to achieve the same end, 
neutralises the positively charged sialic acids, and reduces the lability of the sialic acid 
glycosidic linkage (Miura et al., 2007) thus enabling analysis of sialylated glycans by MALDI 
time of flight (TOF) mass spectrometry and single step HPLC analysis. 
Figure 1.15: A) Schematic diagram of the steps involved in BlotGlyco glycan purification. The sample can be pure 
protein or a crude mixture e.g. cell culture media. The sample is enzymatically deglycosylated before applying to 
the BlotGlyco resin. Glycans are selectively extracted from the sample by covalent linkage to the resin by 
hydrozone bond formation in mild acidic conditions. The glycan-associated resin is then subjected to multiple, 
exhaustive wash steps to remove non-covalently associated impurities. Methyl esterification is carried out in 
solid phase to neutralise the COO- group on sialylated glycans and the glycan is then released by hydrozone-to-
hydrozone or hydrozone-to-oxime transamination substitution. The released, tagged glycans are now pure 
enough for analysis by a method of choice. Image taken and adapted from Terashima et al. (2014). B) Reaction 
mechanism of the covalent attachment of carbohydrates to BlotGlyco resin by the formation of a hydrazone 
bond. C) Glycans are released from BlotGlyco beads by a hydrozone-to-oxime transamination substitution 
reaction in the presence of aoWR tag. AoWR tagged glycans are then washed off the beads and collect for 
analysis by MALDI-TOF MS. Glucose is shown here as an example, but any glycan with a free reducing terminus, 




BlotGlyco was used throughout this study to purify whole glycans enzymatically cleaved 
from both purified samples of different glycoforms of FH and in the purification of glycans 
from crude P. pastoris culture media. Shinohara et al. (2004) found that guanidino and 
hydrophobic functional groups on tags used to derivatise glycans greatly improved the 
ionisation potential. Building upon this Uematsu et al. (2005) developed the dipeptide tag 
aminooxy-tryptophanylarginine (aoWR). This tag was used to release BlotGlyco captured 
glycans for efficient, highly sensitive qualification of glycan mass and structure by MALDI-
TOF mass spectrometry. 
 
1.6 inABLE: Multipart DNA assembly technique 
 
As well as the more traditional DNA assembly techniques, e.g. cloning, a multipart DNA 
assembly technique called inABLE was used throughout this present work to assemble 
individual DNA sequences into a single contiguous sequence. A detailed description of the 
inABLE procedure is given below, as well as a more complex “nested” inABLE assembly 
approach. 
 
1.6.1 The inABLE procedure 
 
inABLE is a proprietary ‘onepot’ DNA assembly technology (Che et al., 2010). inABLE allows 
for the highly specific assembly of multiple DNA ‘parts’ to create a single, much larger DNA 
sequence. This process is useful in joining upwards of two sequences for a range of 
purposes, such as, inserting a gene sequence into an expression vector or creating multi-
gene operons on a single DNA plasmid. 
 
inABLE works by taking each part and dividing it into three double-stranded segments. 
These are, in order of 5’ to 3’, i) Linker Oligonucleotide (LO), ii) Part Oligonucleotide (PO) 
and iii) Truncated Part (TP). All LOs have the same overhang triplet sequence at the 5’-end 
of each sense-strand and the complementary triplet sequence is on the 5’-end of the TP 
anti-sense strand. This would allow for any TP to be ligated to any LO. 
The assembly specificity is provided by the triplet sequence on the 5’-end of the TP sense 
strand and its complement on the 5’-end of the anti-sense strand of the TP associated PO. 
Thus, only specific TPs can be associated with specific POs. 
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Each associated PO and LO have long, (~16 bp), complementary overhangs that facilitate 
the association of two or more different parts by complementary base pairing followed by 
ligation. 
 
As an example (fig. 1.16), a two-part assembly consisting of a gene – part A – and a 
backbone vector plasmid – part B – would be assembled such that the PO of part A (PO_A) 
is attached to the 5’-end and the LO of part B (LO_B) attached to the 3’-end of TP_A. For 
part B, PO_B is attached at the 5’-end and LO_A attached to the 3’-end, respectively. These 
two ligations are carried out independently. 
 
The sequences PO_B – TP_B – LO_A and PO_A – TP_A – LO_B are then incubated together 
resulting in ligation of the two parts by complementary base pairing between the 
overhangs of PO_A with LO_A and PO_B with LO_B, respectively. 
 
The long sequence complementarity between associated PO and LO (e.g. PO_A and LO_A) 
offers exquisite specificity in part-part association, whilst the paired triplet sequence on 
LOs and TPs allows for flexibility in part-part associations (e.g. TP_A can be associated with 
either LO_B or LO_C or LO_D, etc). Thus, this allows for the controlled assembly of multiple 














In the original part, placed upstream and downstream of the triplet sequences – either by 
inclusion of the sequence in PCR primers or when the part is synthesised – is the same type 
II S restriction endonuclease (RE) recognition sequence, such that there are two copies of 
this sequence flanking the part in opposite orientation -  or mirror images - of one another. 
Type IIS RE are a group of RE which cleave at a location a defined distance from the DNA 
recognition sequence. 
Each TP, when generated by synthesis or PCR, can be cloned into a backbone plasmid to 
generate a library of TPs. The library of TPs are in a readily useable format for direct ligation 
to the desired PO and LO segments by type IIS RE-mediated excision. 
 
1.6.2 The inABLE procedure: a “nested” approach 
 
A limitation of the inABLE technology is that assembly efficiency decreases as the number 
of parts increases. DNA assemblies of no more than 6-7 parts are feasible by the standard 
inABLE methodology. However, by using a 2-step “nested” approach the assembly 
efficiency limitations are overcome, which allows for many more parts to be used in the 
process. 
Figure 1.16: Schematic diagram of a two-part inABLE assembly. First, gene sequences A and B are segmented in 
silico to give the LO, PO and TP sequences. LO and PO sequences are assembled from single-stranded 
oligonucleotide sequences annealed together and phosphorylated and the TP is constructed either by DNA synthesis 
or PCR. Part-linker fusion reactions are set up to fuse PO_A to TP_A to LO_B and PO_B to TP_B to LO_A. The 
complementary triplet overhangs (red lines) are identical for all DNA parts and allow for any TP to be joined to any 
LO. Part-linker fusion products are placed in a single-pot reaction. Complementary base pairing of LO_A to PO_A and 
LO_B to PO_B results in the joining together of Part A and B as a single contiguous sequence. 
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To use a nine-part assembly as an example (fig. 1.17), in the first step of the “nested” 
approach the nine parts are divided into three groups of three. Each group (comprising 
parts A1-3, B1-3 and C1-3) is assembled independently by the inABLE procedure to form 
three “nested” parts (A, B and C). Crucial to this first step is that the PO (PO_x and its 
complimentary LO_x), associated with parts A1, B1 and C1, contains a type IIS restriction 
site. Crucially a fourth part, a plasmid backbone for selection and amplification in E. coli, is 
introduce that has in its LO the same type IIS-RE site in reverse orientation to the one in the 
“nested” LO of A1, B1 and C1. In the second step of a nested assembly, digestion of 
“nested” parts A, B and C with the type II S RE removes the “nested” LO_x and PO_x and 
creates a three-base pair overhang (triplet sequence) at the 5’ and 3’ ends of “nested” 
parts A, B and C. The resulting truncated “nested” parts A, B and C can now be ligated, 
using DNA ligase, to the true LO and PO associated with part A1, B1, and C1, respectively. 


























The overall goal of the current study was to produce therapeutically useful quantities of 
recombinant human FH with humanised glycosylation in P. pastoris. In endeavouring to 
achieve this principle aim the following objectives were set: 
Figure 1.17: Schematic diagram of a nine part “nested” assembly. The nine parts are divided in to three groups 
(A1-3, B1-3 and C1-3) and assembled into three “nested” parts (A, B and C) in a process identical to that set out 
in figure 1.15 (just assembly of nested part A is shown here), except that the LOs and POs associated with part 
A1, B1 and C1 is swapped for the “nested” LO_x and PO_x. LO_x and PO_x contain type II S restriction 
endonuclease (RE) sites. After assembly of each “nested” part (A, B and C), the nested parts can be digested 
with the type II S RE which create overhangs for the attachment to the original PO and LO associated with parts 
A1, B1 or C1, in a part-linker fusion reaction. This enables association of “nested” part A to B to C as one 
contiguous sequence.  
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(i) The glycosylation profile of human FH must be characterised to verify, or 
otherwise, the sole, detailed study in the literature (Fenaille et al., 2007a) and to 
determine the target glycan for glycoengineering. 
(ii) The GlycoSwitch technology should be introduced, sequentially, into P. pastoris 
and a strain expressing recombinant FH with human-like complex-type diantennary 
digalactosylated glycans (Gal2GlcNAc2Man3GlcNAc2) selected by lectin western blot 
and the glycoprofile validated by MALDI-TOF mass spectrometry. 
(iii) The GlycoSwitch plasmid technology, currently consisting of four genes on four 
plasmids, should be consolidated onto a single expression plasmid, using inABLE 
“nested” assembly approach, in order to make available antibiotic selectable 
markers for in vivo sialylation. 
(iv) Time limitations prevented attempts at in vivo sialylation of glycans on FH. 
However, recombinant FH expressed in glycoengineered P. pastoris was purified 
and sialylated in vitro using the bacterial α(2,6)-sialyltransferase, recombinantly 
expressed in E.coli. 
(v) The functional activity of terminally galactosylated and terminally sialylated 
recombinant FH is to be compared to the well characterised human plasma-derived 
FH and deglycosylated recombinant FH. Analysis will first be conducted in vitro by 
Biacore-based assays, comparing binding affinity of the different glycoforms to C3b 
and C3d and measuring the ability to accelerate the decay of the C3 convertase 
complex C3bBb, and a gel based cofactor activity assay. In vivo analysis will be 
carried out in wild-type mice, to assess half-life in blood circulation, and in cfh-/- 















This chapter used the substrate recognition properties of the endoglycosidases and lectins 
referenced in Chapter 1 section 1.5.1 and MALDI-TOF mass spectrometry to confirm the 
findings of Fenaille et al. (2007a) in terms of the whole-protein glycoprofile of human FH.  
Further, and as discussed in Chapter 1 section 1.2.2, FH may interact with its own sialic 
acids possibly permitting tighter regulation of FH binding to self-surfaces. Therefore, the 
aim of the current work is to explore the role FH sialic acids have in the function of FH. 
 
2.2 Materials and Methods 
 
2.2.1 Purification of human factor H from blood plasma 
 
2.2.1.1 PspCN affinity chromatography 
 
Non-sterile, citrated human blood plasma (TCS Biosciences, PR100-1L) was clotted by the 
addition of 1 M CaCl2 in a 1:20 ratio (CaCl2 solution to plasma) and incubation at 37 °C for 
90 minutes. Coagulated proteins were removed by centrifugation, in a Fiberlite F12-6X500 
LEX fixed angle rotor (ThermoFisher Scientific) in a Sorval Lynx4000 centrifuge 
(ThermoFisher Scientific), at 6000 g for 30 minutes at 4 °C. The supernatant was mixed 1:1 
with buffer (Phosphate buffer saline (PBS), containing 300 mM NaCl and 20 mM EDTA) 
before filter sterilisation through 0.22-μm filters (Nalgene Rapid-flow PES filter units, 
FIL8416). 
Purification was carried out on a Tricorn 5/100 column (GE Healthcare Life Sciences), 
prepared in-house by Dr. Andrew Herbert, containing UltraLink Iodoacetyl resin 
(ThermoFisher Scientific, 53155) modified with PspCN. The column was equilibrated in 20 
mM potassium phosphate buffer, pH 7.0; approximately 400 mL diluted human blood 
plasma, free of clotting factors, was loaded at 5 mL/min onto the PspCN-UltraLink column. 
The column was washed with 7 column volumes (CV) buffer A1 (20 mM potassium 
phosphate buffer, pH 7.0), a 2 CV linear gradient to 50% buffer B (20 mM potassium 
phosphate buffer, 1 M NaCl, pH 7.0) and a 5 CV equilibration into 50% buffer B and 50% 
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buffer A2 (0.1 M glycine, pH 2.5). Fractions were eluted in a 4 CV gradient of 50% - 100% 
buffer A2. 1.5 mL fractions were collected and to each fraction was added a one-tenth 
volume of 1 M Tris buffer, pH 8.0. This process was repeated for a total of four runs. 
 
Aliquots of 2 µL of (i) blood plasma after removal of clotting factors, (ii) column flow 
through ten-times concentrated by centrifugation of 500 μL in 10 kDa molecular weight 
cut-off Pierce Protein Concentrators (PES, 0.5 mL, ThermoFisher Scientific, 88513) at 10,000 
rpm for 5 minutes (Centrifuge 5415R, Eppendorf), and (iii) selected fractions (400 – 445 mL 
(wash fraction) and 510 mL – 541 mL (D11-F8) – elution volume) (fig. 2.1), were each mixed 
with 14 µL SDS-PAGE loading buffer (in duplicate, with and without reducing agent). These 
samples were loaded onto polyacrylamide gels (NuPAGE 4-12% bis-tris, ThermoFisher 
Scientific, NP03222). The gels were run (XCell SureLock Mini-Cell, MOPS buffer, 200 V, 1 
hour) and stained with Coomassie Brilliant Blue G250. 
 
2.2.1.2 Cation exchange chromatography 
 
Based on the chromatogram and the appearance of the gels, appropriate fractions were 
pooled, placed in 10 kDa molecular weight cut-off dialysis tubing (SnakeSkin, ThermoFisher 
Scientific, 88245) and dialysed overnight, at 4 °C, against cation-exchange buffer A (20 mM 
potassium phosphate, pH 7.0), with buffer exchange after 2 hours. Cation-exchange 
chromatography was carried out on a tricorn 5/100 column (GE Healthcare Life Sciences, 
28406410)  pre-packed with Source 15S cation-exchange resin (GE Healthcare Life Sciences, 
17094401), the column was equilibrated in 3 CV buffer A, sample was loaded at 6 mL/min 
and the column was washed with 3 CV buffer A before eluting by a 16 CV linear gradient 
from 0 – 50% buffer B (20 mM potassium phosphate, 1 M NaCl, pH 7.0) and a final high salt 
wash over 1CV from 50% - 100% buffer B. 1 mL Fractions were collected and analysed by 
SDS-PAGE (fig. 2.3 and 2.4)  as before. Appropriate fractions (C9 – D9, 158.8 mL to 170.9 mL 
elution volume) were pooled and placed in 10 kDa molecular weight cut-off dialysis tubing 
(SnakeSkin, ThermoFisher Scientific, 88245) and was dialysed against phosphate buffered 
saline, pH 7.4, at 4 °C, overnight, with buffer exchange after 2 hours. Protein was dispensed 






2.2.2 Human factor H glycan characterisation: Endoglycosidase sensitivity 
 
2.2.2.1 SDS-PAGE and Lectin western blot analysis 
 
For SDS-PAGE and lectin-based western blot analysis, Fetuin (New England Biolabs, 
P6042S), Ribonuclease B (RNase B) (New England Biolabs, P7817S) and plasma-derived 
human (h)FH (prepared in-house) were either left untreated or were deglycosylated with 
endoglycosidase Hf (Endo Hf, a maltose-binding protein-tagged version of endoglycosidase 
H, New England Biolabs, P0703S) or Peptide-N-glycosidase F (New England Biolabs, 
P0704S).  
 
For Endo Hf treatment, 20 µg protein was made up to 10 µL with 1 µL glycoprotein-
denaturing buffer (0.5% (w/v) SDS, 40 mM DTT) and double distilled (dd) H2O, and 
denatured by heating to 100 °C for 10 minutes. After cooling, the reaction was made up to 
20 µL with ddH2O, 2 µL glycobuffer 3 (50 mM sodium acetate, pH 6.0) and 1 µL (1kU) Endo 
Hf. For PNGase F treatment, 20 µg protein was made up to 10 µL with 1 µL glycoprotein-
denaturing buffer ddH2O, and denatured by heating to 100 °C for 10 minutes. After cooling, 
the reaction was made up to 20 µL with ddH2O, 2 µL glycobuffer 2 (50 mM sodium 
phosphate, pH 7.5), 2 µL 10% (v/v) NP40 and 1 µL (500U) PNGase F. For the untreated 
samples, 20 µg protein was made up to 20 µL as with the PNGase F reaction, but 1μL ddH2O 
was added instead of PNGase F. 
After mixing, both treated and untreated samples were incubated overnight (16 hours) at 
37 °C. Then 500 ng (for SDS-PAGE) or 200 ng (for lectin-based western blot) protein was 
loaded onto gels (Bolt 4 – 12% bis-tris plus gels, ThermoFisher Scientific, NW04120BOX), 
and run (Invitrogen Mini Gel Tank, MES buffer, 200 V, 35 minutes). One gel was stained 
using InstantBlue (Expedeon, ISB1-1L) Coomassie stain whilst the rest were subjected to 
three lectin-based western blots to assess binding by the core N-linked glycan binding lectin 
ConA, the sialic acid binding lectin SNA and the galactose binding lectin ECL. 
 
All gels for lectin western blotting are run with three hFH derived glycosylation standards. 
These standards are: i) untreated hFH, terminal sialic acid allows for binding by SNA and is 
therefore a positive control for SNA and ConA ii) hFH desialylated with α(2-3,6,8)-
neuraminidase (New England Biolabs), exposure of galactose allows for binding by ECL and 
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is therefore a positive control for ECL and ConA; and iii) hFH deglycosylated with PNGase F 
(New England Biolabs), acts as a negative control for all three lectin westerns. 
Lectin western blot standards were prepared as follows. For the untreated hFH standard, 
10 µg plasma purified hFH was diluted in ddH2O to a concentration of 91 ng/µL. For the 
desialylated hFH standard, a solution containing 10 µg plasma purified hFH, 10 µL 
glycobuffer 1 (50 mM sodium acetate, 5mM CaCl2, pH 5.5), 500 U α(2-3,6,8)-neuraminidase 
was made up to 110 µL. For the deglycosylated standard, 10 µg plasma purified hFH was 
mixed with 10 µL denaturing buffer and made up to 50 µL with ddH2O. This solution was 
briefly mixed before incubating at 100 °C for 10 mins. The solution was cooled on ice and 
centrifuged briefly before 10 µL each of glycobuffer 2 and 10% NP-40 was added together 
with 5 kU PNGase F. The solution was made up to 110 µL with ddH2O. All standards were 
incubated at 37 °C for 16 hours. 
 
 After gel electrophoresis of samples for lectin western analysis, polyacrylamide gels were 
placed in a western blot transfer stack (iBlot 2 Transfer Stacks, PVDF, mini, ThermoFisher 
Scientific, IB24002) and transferred to the iBlot 2 Dry Blotting System (ThermoFisher 
Scientific). Protein was transferred onto the polyvinylidene fluoride (PVDF) membrane by 
electrophoresis at 25 V for 7 minutes. Membranes were removed and placed in blocking 
buffer (1 x Carbo-Free Blocking Solution, Vector Laboratories, SP-5040), a buffer free of 
carbohydrates that could otherwise cause interference with lectin-glycan binding, and 
incubated at room temperature (20 – 25 °C) for 30 minutes and 40 rpm rocking. For all 
three gels blocking buffer was poured off and replaced by a 20 mL solution of 0.5 µg/mL 
lectin in blocking buffer. The first PVDF membrane was placed in diluted biotinylated lectin 
ConA (Vector Biolaboratories, B-1005) solution, the second in biotinylated lectin SNA 
(Vector Biolaboratories, B-1305) solution and the third in biotinylated lectin ECL (Vector 
Biolaboratories, B-1145) solution. PVDF membranes were incubated in lectin solution at 
room temperature (20 – 25 °C) for 30 minutes and 40 rpm rocking. Lectin solutions were 
poured off and the membranes were washed thrice in TPBS buffer (1% (v/v) tween-20, 10 
mM phosphate buffer, 137 mM NaCl, 2.7 mM KCl, pH 7.4). After washing, membranes were 
placed in a 20 mL solution of Streptavidin-Peroxidase polymer (Ultrasensitive, Sigma-
Aldrich, S2438-250UG) diluted 1:20,000 in blocking buffer and incubated at room 
temperature (20 – 25 °C) for 30 minutes and 40 rpm rocking. Diluted Streptavidin-
Peroxidase polymer solution was poured off and membranes were washed thrice as 
before. Bands were developed by incubating membranes in a 10 mL volume of metal 
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enhanced DAB (ThermoFisher Scientific, 34065) diluted 1:10 with stable peroxide buffer 
(ThermoFisher Scientific) until bands begin to appear, at room temperature (20 – 25 °C) 
and 40 rpm rocking. The reaction was stopped by dilution with ddH2O, before pouring off 
diluted DAB solution. 
 
2.2.2.2 Whole protein MALDI-TOF mass spectrometry 
 
Whole protein MALDI—TOF mass spectrometry analysis was carried out on hFH, fetuin and 
RNase B and samples were either untreated or deglycosylated with either PNGase F and 
Endo Hf. 2.5 mU PNGase F or 5 mU Endo Hf was added to 48.4 pmol of protein sample. Each 
enzyme-treated sample, together with a sample consisting of 48.4 pmol untreated protein, 
was made up to 7.5 µL with 60% acetonitrile. Samples were then mixed and incubate at 37 
°C for one hour. A 0.5 µL sample was taken and mixed 1:1 with 10 mg/mL sinapinic acid (in 
50% v/v acetonitrile, 0.1% v/v TFA, in H2O).  
Proteins were analysed by MALDI-TOF mass spectrometry by mixing the protein solution 
1:1 with 10 mg/mL sinapinic acid (Sigma-aldrich, D7927-1G) in 1:1 acetonitrile:HPLC grade 
H2O (Fisher Scientific) and 0.1% (v/v) trifluoroacetic acid (Sigma-aldrich)  before spotting 2 
µL onto a MALDI-TOF plate and allowing to air dry. Samples were subjected to MALDI-TOF 
mass spectrometry analysis using an Ultraflex II TOF-TOF mass spectrometer (Bruker 
Daltonics) controlled by the FlexControl 2.0 software package. Spectra were obtained in 
linear positive ion mode using an acceleration voltage of 25 kV. All spectra were the result 
of signal averaging of 2,000 laser shots.  
 
2.2.3 Human factor H glycan characterisation: Monosaccharide composition 
 
2.2.3.1 SDS-PAGE and Lectin western blot analysis 
 
For desialylation of the native protein, human plasma - purified FH was dialysed against 1x 
glycobuffer 1. α(2-3,6,8)-neuraminidase (New England Biolabs, P0720) was combined with 
dialysed plasma-derived pure FH in a ratio of 6.8 kU neuraminidase to 1 mg FH. This 
desialylation reaction was allowed to proceed for 24 hours at 37 °C.  
 
For analysis, 500 ng (for SDS-PAGE) or 200 ng (for lectin-based western blot) were loaded 
onto either 3-8% tris-acetate gel (for SDS-PAGE, Thermofisher, NuPAGE, EA0375) or 4-12% 
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bis-tris gel (for lectin western blot). The 4-12% bis-tris gels were run, protein western 
transfer and stained as before. The molecular weight ladder used for 3-8% tris-acetate gel 
was HiMark pre-stained (Thermofisher, LC5699) and the gel was run at 150 V for 60 
minutes and stained with InstantBlue. 
 
2.2.3.2 Glycan release, purification and analysis by MALDI-TOF mass spectrometry 
 
Glycans were released for purification and analysis by MALDI-TOF mass spectrometry as 
follows. 20 µg hFH was denatured with 1 µL denaturing buffer and heating to 100 °C for 10 
minutes. After cooling the solution was made up to 25 µL with 2.5 µL glycobuffer 2, 2.5 µL 
10% NP-40 and dH2O before adding 550 U PNGase F, mixing and incubating for 
approximately 16 hours at 37 °C. hFH desialylated as above was also deglycosylated in the 
same way. Released glycans were purified using BlotGlyco spin columns (Sumitomo 
Bakelite, BS-45403Z). Crude sample containing released glycans was loaded onto a single 
BlotGlyco spin column, containing hydrazide functionalised resin, before adding 180 µL 2% 
(v/v) acetic acid in acetonitrile and incubating at 80 °C for one hour. Resin conjugated 
glycans were washed extensively with 200 µL each of 2 M guanidine HCL twice, ddH2O 
twice and 1% (v/v) triethylamine in methanol twice. Residual hydrazides were blocked by 
incubating the glycan conjugated resin in 100 µL 10% (v/v) acetic anhydride in methanol at 
room temperature for 30 minutes. The glycan conjugated resin was washed again with 200 
µL each of 10 mM HCl twice, methanol twice and DMSO twice. For hFH samples the sialic 
acids were “protected” by methyl esterification as follows, the glycan conjugated resin was 
incubated in 100 µL solution of 500 mM 3-methyl-1-(p-tolyl)triazene in DMSO at 60 °C for 1 
hour. Followed by washing with 200 µL each of methanol twice and ddH2O twice. 
Enzymatically desialylated hFH was not subjected to the methyl esterification procedure. 
Glycans were released by the addition to the glycan conjugated resin of 20 µL of the 
dipeptide labelling reagent N-α-aminooxyacetyltryptophanylarginine methyl ester (aoWR) 
and 180 µL 2% (v/v) acetic acid in acetonitrile followed by incubation at 60 °C for 1 hour. 
Released and aoWR tagged glycans were collected by addition of 50 µL 10 mM HCl and 
centrifugation of the spin columns (2000 g, 10 seconds). The glycan solution was diluted 
1:20 with acetonitrile and applied to BlotGlyco clean-up columns to remove excess aoWR 
label reagent. Cleaned glycans were eluted from the BlotGlyco clean-up column by the 
addition of 50 µL ddH2O and centrifugation (2000 g, 10 seconds). 
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Glycans were analysed by MALDI-TOF mass spectrometry by mixing the glycan solution 1:3 
with 10 mg/mL super DHB (Sigma-aldrich, 50862-1G-F) in 3:7 acetonitrile and HPLC grade 
H2O (Fisher Scientific) before spotting 2 µL onto a MALDI-TOF plate and allowing to air dry. 
Samples were subjected to MALDI-TOF mass spectrometry analysis using an Ultraflex II 
TOF-TOF mass spectrometer (Bruker Daltonics) controlled by the FlexControl 2.0 software 
package. Spectra were obtained in positive ion mode with reflectron using an acceleration 
voltage of 25 kV, a reflector voltage of 22.6 kV and a pulsed ion extraction of 160 ns. All 
spectra were the result of signal averaging of 10,000 laser shots. Peaks were picked using 
GlycoWorkBench 2 software. 
 
2.2.4 Human factor H glycan characterisation: Role of sialic acids in the function of factor H 
 
2.2.4.1 Purification of desialylated human factor H 
 
Cation-exchange chromatography of desialylated human plasma FH was carried out on a 
Mono S 5/50 GL column (GE Healthcare Life Sciences, 17516801), conditions as before, and 
SDS-PAGE gels run. 1 µg of each fraction was loaded onto the gel, except fraction E6 where 
10 µL of fraction was loaded, in duplicate under reducing and non-reducing conditions. 
 
2.2.4.2 C3b and C3d binding assays 
 
C3b and C3d binding assays were performed using a Biacore T200 instrument at 25 °C. 150 
and 300 RUs C3b and 50 RUs C3d were attached by standard amine coupling to different 
flow cells of a C1 sensor-chip (GE Healthcare Life Sciences), the other available flow cell was 
left blank for background subtraction. 2-fold dilution series of each glycoform of FH (hFH, 
desialylated hFH and deglycosylated recombinant (r) FH) was performed in 10 mM HEPES, 
150 mM NaCl, 0.05% (v/v) surfactant P20 (HBS-P+ buffer, GE Healthcare Life Sciences). 
Glycoform dilutions were injected for 150 s at a flow rate of 30 µL/min followed by a 
dissociation time of 300 s. For each dilution series, a negative control sample containing 
PBS diluted in HBS-P+ buffer was also injected. The sensor-chip was regenerated by three 
injections of 1 M NaCl for 30 s at a flow-rate of 30 µL/min. Data were analysed using the 





2.2.4.3 SPR-based decay acceleration assay 
 
Decay-accelerating activity was measured in a surface plasmon resonance (SPR)-based 
assay performed using a Biacore T200 instrument at 25 °C. 1000 RUs of C3b was attached 
to a single flow-cell of Biacore CM5-sensor chip (GE Healthcare Life Sciences) using 
standard amine coupling. A second flow-cell was left blank for background subtraction. 
C3bBb was assembled on the chip by a 180 s 10 µL/min injection of a solution containing 
500 nM Factor B (CompTech, A135) and 50 nM Factor D (CompTech, A136). The formation 
of the C3 convertase complex C3bBb was monitored (~150 RUs), and then allowed to decay 
naturally, during a dissociation phase lasting 240 s, to observe intrinsic convertase decay. 
Glycoforms of FH, or PBS, were injected for 180 s at a flow-rate of 10 µL/min and a further 
dissociation phase was monitored. The sensor-chip was regenerated between cycles by a 
single 30 s injection of 0.1 M hFH followed by three 30 s injections of 1 M NaCl at a flow 
rate of 10 µL/min.  
 
2.2.4.4 Cofactor assay 
 
The activity of FH as a cofactor for C3b cleavage catalysed by FI was measured by detection 
of C3b 63 and 39 kDa α′-chain proteolytic products following SDS-PAGE. The non-cleaved β-
chain served as an internal control. The 16-μl reaction mixture contained 1.7 μM C3b, 14 
nM factor I (FI) (CompTech, A138), and a range of concentrations (80, 40, 20, 10 nM) of 
each glycoform of FH. The reaction mixture was incubated for 30 min (37°C), then stopped 
by addition of SDS-PAGE loading buffer. The mixture was boiled for 5 minutes and 
subjected to polyacrylamide gel electrophoresis, as before. Densitometry values were 




2.3.1 Purification of human factor H from blood plasma 
 
Because of its role as the principal soluble regulator of the complement system, FH is a 
target for microbial hijack (Zipfel et al., 2002).  By anchoring FH on their surfaces, bacteria 
attempt to protect themselves from C3b deposition and amplification that would otherwise 
lead to clearance or cell killing. The N-terminal region of the choline-binding protein 
(PspCN), from the nasopharyngeal bacterium Streptococcus pneumoniae, binds FH with 
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picomolar affinity (Herbert et al., 2015). This high binding affinity can be exploited to 
capture FH in blood plasma. 
PspCN, when attached to a supporting resin, was used to capture FH from citrated human 
blood plasma in the first of a two-step chromatographic purification process. (fig. 2.1 and 
2.2). In the second “polishing” step, cation-exchange chromatography (fig. 2.3 and 2.4) was 
used to prepare homogenous material. 
 
In the first purification step, approximately 400 mL diluted citrated human blood plasma 
with clotting factors removed (blood serum) was loaded onto a 7.5 mL PspCN-UltraLink 
iodoacetyl resin tricorn column. Protein was eluted and selected peak fractions were 
evaluated for FH content by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (fig. 2.1 and 2.2). This process was repeated 4 times until all 1.6 L diluted 





































































The 40 disulphide bonds in FH cause the protein to have different electrophoretic 
mobilities by SDS-PAGE depending on whether its reduced or not. When not reduced, the 
disulphide bonds compact the polypeptide chain resulting in greater electrophoretic 
Figure 2.1: Chromatogram of the purification of FH from citrated human blood plasma by PspCN affinity 
chromatography. The peak just after 500 mL elution volume contains FH according to analysis using 
SDS-PAGE.  
 
Figure 2.2: SDS-PAGE analysis of PspCN – affinity chromatography fractions corresponding to peaks. Flow-
through and wash fractions were concentrated ten times prior to loading. Fractions were collected in 1.5 mL 
volumes. D11 – F8 corresponds to elution volume of 510 mL to 541 mL on chromatogram (fig. 2.1). Every third 
fraction from D11 – F8 was loaded onto the polyacrylamide gels. 2  μL human blood serum, flow-through, wash 
and collect fractions were added to 14 mL SDS-Buffer and all 16 μL was loaded onto polyacrylamide gels. The 
molecular weight of FH is 155 kDa and molecular weight markers measured in kDa. 
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mobility. When these bonds are reduced, the polypeptide chain is more open resulting in 
reduced electrophoretic mobility. This difference in mobility may be seen by comparing the 
two gels in Figure 2.2.  
 
Based on inspection of the outcome of SDS-PAGE (fig 2.2), fractions E8 to F8 (523.2 – 541.3 
mL), inclusive, were pooled together with a further 67 fractions from five repeated 
chromatographic runs in a 120 mL volume.  
As can be seen from table 2.1, the protein concentration (as measured by Ultraviolet – 
visible light spectroscopy absorbance readings at 280 nm) is 0.446 mg/mL yielding 53.5 mg 
of protein. However, after dialysis of pooled fractions against low-salt buffer and filtration 
through 0.22μm filter the concentration dropped to 0.22 mg/mL whilst the volume 
remained approximately the same, yielding 26.4 mg of protein. 
This difference could be due to human error in the measurement of either concentration or 
it could be that a small molecular weight contaminant that absorbed at 280nm was co-
eluting with FH on the PspCN column and which was subsequently lost after dialysis. 
 
400 mL diluted citrated human blood sera was loaded onto the PspCN column for each of 
the five repeated runs. Approximately the same volume was collected as flow-through and 
45 mL collected as a wash fraction. Although the flow – through and wash fractions loaded 
onto the polyacrylamide gels (fig. 2.2) were ten-times concentrated, there is a significant 
amount of FH in both of these fractions.  
This suggests that the column was overloaded which prevented complete (or near 
complete) depletion of FH from blood sera. Re-applying the flow-through and wash 
fractions to the PspCN column would have increased yields of FH. 
 
Pooled fractions were dialysed against low – salt buffer before being subjected to a second 








After dialysis against cation-buffer A, all 120 mL PspCN purified protein was loaded onto a 
5/100 tricorn column pre – packed with source 15S cation – exchange resin.  
Figure 2.3: Chromatogram of the second and final step in the purification of FH from human blood plasma, 
obtained by cation exchange chromatography. 
Figure 2.4: SDS-PAGE analysis of cation – exchange chromatography peak fractions. Fractions were collected in 
1.5mL volumes. C9 – D9 corresponds to elution volume of 158.8 mL to 170.9 mL on chromatogram (fig. 2.3). 
Every second fraction from C11 – D9 was loaded onto the polyacrylamide gels. 2 μL PspCN chromatography 
pooled fraction (PF), flow-through, wash and collect fractions were added to 14 mL SDS-Buffer and all 16 μL was 


























The chromatogram (fig. 2.4) shows protein eluting at 140 – 185 mL and at this elution 
volume there is a central peak (155 – 175 mL) flanked by two smaller peaks. 
SDS-PAGE analysis of fractions C9 – D9 (158.8 mL – 170.9 mL elution volume) show that FH 
is contained within this large central peak. These thirteen fractions were pooled together 
and dialysed against phosphate – buffered saline and filtered through 0.2 μm filters. The 
UV-Vis absorbance readings for wavelengths 280, 260 and 320 nm were measured and 
protein concentrations predicted (see table 2.1). 
26.4 mg PspCN – column purified protein was loaded onto the cation – exchange column 
which – after a purification run, dialysis and filtration – yielded of 21.7 mg of high purity, 
low DNA contamination (A260/280 nm ratio is approximately 0.6) FH. 
The average circulatory concentration of FH in human blood sera is approximately 200 – 
300 mg/L (Hakobyan et al., 2008 and Sofat et al., 2013). After clotting factor removal but 
before dilution 1:1 in dilution buffer (see 2.1.1 materials and methods), human FH was 
purified from approximately 900 mL human blood sera. 
In this sera there is expected to be 180 – 270 mg of FH. A yield of 21.7 mg FH (table 2.1) 
indicates that just one tenth of the available FH was purified from human blood sera. 
This supports the finding that a significant amount of FH is eluting in the flow – through and 
wash fractions after the PspCN chromatography, as assessed by SDS-PAGE (fig. 2.2).  
Yields of FH for PspCN – column purification could have been improved by reducing load 
volumes or increasing the capacity (resin bed volume) as well as reapplying flow – through 
and wash fractions, containing a significant amount of FH. 
The cation – exchange chromatography purification step had the smallest loss of protein of 
the two purification steps, with 26.4 mg protein in a 120 mL volume applied to the column 
and 21.7 mg protein in a 12 mL volume after elution, dialysis against phosphate – buffered 
saline and filtration (table 2.1). There is no FH in the flow – through and wash fractions (fig. 
2.4) indicating that the column was not overloaded. 
Table 2.1: Table containing protein absorbance readings, concentrations, volumes, protein yields and purity at each 




Reducing the fractions sizes and/or reducing the steepness of the elution gradient could 
have increased the separation of the smaller peaks from the main central peak – 
potentially improving yields of FH slightly.  
 
2.3.2 Human factor H glycan characterisation: Endoglycosidase sensitivity 
 
As previously discussed in Chapter 1 section 1.5.1, endoglycosidases are a group of 
enzymes that cleave glycans attached to proteins within the polysaccharide chain. Due to 
their different substrate specificities the two enzymes, Endo Hf and PNGase F, can be used 
to broadly characterise the glycosylation-type of glycoproteins. 
 
Fenaille et al. (2007a) showed that all of the glycans present on human FH are complex-
type. If this is the case, human FH should be insensitive to glycan cleavage by the high-
mannose and hybrid-type glycan-cleaving enzyme Endo Hf. In contrast, human FH should 
be sensitive to glycan cleavage by PNGase F which can cleave the same glycan-types as 












Bovine pancreas ribonuclease B (RNase B) is a well-studied model mammalian glycoprotein 
with a single N-linked glycosylation site conjugated to a high-mannose glycan (Plummer 
and Hirs, 1964; Plummer et al., 1968 and, Liang et al., 1980). Calf serum fetuin is another 
well-studied mammalian glycoprotein that contains three N-linked, as well as three O-
linked, glycans. In contrast to RNase B, the N-linked glycans conjugated to Fetuin are 
complex-type (Spiro and Bhoyroo, 1974; Baenziger and Fiete, 1979 and, Green et al, 1988). 
These proteins were used as standards in an experiment conducted to confirm the type of 
N-linked glycosylation present on human plasma-derived FH.  
 
Analysis by molecular-weight shift on SDS-PAGE (fig 2.5 A) shows that human FH glycans 
can be removed by PNGase F, but not by Endo Hf. This seems to support the published 
findings that FH has complex-type glycans. However, the sensitivity limit of protein 
detection by Coomassie staining is about 30 ng per band. Therefore, it remains possible 
Figure 2.5: Different glycoproteins were treated with either PNGase F, Endo Hf or were untreated and analysed by A) 
SDS-PAGE, B) concanavalin A lectin western blot and C) whole protein MALDI-TOF mass spectrometry. Values in black 
boxes are peak m/z values. The molecular weight of glycosylated RNase B is 17 kDa, Fetuin 64 kDa and FH 155 kDa. 




that not all of the FH has been deglycosylated by PNGase F. MALDI-TOF mass spectrometry 
(MS) (fig. 2.5 C) is also consistent with glycan cleavage by PNGase F but cannot confirm 
complete deglycosylation due to the broadness of the mass peaks. 
 
Concanavalin A (ConA)-based western blotting, however, is more sensitive than coomasie 
staining for detecting glycosylated proteins (compare the first RNase B lane in SDS-PAGE 
against the same lane in the ConA blot (fig. 2.5 A and B); a band at ~35kDa is visible in the 
ConA blot but not present in SDS-PAGE). The more sensitive ConA western blot thus further 
confirms that FH is exhaustively deglycosylated by PNGase F, but not by Endo Hf.  
 
In contrast, RNase B appears not to be completely deglycosylated by PNGase F given that a 
faint band for glycosylated RNase B remains visible on SDS-PAGE, while a strong band at 
the same molecular weight is present in the lectin-based western blot. This could be 
because the glycosylation site on RNase B is partially obstructed, hindering cleavage by 
PNGase F that cleaves between Asn and the first GlcNAc. Endo Hf, which cleaves between 
the two GlcNAc residues in the chitobiose core, may be less susceptible to hindrance.  
However, in both cases RNase B was denatured prior to deglycosylation – it could be that 
RNase B was more thoroughly denatured in the Endo Hf reaction compared to the PNGase 
F reaction. This would account for the reduced deglycosylation efficiency in the PNGase F 
reaction. An alternative, but unlikely explanation is that, PNGase F displays a reduced 
activity towards glycans with an α(1,3)-fucose linked to the chitobiose core (Tretter et al., 
1991) and that these might be present in RNase B. Plummer and Hirs (1964) report the 
presence of fucose in the glycosylation of RNase C and D. However, Liang et al., (1980) and 
Prien et al, (2009) do not detect fucosylation of RNase B glycans.  
 
In contrast to the SDS-PAGE and lectin western analysis, RNase B does not appear to be 
deglycosylated by either PNGase F or Endo Hf when assessed by whole protein MALDI-TOF 
MS (fig. 2.5 C). 
The conditions used in this study for deglycosylation for MALDI-TOF MS were different to 
those used for SDS-PAGE and western blot analysis, however the same conditions for 
MALDI-TOF analysis were used for all three glycoproteins studied – and deglycosylation 
was shown to occur in at least the PNGase F treated FH and Fetuin samples. 
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 Additionally, Fenaille et al., (2007b) were able to show, by MALDI-TOF MS, that the MW of 
RNase B shifts from 14.8 kDa (untreated) to 13.685 and 13.887 kDa when treated with 
PNGase F and Endo H, respectively. 
Fenaille et al., (2007b) used 2’, 4’, 6’ – trihydroxyacetophenone monohydrate (THAP) as a 
MALDI-TOF MS matrix, compared to the sinapinic acid used in this study. Perhaps the 
sinapinic acid favours ionisation of the glycosylated form of RNase B, however this is 
unlikely as the same effect is not see with Fetuin or FH. 
 
Regardless, RNase B deglycosylation with PNGase F and Endo Hf must be repeated to 
include longer incubation times with both enzymes in preparations for western blot and 
MALDI-TOF analysis. 
 
Fetuin has multiple N- and O- linked glycosylation sites and demonstrable glycan 
heterogeneity (Nwosu et al., 2011). This is supported in the current work by the smeared 
appearance of its bands in SDS -PAGE. Additionally, Fetuin migrates as though it had a 
lower molecular weight (MW) on SDS-PAGE than its actual MW (~50 kDa by SDS-PAGE vs its 
calculated MW of 64 kDa). Fetuin is a heavily sialylated glycoprotein (Spiro, 1960) with 
three sialic acid monomers per N-linked glycan (Baenziger and Fiete, 1978; Green et al, 
1988) and at least some of the O-linked glycans terminating in one or more sialic acid 
monomers (Spiro and Bhoyroo, 1974; Windwarder and Altmann, 2014). The additional 
negative charge conferred by the extensive sialylation could enhance the electrophoretic 
mobility of fetuin. Fetuin N-linked glycans are insensitive to enzymatic removal by Endo Hf 
but are however, sensitive to removal by PNGase F, as assessed by molecular weight (MW) 
shift in SDS-PAGE and by whole protein MALDI-TOF MS analysis (fig. 2.5 A and C). This 
supports the literature findings that the N-linked glycans on Fetuin are complex-type. 
 
Taken together, the insensitivity of FH glycans to cleavage by Endo Hf, but sensitivity to 
cleavage by PNGase F, indicate that FH glycans are complex-type mammalian glycans. 
 
Finally, this study demonstrates that the endoglycosidase toolkit can be used to distinguish 






2.3.3 Human factor H glycan characterisation: Monosaccharide composition 
 
Most mammalian complex-type glycans terminate in sialic acid and, indeed, Fenaille et al. 
(2007a) show that human plasma FH glycans are predominantly sialylated. 
As established above, the current work set out to explore the role of sialic acids in the 
function of FH.  First it was important to show that our methodology is able to confirm FH is 
predominantly sialylated and then show that these sialic acids have been removed under 
native, non-denaturing conditions. 
 
Human plasma FH was treated, under native conditions (i.e. not under reducing 
conditions), with α(2-3,6,8)-neuraminidase, an enzyme able to cleave a range of sialic acid 
glycosidic linkages. The removal of sialic acid from native, fully folded human FH was 
assessed by molecular weight-shift on SDS-PAGE, the presence or absence of signals by 
lectin-based western blots and by MALDI-TOF MS of glycans after protein denaturation, 

















































Judged by SDS-PAGE (fig 3.6 A), a slight reduction in MW occurs when native, fully folded 
human FH is treated with the neuraminidase indicating sialic acid removal. In further 
support of sialic acid having been removed, no sialic acid was detected by Sambucus nigra 
lectin (SNA) following treatment of native FH with neuraminidase (fig. 2.6 C). 
Complementary to this, galactose is detected after native FH treatment with 
neuraminidase consistent with removal of sialic acid to expose galactose for binding by 
Erythrina cristagalli lectin (ECL) (fig. 2.6 D).  
 
A) 
B) C) D) 
Figure 2.6: Human plasma-derived FH (hFH) treated with α(2-3,6,8)-neuraminidase (Neur.) under non-denaturing 
conditions and analysed for desialylation by A) SDS-PAGE, B), C) and D) lectin western blot. Concanavalin A (ConA) was 
used in B) to detect for glycans, Sambucus nigra lectin (SNA) was used in C) to detect for terminal sialic acid and 
Erythrina cristagalli lectin (ECL) was used in D) to detect for terminal galactose. Fetuin and human plasma standards 
were desialylated with Neur and deglycosylated with PNGase F under optimal, denatured conditions. MW markers 




In further analysis, human FH and human FH treated with neuraminidase under native 
conditions was subsequently denatured and glycans enzymatically cleaved from FH by 
incubation with PNGase F. Free glycans were purified by “glycoblotting” to a hydrazide 
resin and released with a dipeptide tag at the reducing terminus (reviewed in chapter 1 
section 1.5.2) and analysed by MALDI-TOF MS. This gave a more detailed picture of the 
glycans present on plasma FH (fig 2.7). 
 
MALDI-TOF MS characterisation of glycans released from human plasma FH, using PNGase 
F, showed that, in agreement with the findings of Fenaille et al. (2007a), the predominant 
glycan present has a MW identical to what would be expected for a diantennary 
disialylated glycan, Sia2Gal2GlcNAc2Man3GlcNAc2. The peak with the second highest 
intensity corresponds to the monosialylated diantennary glycan, 
Sia1Gal2GlcNAc2Man3GlcNAc2. Some of the glycans on FH are fucosylated, as can be seen by 
peak masses of 2507.6 and 2813.9 (fig. 2.7 A) which correspond to fucosylated mono- and 
disialylated diantennary complex-type glycans, respectively. And peak masses of 2201.8 
and 2567.6 (fig. 2.7 B) which correspond to fucosylated desialylated di- and triantennary 
complex-type glycans, respectively. Additionally, there are some peaks (e.g. peaks above 























Contrary to the findings of Fenaille et al. (2007a), no triantennary structures could be 
detected amongst the glycans cleaved from human plasma-derived FH (fig. 2.7 A). 
But in contrast, desialylation of human plasma FH glycans yielded detectable quantities of 
triantennary glycans (fig 2.7 B) implying that triantennary species are present on human 
plasma-derived FH. It is possible that some of the unassigned peaks over m/z 3000 in figure 
2.7 A are (mono-, di- and tri -) sialylated triantennary structures and that desialylation 
enriches these structures into a single homogenous non-sialylated triantennary peak in 
Figure 2.7: Glycans isolated and purified from A) human plasma FH and, B) human plasma FH after 








figure 2.7 B. Alternatively, MALDI-TOF mass spectrometry was carried out in positive ion 
mode, the excessive negative charge conferred by sialic acids on trisialylated glycans may 
affect detection of these species in positive mode, desialylation of these species reduces 
the net negative charge facilitating detection in positive ion mode. 
The lack of sialylated glycans assignable to any peaks in the mass spectrum shown in figure 
2.7 B is consistent with near-complete prior desialylation of human plasma FH by α(2-
3,6,8)-neuraminidase.   
 
2.3.4 Production and purification of desialylated human plasma-derived factor H 
 
In order to elucidate the role, if any, of sialic acids in the function of FH, desialylated plasma 
FH must be prepared in a highly purified form. This involves purifying it away from the 
contaminating α(2-3,6,8)-neuraminidase and any free sialic acids. To prepare pure 
desialylated FH, cation-exchange chromatography was performed (figs. 2.8 and 2.9).  The 
ExPASy ProtParam tool predicted the pI of α(2-3,6,8)-neuraminidase to be 5.47. This is well 
below the neutral pH at which cation-exchange chromatography was carried out.  
ExPASy ProtParam pI predicts the pI of FH as 6.12. At pH 7.0 FH the protein must have an 
overall net negative charge. However, FH is known to interact ionically with negatively 
charged sialic acids and sulphated glycosaminoglycans (GAGs) (Meri and Pangburn, 1990 
and, Pangburn et al., 1991) at physiological pH. These sialic acid- and sulphated GAG-
binding regions on FH are likely to be pockets of positive charge within an overall 
electronegative surface at physiological pH. This can be exploited for purification of FH by 
cation-exchange chromatography at pH 7 (Herbert et al., 2006; Schmidt et al., 2008 and, 






























There is no detectable α(2-3,6,8)-neuraminidase in peak fractions D11-E3 (23.14 – 25.14 
mL) or the peak shoulder fraction E6 (23.14 – 25.14 mL and 26.14 – 26.64 mL elution 
volume, respectively) (fig 2.9).  
Approximately 3 mg of human FH desialylated, under native conditions, with α(2-3,6,8)-
neuraminidase was loaded onto the cation-exchange column. 0.5 mL fractions D11 – E2 
(23.14 – 24.64 mL) were shown, by SDS-PAGE analysis (fig. 2.9), to contain high purity FH 
and were measured, by absorbance at 280 nm wavelength, to have the highest protein 
concentration. These fractions were pooled and dialysed against phosphate buffered saline 
to yield approximately 1 milligram of purified desialylated human plasma FH. 
Figure 2.8: Purification of desialylated human plasma FH from α(2-3,6,8)-neuraminidase by cation 
exchange chromatography. 
 
Figure 2.9: SDS-PAGE of peak fractions for the separation of desialylated human plasma-derived FH from 
α(2-3,6,8)-neuraminidase (Neur.) by cation-exchange chromatography on a Mono S 5/50 GL column. 1 μg 
of each fraction, except E6 where 10 μL was used, was made up to 16 μL in SDS loading buffer and all 6μL 
was loaded onto the 4-12% bis-tris polyacrylamide gel. 0.5 mL fractions were collected, D11 – E3 
corresponds to an elution volume of 23.14 – 25.14 mL and E6 to 26.14 – 26.64 mL. The flow-through 
fraction was ten times concentrated in a pierce 10 kDa MW cut-off PES protein concentrator. The MW of 
α(2-3,6,8)-neuraminidase is 43 kDa. MW markers measured in kDa. 
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2.3.5 Human factor H glycan characterisation: Role of sialic acids in the function of factor 
H 
 
The effect of sialic acids on the function of FH was assessed, in vitro. First, surface plasmon 
resonance (SPR)-based assays were used to measure the affinity of FH for the protein 
ligands C3b and C3d (C3d is a proteolytic cleavage product of C3b corresponding to its 
thioester domain), and to assess the decay-acceleration activity of FH on the C3-convertase 
complex, C3bBb. Second, the ability of FH to recruit Factor I (FI) for cleavage of the α’-chain 
of C3b was assessed using an SDS-PAGE-based cofactor assay. 
 
Deglycosylated rFH (made in Pichia pastoris) was used as a control in these experiments. 
This protein has been well characterised in regard to its C3b and C3d binding, its decay 
acceleration and its cofactor activity (Schmidt et al., 2011 and, Kerr et al., 2017). 
 
The C3b/d-binding affinity measurements were conducted by immobilising, by amine 
coupling, 150 and 300 RUs C3b and 50 RUs C3d to three flow cells of a C1 sensor-chip. A 
fourth flow cell was used as a blank. Binding of each concentration of a serial dilution series 
(1 in 2) of three glycoforms of FH (sialylated (i.e. native, untreated) and enzymatically 
desialylated human plasma-derived FH (see section 2.2.4) and, enzymatically 
deglycosylated human rFH expressed in Pichia pastoris) was measured, in duplicate. 
 
The interaction between the three different glycoforms of FH and C3b was investigated (fig. 
2.10). Duplicates of each glycoform at each concentration were performed, but the second 
of each duplicate was omitted from the sensograms for clarity. The sensorgrams are 















A second C3b binding experiment, to 150 RUs C3b, was also conducted (sensograms and 














Figure 2.10: C3b binding assays. C3b was immobilised on a Biacore sensor chip surface (inset). Sensograms (A), B) and 
C)) and affinity curves (D), E) and F) ) of plasma FH ( A) and D) ), desialylated plasma FH (B) and E) ) and recombinant 
deglycosylated FH variant VYE (C) and F) ) binding to 300 RUs of C3b. Sensograms were generated from duplicate 
injections of eight concentrations of each glycoform of FH and a blank for 150 s at 30 μL/min followed by dissociation 
for 360 s. Sensograms were reference and blank subtracted and 1:1 steady state kinetic model was fitted to 
sensograms to generate the affinity curves. Sia-FH is human plasma FH, DES-FH is desialylated human plasma FH and 
VYE-rFH is deglycosylated recombinant FH variant VYE. 
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Next the interaction between the three different glycoforms of FH and C3d, a breakdown 
product of C3b that remains surface bound after degradation of C3b, was investigated (fig. 
2.11). Duplicates of each glycoform at each concentration were performed, but the second 
of each duplicate was omitted from the sensorgrams for clarity. The sensorgrams are 














Figure 2.11: C3d binding assays. C3d was immobilised on a Biacore sensor chip surface (inset). Sensorgrams (A), B) 
and C)) and affinity curves (D), E) and F) ) of plasma FH (A) and D) ), desialylated plasma FH (B) and E) ) and 
recombinant deglycosylated FH variant VYE (C) and F) ) binding to 50 RUs of C3d. Sensograms were generated from 
duplicate injections of eight concentrations of each glycoform of FH and a blank 150 s at 30 μL/min followed by 
dissociation for 360 s.  Sensograms were reference and blank subtracted and 1:1 steady state kinetic model was fitted 
to sensorgrams to generate the affinity curves. Sia-FH is human plasma FH, DES-FH is desialylated human plasma FH 




Duplicate concentrations of FH glycoforms were assessed for binding to C3b (at 150 RUs 
and 300 RUs C3b) and C3d (50 RUs) to obtain steady state sensorgrams. The steady state 
sensorgrams were used to calculate the affinity of the three different glycoforms of FH for 
C3b and C3d. The affinities were calculated by fitting the steady-state sensorgrams to a 
simple 1:1 interaction model. The calculated affinities (dissociation constant, KD), 
theoretical maximum response (Rmax) and chi-squared (χ2) values are displayed in table 2.2.  
 
No parameters could be fitted for the very weak binding of plasma-derived FH and 
desialylated FH for C3d. Sialylated FH and deglycosylated rFH both have similar KD values of 
about 0.7 μM for binding to C3b, whilst desialylated FH has a slightly higher KD value of 
about 1 μM (Table 2.2). The slightly weaker affinity of desialylated FH, compared to 
sialylated FH, suggests that the negatively charged sialic acids on FH may play a small role 
in facilitating the interaction of FH with C3b, but these differences are small and it is hard 
to draw many conclusions regarding the relative affinities of these molecules. The similarity 
in KD values for human plasma-derived (sialylated) and deglycosylated human rFH is 
surprising given that previous comparison of these two glycoforms in the literature 
(Schmidt et al., 2011 and, Kerr et al., 2017) consistently shows deglycosylated rFH having a 
lower KD compared to human plasma-derived FH. For example, Schmidt et al. (2011) 
measured a KD of human plasma-derived FH and deglycosylated rFH for C3b binding to be 
2.9 and 1.4 μM, respectively. Similarly, Kerr et al. (2017) KD values for C3b binding by 
human plasma-derived FH were measured to be 0.33 μM and two isoforms of 
deglycosylated rFH (I62 and V62) were measured to be 0.21 and 0.27 μM, respectively.  
 
The presence in the FH N-glycans of sialic acids could influence interactions between FH 
and C3b in two ways. The sialic acids might interact directly with C3b, possibly by ionic 
interactions. Another possibility is that electrostatic repulsion between sialic acids (and 
other negatively charged sites on the molecule), or favourable intramolecular interactions 
between sialic acids and sialic acid-binding sites such as found in CCP 7 and CCP 20, limit 
Sample KD (µM) SE KD Rmax (RU) χ
2 (RU2) Offset (RU) KD (µM) SE KD Rmax (RU) χ
2 (RU2) Offset (RU) KD (µM) SE KD Rmax (RU) χ
2 (RU2) Offset (RU)
Plasma FH 0.67 0.035 51.43 0.309 2.34 0.65 0.041 97.31 1.63 5.71
Desialyl-FH 0.97 0.057 66.67 0.461 3.02 0.86 0.063 117.00 2.51 7.36
Deglycolyl-rFH 0.72 0.048 76.46 1.040 3.70 0.65 0.046 135.00 4.08 9.27 2.54 0.16 80.46 0.144 0.27
150RUs C3b 300RUs C3b 50RUs C3d
Table 2.2: Summary of the parameters fitted for the SPR-based binding studies of three different glycoforms of FH to the 
ligands C3b and C3d. Binding to 150 RUs and 300 RUs of C3b and, 50 RUs of C3d was measured. The three glycoforms of 
FH are plasma derived (sialylated) human FH, enzymatically desialylated plasma derived human FH and enzymatically 
deglycosylated recombinant human FH. SE = standard error. 
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the conformational freedom of FH, potentially holding the molecular in a conformation 
primed for C3b-binding.  
 
If the latter possibility were the case then it would be expected that removal of the entire 
glycan chain (including the sialic acids) from FH would have a similar effect to removing just 
the sialic acids – i.e. an improvement in affinity of FH for C3b. But, in the present study no 
marked improvement in C3b-binding affinity was observed.   
 
Deglycosylated rFH and desialylated human plasma-derived FH both have higher Rmax 
values than (sialylated) human plasma-derived FH (Table 2.2). The relative difference in 
Rmax values of these glycoforms of FH is consistent across the two loadings of C3b. In 
addition, the χ2 values are less than 10% of Rmax indicating an acceptable fit of the data to a 
1:1 steady state kinetics. 
 
Neither sialylated or desialylated plasma FH bind C3d strongly enough to give a reliable KD. 
Conversely, deglycosylated recombinant FH does bind C3d relatively well, with a Rmax of 
80.46 and a calculated KD of 2.5 M. This is in good agreement with findings in the 
literature, for example Kerr et al. (2017) also reported binding of human plasma-derived FH 
to C3d to be too weak to measure, and that two isoforms of deglycosylated rFH (I62 and 
V62) bind C3d appreciably (KD values of 1.8 and 2.1 μM, respectively).  
 
Fitting of the sensograms curves allows estimation of Rmax values. This is a measure of the 
maximum amount of FH resident on the chip surface per unit area when all binding sites 
are occupied – approximately 1 RU corresponds to 1 pg mm-2 (Stenberg et al, 1991). In 
table 2.2 it can be seen that sialylated human plasma FH has the lowest Rmax value, 
deglycosylated recombinant FH has the highest and desialylated human plasma FH has an 
intermediate Rmax and that this relationship is consistent across the two loadings of C3b 
(150 and 300 RUs). The predicted value of Rmax is dependent on multiple considerations: i) 
the number of ligand molecules (C3b/d) per unit area immobilised on the chip surface, ii) 
the MW of the analyte (FH) and the iii) stoichiometry of the complex. Of these three 
considerations, the amount of C3b/d loaded is consistent for all glycoforms and the 
different MWs of the each glycoform of FH (the analyte) was taken into account when 
fitting the 1:1 steady state kinetic model. Therefore, the differences in Rmax values indicate 
that these differences are due to stoichiometry and show that more desialylated human 
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plasma FH is binding to the C3b-decorated chip surface, compared to sialylated human 
plasma FH, despite the sialylated material having a higher affinity. In addition, more 
deglycosylated rFH is binding to the chip, then either sialylated or desialylated human 
plasma FH.  
 
As discussed in Chapter 1 section 1.2.2, FH is capable of binding to two primary sites on C3b 
(Schmidt et al., 2008):  i) the N-terminal CCPs 1-4 bind the length of C3b and ii) the C-
terminal CCP 20 binds in the TED domain of C3b (which becomes C3d after proteolytic 
degradation of C3b). 
Additionally, studies where FH was assessed for binding to C3b and C3d, by SPR, in the 
presence and absence of PspCN showed a marked increase in affinity (KD) and Rmax when FH 
was in the presence of PspCN (Herbert et al., 2015 and Kerr et al., 2017). This suggests 
PspCN activates FH facilitating tighter binding and binding to a greater proportion of C3b 
molecules – possibly by permitting initial engagement with C3b at either of the two C3b 
primary binding sites rather than at just one site (followed by a further binding event at the 
other binding site once FH is engaged with C3b). 
C3b is presumed to be in different orientations on the chip surface because the amine 
which tethers a particular C3b molecule to the chip surface is random. 
Therefore, the two primary binding sites on C3b will be differentially exposed. It is 
conceivable that a glycoform of FH that is able to bind to either or both primary binding 
sites might find more molecules of C3b it can interact with compared to a glycoform that 
can only interact with one site. 
The Rmax values indicate that deglycosylated rFH is capable of forming the most FH:C3b 
complexes and that desialylated FH could form more FH:C3b complexes than sialylated 
plasma-derived FH. 
Removal of the glycans from FH may liberate the conformational freedom of the molecule, 
allowing for independent interaction at both primary C3b interaction sites. In addition, 
removal of sialic acids may confer a similar, but less pronounced, increase in 
conformational freedom, perhaps by reducing electrostatic repulsion between sialic acids 
or neighbouring glycans.  
However, considering FH binds to both C3b and the surface to which C3b is attached it is 
not known what electrostatic effect sialic acid removal would have on the interaction of FH 




Next, the ability of the three different glycoforms of FH to accelerate the decay of the 
bimolecular C3-convertase complex, C3bBb, was investigated using an SPR-based decay 
acceleration activity (DAA) assay. In these experiments, 1000 RUs of C3b was immobilised 
on the surface of a CM5 sensor-chip by standard amine coupling. Then the C3bBb, C3-
convertase, complex was generated by the addition of complement factors B (FB) and D 
(FD). Formation of the C3-convertase complex was monitored (~ 150 RUs) and then 
allowed to decay naturally (in the absence of FB and FD) for a short time to observe 
intrinsic convertase decay, prior to addition, in duplicate, of the different glycoforms of FH 
to be tested. Plotting several such experiments on the same graph allowed a direct 
comparison of the dissociation rate of the C3-convertase complex on its own and in the 
presence of the different glycoforms of FH (fig. 2.12). Each glycoform DAA assay was 














C3b was amine coupled to the surface of a CM5 sensor-chip prior to the addition of FB and 
FD (marked on fig 2.12). A rising response occurs over the range of ~20 s – 200 s (fig. 2.12), 
which is consistent with the binding of Factor B to surface immobilised C3b, and the 
subsequent cleavage of Factor B by Factor D to form the C3-convertase complex, C3bBb. An 
Figure 2.12: Sensorgram showing the results of a decay acceleration activity (DAA) assay of various glycoforms of 
FH on the C3-convertase complex, C3bBb. Approximately 1000 RUs C3b was amine coupled to the surface of a 
CM5 sensor-chip, C3bBb was assembled by an injection of 500 nM FB 50 nM FD lasting 180 s. After formation of 
~150 RUs C3bB, the complex was allowed to naturally decay for 240 s followed by the addition of three 
glycoforms of FH, in duplicate, at 10 μL/min for 180 s. Duplicate traces have been omitted for clarity. Sia-FH is 





exponential decline in response units between ~200 s – 450 s represents the natural 
dissociation of the C3bBb complex. At approximately 460 s (marked on fig 2.12), the FH 
samples (20 nM) were injected, resulting in an accelerated decline in RU. This corresponds 






Duplicates of each glycoform were assessed for DAA of C3bBb and decay half-life of the 
C3bBb complex was calculated before and after the addition of each glycoform. Averages 
of each duplicate were taken to find the mean half-life for each glycoform (Table 2.3). 
Changes in half-life were calculated for each sample relative to the initial natural decay of 
the C3bBb complex. Deglycosylated rFH has the highest change with an approximately 2.5-
fold reduction in half-life after the addition of deglycosylated rFH. Desialylated human 
plasma-derived FH has the next highest change, with an approximately 2-fold reduction in 
half-life after the addition of desialylated FH. Human plasma-derived (sialylated) FH has the 
lowest change in half-life, a half-life decay 1.5-fold greater than C3bBb decaying naturally. 
The data suggest that glycans and sialic acid may have a cumulative effect on reducing the 
DAA of FH on the C3-convertase complex C3bBb. Although duplicate samples were in good 
agreement for all glycoforms analysed, inferring a trend from just 6 data points is difficult. 
Therefore, the experiments need to be repeated to validate the findings.  
 
Table 2.3: Calculated half-life (s) for decay of the C3bBb complex before and after the addition of FH. The change in 
half-life was calculated by dividing the mean half-life after the addition of FH by the mean half-life before the 
addition of FH.  








































Finally, the role of sialic acids in the ability of FH to act as a cofactor for Factor I (FI)-
mediated proteolysis of C3b was investigated. Four different concentrations (80, 40, 20 and 
10 nM) of each glycoform of FH were incubated with C3b (1.9 μM) and FI (1.6 nM), and the 
extent of cleavage of the α’-chain of C3b was assessed by SDS-PAGE (fig. 2.12 A). Each 
reaction was carried out as independent duplicates. Image J software densitometry 
function was used to measure density of each band. The β-chain was used as an internal 
standard against which band intensities for the α’-chain, 63 kDa and 39 kDa fragments 
were normalised against. The mean of normalised duplicate band intensities were plotted 























Inspection of the SDS-PAGE gels (fig 2.13 A) shows that, as expected, in the presence of FH, 
FI cleaves the α’-chain of C3b to form two products of molecular weight 63 kDa and 39 kDa 
whilst leaving the β-chain of C3b intact. In the absence of FH the α’-chain is not cleaved by 
FI. Densitometry performed on the gels (fig 2.13 A, B, C and D) indicates that sialylated (i.e. 









Figure 2.13: A) SDS-PAGE of the cofactor assay of three different glycoforms of FH incubated with C3b and Factor I. B) 
Band intensity of the α’-chain, C) band intensity of the 63 kDa chain, D) band intensity of the 39 kDa chain. Band 
intensities were measured using Image J software and normalised against the β-chain in the same lane as the 
measured band. Each sample was run in duplicate (duplicates not shown in A)). Error bars are standard deviation. Sia-
FH is human plasma FH, DES-FH is desialylated human plasma FH, VYE-rFH is deglycosylated recombinant FH variant 




cleavage of the α’-chain to similar extents, while less α’-chain cleavage was obtained when 
using equivalent concentrations of deglycosylated recombinant FH. 
 
These findings contrast with the C3b/d-binding and DAA assays. They suggest the absence 
of sialic acids makes no difference to the cofactor activity of FH. These data further suggest 
that, although not essential for cofactor activity, the presence of the majority of the glycan 




Results in this chapter confirmed findings in the literature (Fenaille et al, 2007a), that the 
N-linked glycosylation on plasma FH is moderately heterogeneous – comprising mainly 
diantennary mono- and disialylated species as well as triantennary species and, in addition 
to being non-fucosylated, these species can also be fucosylated. Nonetheless, all the glycan 
species detected are complex-type and the majority are diantennary disialylated glycans. 
 
However, further work needs to be done to understand the glycosylation of FH. There is 
currently no information on the types of glycosidic linkage between monosaccharides. For 
example, in humans, sialic acid can exist in an α(2,3)- and an α(2,6)- linkage with galactose. 
It is not known whether either or both of these sialic acid linkages are present on FH and 
what effect having either or both has on the function of FH. 
The presence of fucose on FH could also be investigated further. It was previously shown 
that the absence of fucose on the chitobiose core of N-linked antibody glycans improves 
antibody binding to lymphocyte receptors, and therefore, improves the triggering of 
antibody-dependent cytotoxicity (ADCC) (Shields et al., 2002).  In contrast, other 
monosaccharide constituents, such as galactose, were shown to have no effect on 
enhancing ADCC (Shinkawa et al., 2003).  Fenaille et al (2007a) showed that fucosylation is 
not specific to a particular glycan at a particular glycosylation site, but that fucosylation is 
present at low levels on glycans at all eight of the glycosylation sites on FH. This would 
suggest that fucosylation is an optional extra in the glycosylation of the protein. But is it a 
by-product of errors in the glycosylation pathway or does having low levels of fucosylated 
FH confer an advantage in some way? For example, FH was shown to bind human L-
selectin, a member of the sialic acid binding class of lectins, and that this interaction is 
inhibited in the presence of fucoidan (Malhotra et al, 1999), a polysaccharide composed of 
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sulphated fucose. However, Malhotra et al. (1999) showed that the strength of interaction 
was reduced upon desialylation of human FH and, therefore, the interaction is unlikely to 
be fucose dependent. The fact is that there is a sub-population of fucosylated FH molecules 
and it is attractive to speculate that fucosylation has an intended purpose e.g. enrichment 
of FH at a particular surface via binding to a fucose receptor or modulation of activity in a 
similar way to non-fucosylated versus fucosylated antibodies.  
  
FH is expressed in a range of tissue-types including: i) hepatocytes (Morris et al., 1982 and 
Schwaeble et al., 1987), thought to be the major source of plasma FH, ii) blood monocytes 
(Whaley, 1980), iii) skin fibroblasts (Katz and Strunk, 1988), iv) platelets (Devine and Rosse, 
1987), v) endothelial cells (Brooimans et al., 1990) and vi) retinal pigment epithelial cells 
(Chen et al., 2007). This, therefore, raises the question: is the glycosylation profile of FH 
expressed in different tissues the same or different? For example, Ceciliani et al. (2007) 
found that α1-Acid glycoprotein (AGP) has differential glycosylation depending on the cell 
type in which it is expressed. More diantennary and fucosylated structures were present on 
somatic cell expressed AGP compared to mammary gland expressed AGP.  
If the glycosylation of FH expressed in different tissues is different, what effect does this 
have on the function of FH? For example, glycodelin (Gd) is a glycoprotein with four 
reported glycoforms (Gd –A, -F, -C and –S) which have identical protein cores yet markedly 
different glycosylation patterns. Yet, Gd-A and Gd-F inhibit proliferation, supress 
interleukin-2 secretion and induce cell death of Jurkat cells and blood mononuclear cells 
whilst Gd-C and Gd-S exhibit no immunosuppressive effects (Lee et al., 2009). In addition to 
this, Gd-S has been shown to inhibit sperm-zona pellucida binding whilst Gd-A does not 
inhibit this process (Morris et al., 1996). The only difference in these glycoforms is the 
glycosylation profile, therefore the difference in function of these glycoforms is likely due 
to differential glycosylation.  
 
A comparison of the functions of native (sialylated) plasma-derived FH and enzymatically 
desialylated plasma-derived FH suggested that removal of sialic acids from plasma FH 
reduces the binding affinity of FH for C3b. But, adding deglycosylated rFH in to the 
comparison suggested that complete removal of the glycan chains from FH abrogates this 
reduction in C3b affinity. However, the literature consistently shows that deglycosylated 
rFH has a higher affinity for C3b than plasma-derived FH (Schmidt et al., 2011 and, Kerr et 
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al., 2017) and therefore the C3b binding assay conducted here must be repeated for 
validity.  
The C3b binding regions on FH, N-terminal CCPs 1-4 and C-terminal CCPs 19-20, were 
shown to bind to C3b on a CM5 chip and C1 chip with KDs of 14 μM and 3.5 μM and, 10 μM 
and 4.5 μM, respectively (Schmidt et al., 2008). These values are well above the KDs 
reported here and elsewhere in the literature for full length FH (Schmidt et al., 2011 and 
Kerr et al., 2017) but they indicate that the C-terminal region of FH binds with tighter 
affinity than the N-terminal region of FH. 
Additionally, the bacterial FH binding protein PspCN has been shown to significantly 
improve affinity of FH for C3b and to confer affinity of FH for C3d (the TED domain and CCP 
19-20 binding region of C3b) (Herbert et al., 2015 and, Kerr et al. 2017). Cross-linking mass 
spectrometry analysis of FH in the presence and absence of PspCN suggests that a 
conformational change in FH occurs and that this conformational change is attributable to 
the improvement of affinity of FH for C3b and C3d (Herbert et al., 2015) i.e. PspCN bound 
to FH induces a conformational change in FH to expose the previously hidden C-terminal 
C3b (TED domain) binding site on FH which, as alluded to above, has a higher affinity for 
C3b than the N-terminal C3b binding site.  
It is significant that deglycosylated rFH binds to C3d here and in the literature (Schmidt et 
al., 2011 and, Kerr et al. 2017) whilst glycosylated human plasma-derived FH does not. In 
addition, it has been shown here (although this needs repeating for validity) that 
desialylated human FH may bind to C3d. Therefore, this would suggest that sialylated 
human FH is held in a conformation that prevents exposure of the CCP 19-20 C3b binding 
site. Desialylation and, to a greater extent, deglycosylation make the CCP 19-20 binding site 
available for C3b binding in the TED domain thus improving affinity for C3b and C3d. In 
addition, this also accounts for the greater Rmax values for deglycosylated rFH and 
desialylated FH compared to human plasma-derived (sialylated) FH. Exposure of the CCP 
19-20 site on FH by desialylation and deglycosylation allows for binding at two sites on C3b 
(fig. 2.14), therefore a greater proportion of randomly orientated C3b molecules is 









































Figure 2.14: Schematic diagram of the propensity for different glycoforms to form a more open, active conformation 
by exposing the second C3b binding site (CCPs 19-20) for binding with C3b. A) in the absence of self-surface polyanions 
and GAGs, fluid phase FH is predominantly in the latent conformation. In this conformation, the N-terminal CCPs 1-4 
are available to bind fluid phase C3b, albeit with low affinity relative to the second C3b binding site in CCPs 19-20, and 
thus regulate complement in fluid phase. In the presence of self-surface polyanions and C3b on self-surfaces, FH is 
pulled into a more active conformation in which the second, and relatively high affinity, C3b binding site in CCPs 19-20 
is exposed for binding to C3b. Thus, FH with sialylated glycans (i.e. the natural glycosylation state of FH) circulates 
predominantly in the latent conformation and only converts to the more active conformation in the presence of self-
surface polyanions and self-surface associated C3b. The negatively charged sialylated glycans on hFH may provide 
steric hinderance and charge repulsion, thus preventing latent hFH from adopting the active conformation in the 
absence of self-surface polyanions and self-surface associated C3b. B) In the absence of self-surface polyanions, like in 
the SPR C3b binding studies carried out here, removal of sialic acids (DeSia-hFH) may increase the propensity with 
which FH can adopt the active conformation by reducing charge repulsion. C) Removal of glycans altogether appears to 
drastically enhance the ability of FH to form the active conformation in the absence of self-surface polyanions. This 
could be due to removal of the steric clashes and charged repulsion effects conferred by glycans that would otherwise 








DAA assays show that deglycosylated rFH has the highest increase (2.5-fold reduction in 
half-life) in decay acceleration of the C3bBb complex whilst human plasma-derived 
(sialylated) has the lowest (1.5-fold reduction in half-life) and desialylated human plasma-
derived FH is intermediate (2.0-fold reduction in half-life). However, this ties in with the 
idea set out above, that desialylation and deglycosylation may expose the CCP 19-20 C3b 
binding site on FH. The C3b molecules on the chip surface are randomly orientated in the 
DAA assay. If desialylated and deglycosylated FH are able to bind to a second site on C3b, a 
greater proportion of C3bBb complexes are available for desialylated and deglycosylated 
FH mediated decay, compared to human plasma derived (sialylated) FH. This would result 
in a higher change in response and, therefore, a higher apparent change in half-life. 
 
It was shown in this study that removal of sialic acid had no effect on the cofactor activity 
of FH. But, removal of total glycan appears to significantly reduce cofactor activity. In 
contrast to the C3b/d and DAA assays the cofactor assay was carried out in solution. 
Therefore, the limitations conferred by differential orientation of C3b on a sensor chip 
surface do not apply in solution cofactor assays – i.e. the two primary FH binding sites on 
C3b are both available for binding, thus a glycoform of FH able to bind both sites is able to 
do so. Therefore, this could account for the lack of difference seen in cofactor activities of 
human plasma-derived FH and desialylated human plasma derived FH. However, 
deglycosylated rFH shows a reduced cofactor activity compared to the glycosylated human 
plasma-derived FH samples.  
Crystal structures of FI in complex with C3b and “miniFH”, a truncated version of FH 
consisting of the C3b binding N-terminal CCPs 1-4 and the C-terminal CCPs 19-20 joined by 
a linker of 12 glycine residues (Schmidt et al., 2013), show that in this complex FI contacts 
FH in CCPs 2 and 3 (Xue et al., 2017). 
Human FH has 8 N-linked glycosylation sites (Fenaille et al., 2007a) two of which are 
located near to the TED domain binding region of FH, on CCPs 17 and 18. A Third 
glycosylation site is on CCP 9 near to CCPs 6-8, a region on FH implicated in binding to C3b 
at a third site (Schmidt et al., 2008). Additionally, the 5 remaining glycosylation sites are 
located on CCPs 12-15 – a potential “hinge” region of FH (Schmidt et al., 2008). To add to 
this, Aslam and Perkins (2001) were able to show that FH has a bent back structure 
enabling the C3b binding regions of CCP 1-4 and 19-20 to come into close proximity and 
that the bent back structure is potentially facilitated by the long linkers located between 
CCPs in central region of FH (i.e, CCPs 11-14). The reduced cofactor activity of 
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deglycosylated FH, compared to glycosylated human plasma derived FH (both sialylated 
and desialylated) could indicate that the glycosylation may play a role in cofactor activity of 
FH. For example, could the glycans located near the C3b binding sites on FH facilitate 
docking of FI in an optimal orientation or could the glycans located near the hinge region of 
FH stabilise a structure of FH conducive for optimal cofactor activity? 
 
Further work needs to be done on investigating glycosylation and, by extension, the role of 
sialic acids in the function of FH. In the work included here sialylated and enzymatically 
desialylated human FH was compared with deglycosylated rFH. Future work will aim to 
compare the human glycoforms with enzymatically deglycosylated human FH – to ensure a 
comparison of “like with like”. As well as this, further replicates would confirm the validity 
of this work. However, this work also raises more questions which would be worthy of 
answers. For example, in a physiological setting, considering FH is able to interact with 
sialic acids and polyanions and that these structures enhance FH interaction with C3b (Meri 
and Pangburn, 1990), how does differential FH glycosylation effect function on a 
physiological surface and in vivo? And finally, does glycosylation differ between FH 




















Glycoengineering P. pastoris for production of recombinant human factor 




In Chapter 2 it was shown that the predominant glycan species on hFH is N-linked 
diantennary disialylated complex-type, Sia2Gal2GlcNAc2Man3GlcNAc2. This glycoform 
became the target for glycoengineering work on P. pastoris.  
As discussed in Chapter 1 section 1.4, the GlycoSwitch glycoengineered strain, SuperMan 5, 
had been modified by Dr Heather Kerr (in the Barlow group) to co-express CFH and a 
chaperone protein. For the current work, the resulting strain is designated SuperMan 5 
CFH. 
The CFH gene had been cloned into the plasmid pPICZα (fig. 3.1) downstream of the alcohol 
oxidase 1 (AOX1) promoter and S. cerevisiae prepro-α-secretion signal thus enabling 
methanol inducible expression and secretion of rFH.  
Unpublished data showed that co-expression of CFH with the chaperone gene resulted in a 
10-fold increase in protein yield of rFH compared to the 10s of milligram yields reported in 











Figure 3.1: Vector plasmid map of plasmid pPICZα. The CFH gene was cloned into the multiple cloning site (MCS) by 
Dr. Heather Kerr. This placed CFH under the control of the methanol inducible AOX1 promoter (green arrow) and 
downstream and in frame of a sequence encoding the S. cerevisiae prepro-α-secretion signal (orange arrow). Also 
encoded in this plasmid is a gene conferring resistance to the antibiotic zeocin (faint blue arrow), for selection 




This chapter documents the process of using the GlycoSwitch technology in order to modify 
the glycan biosynthetic pathway to produce human galactose-terminated diantennary 
complex-type glycans, Gal2GlcNAc2Man3GlcNAc2. This glycan is two sialic acid residues short 
of the fully humanised complex-type N-linked glycans that predominant on human plasma 
FH.  
 
3.2 Materials and Methods 
 
3.2.1 Large-scale fermentation and purification of recombinant factor H expressed in strain 
SuperMan 5 
 
3.2.1.1 Large-scale fermentation 
 
A single colony was picked from YPD agar and used to inoculate a starter culture of 10 mL 
BMGY in 50 mL conical tube (Falcon). The starter culture was incubated for approximately 
16 hours at 30 °C, 250 rpm shaking and used to inoculate two lots of 1.5 L BMGY media in 5 
L baffled shake flasks. The cultures were left to incubate for approximately 72 hours, 30 °C 
at 200 rpm. The shake flask cultures were used to inoculate a 10 L BioFlow 4500 (New 
Brunswick Scientific) fermenter. Initial culture growth occurred by glycerol-fed batch 
fermentation, expression of rFH was induced by switching to a methanol/glycerol 
continuous feed for four days.  
 
3.2.1.2 Purification of recombinant factor H from large scale P. pastoris fermentation: 
cation exchange chromatography 
 
Culture media was centrifuged initially at low speed, the collected supernatant (8 – 9 L) was 
then clarified by a faster centrifugation (6,000 g, 30 minutes). The clarified supernatant was 
collected and the pellet was discarded. Protease inhibitors EDTA (1% (v/v) of a 500 mM 
stock) and PMSF (0.5% (v/v) from 100 mM stock in isopropanol) were added followed by 
dilution of supernatant with ddH2O (1:5). At 4°C, dilute supernatant was flowed over a 
cation-exchange column (50 mL Toyopearl SP 650 M, Sigma-aldrich, XK 26 column, GE 
Healthcare Life Sciences) using an AKTA Pure sample pump at 30 mL/min. 
After sample loading, the column was washed with 2 CV buffer A (20 mM potassium 
phosphate buffer, pH 6.0) and protein was eluted over a gradient of 0-100% buffer B (20 
mM potassium phosphate buffer, 0.5 M sodium chloride, pH 6.0). 2 mL fractions of wash 
and elution steps were collected in 15 mL conical tubess. 2 µL each of peak, wash and flow-
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through fractions, together with recombinant FH positive control, were mixed with 14 µL 
reducing SDS loading buffer, loaded onto a 4-12% bis-tris polyacrylamide gel and run (200 
V, 1 hour) before staining with Coomassie Brilliant Blue G250. 
 
3.2.1.3 Purification of recombinant factor H from large scale P. pastoris fermentation: anion 
exchange chromatography 
 
Appropriate fractions were pooled, placed in 10 kDa molecular weight cut off dialysis 
tubing (SnakeSkin, ThermoFisher Scientific) and dialysed overnight at 4 °C into anion 
exchange chromatography buffer A (20 mM glycine, 80 mM NaCl, pH 9.5), with a buffer 
exchange after 2 hours dialysis. Anion exchange chromatography was carried out using a 6 
mL Resource Q column (GE Healthcare Life Sciences). At a flow-rate of 6 mL/min, the 
column was equilibrated with 6 CV of buffer A, protein sample was loaded onto the column 
and washed with 5 CV buffer A. Protein was eluted in a linear gradient from 0 - 50 % buffer 
B (20 mM glycine, 1M NaCl, pH 9.5). 2 mL fractions were collected. 2 µL each of peak, wash 
and flow-through fractions, together with recombinant FH positive control, were mixed 
with 14 µL reducing SDS loading buffer, loaded onto a 4 - 12% bis-tris polyacrylamide gel 
and run (200 V, 1 hour) before staining with Coomassie Brilliant Blue G250. Appropriate 
fractions were pooled, placed in 10 kDa molecular weight cut off dialysis tubing and 
dialysed against phosphate buffered saline, pH 7.4, at 4 °C for approximately 16 hours, with 
a buffer exchange after 2 hours dialysis. 
 
3.2.1 Transformation of P. pastoris strain SuperMan 5 with GlycoSwitch plasmids 
 
3.2.1.1 Plasmid amplification in E. coli 
 
In separate transformations, 1 µL of each GlycoSwitch plasmid (Biogrammatics) (fig. 3.6) 
was used to transform electrocompetent E. coli strain TOP10 (One Shot TOP10 Electrocomp 
E. coli, ThermoFisher Scientific, C404050) by electroporation (1.7 kV, 25 µF). Transformed 
cells were recovered in 1 mL SOC media (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose) for 1 hour, 37 °C and 250 rpm 
shaking. Recovered cells were spread plated onto LB agar (1% (w/v) tryptone, 0.5% yeast 
extract, 170 mM NaCl, 1.5% (w/v) agar, pH 7.5) containing the appropriate selection 
antibiotic (pGlycoSwitch-GnTI – no selection, pGlycoSwitch-GalT 50 µg/mL nourseothricin 
(Carbosynth), pGlycoSwitch-ManII 50 µg/mL kanamycin sulphate (ThermoFisher Scientific) 
83 
 
and pGlycoSwitch-GnTII ampicillin 50 µg/mL (ThermoFisher Scientific)) and incubated for 
approximately 16 hours. Clones were picked and used to inoculate 100 mL LB media, 
containing the appropriate antibiotic, in 500 mL baffled shake flasks. Cultures were left to 
incubate for approximately 16 hours at 37 °C, 250 rpm shaking. Cultures were centrifuged 
(3,500 rpm, 20 minutes) and supernatant was discarded. Plasmids were isolated from the 
pelleted cells by Midi prep (Qiagen) standard procedure (Qiagen plasmid purification 
handbook, www.qiagen.com/handbooks).  
 
3.2.1.2 Plasmid linearisation by restriction endonuclease digestion and linear plasmid 
concentration by isopropanol precipitation 
 
Isolated plasmids were linearised using either the restriction endonuclease AvrII (New 
England Biolabs, R0174S) (pGlycoSwitch-GnTI, -GalT and -ManII) or SapI (New England 
Biolabs, R0569) (pGlycoSwitch-GnTII). Briefly, >10 µg plasmid was mixed with 50 µL 
cutsmart buffer (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium 
acetate, 100 µg/mL bovine serum albumin, pH7.9, New England Biolabs), either 50 U AvrII 
or 100 U SapI, and made up to 500 µL with ddH2O before incubating for 16 hours at 37 °C. 
Linearisation was assessed by 1% (w/v) agarose DNA electrophoresis of digested and 
undigested plasmid (data not shown). 
 
Linearised plasmids were concentrated using isopropanol precipitation to yield >2 µg linear 
plasmid. Briefly, sodium acetate was added to linearised DNA to yield a final concentration 
of 0.3 M and pH 5.2. To this, room-temperature isopropanol was added at 0.7 of the 
volume of linear DNA and the solution was mixed by pipetting before centrifugation 
(15,000 g, 30 minutes, 4 °C). The supernatant was removed and the pellet washed with 1.5 
mL 70% (v/v) ethanol in distilled water followed by centrifugation (15,000 g, 15 minutes, 4 
°C). The supernatant was removed and the pellet air dried for 10-20 minutes. The DNA was 
dissolved in ddH2O, in a water bath (40-50°C), prior to transformation. 
 
3.2.1.3 Transformation of P. pastoris strain SuperMan 5 CFH with GlycoSwitch plasmids 
pGlycoSwitch-GnTI and pGlycoSwitch-GalT 
 
P. pastoris SuperMan 5 CFH was made competent according to the methodology of Lin-
Cereghino et al. (2005). Briefly, P. pastoris strain SuperMan 5 CFH was cultured in a 50 mL 
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volume of buffered complex media containing glycerol (BMGY) (1% (w/v) yeast extract, 2% 
(w/v) peptone, 1.34% (w/v) yeast nitrogen base with ammonium sulphate and without 
amino acids, 4x10-5% (w/v) biotin, 1% (v/v) glycerol, 100 mM potassium phosphate buffer, 
pH 6.0) to an optical density at 600 nm wavelength (OD600) of between 0.8 – 1.5. Cells were 
centrifuged (3000 rpm, 5 minutes), the supernatant discarded and the pellet suspended in 
9 mL BEDS solution (3% (v/v) ethylene glycol, 5% (v/v) DMSO, 1 M sorbitol, 10 mM bicine-
NaOH, pH 8.3) and 1 mL 1M DTT, followed by incubating at 30 °C, 250 rpm for 5 minutes. 
Cells were centrifuged as before, supernatant discarded and the pellet was suspended in 1 
mL BEDS solution. 
 
Linearised plasmids pGlycoSwitch-GnTI and -GalT were mixed, by pipetting, in equimolar 
quantities before co-transformation by electroporation (1.5 kV, 25 µF) into P. pastoris 
strain SuperMan 5. Transformed cells were placed into 14 mL round bottom tubes with 1 
mL recovery media (1:1 mixture of BMGY and 2 M sorbitol) before incubating at 30 °C, 250 
rpm for 2 – 3 hours. After transformation, cells were plated onto yeast peptone dextrose 
sorbitol (YPDS) (1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose, 1 M sorbitol, 
2% (w/v) agar) media, prepared according to the method outlined in the “EasySelect Pichia 
Expression Kit” user manual (Invitrogen, manual part number 25-0172, pp 54-58), including 
the antibiotics 300 µg/mL Zeocin (Invitrogen) and 100 µg/mL nourseothricin sulphate. 
Plates were incubated at 30°C for 10 days. Clones were picked and assessed for the 
presence of both pGlycoSwitch plasmids (-GnTI and -GalT) and assessed for the presence of 
the target hybrid, galactose terminal glycan catalysed by the GnTI and GalT gene products. 
A strain identified to produce this hybrid glycan was called HyGal CFH. HyGal CFH was made 
competent by the same procedure outlined above. Colony PCR and hybrid glycan analysis 
methods are detailed below. 
 
3.2.1.4 Transformation of P. pastoris strain HyGal CFH with GlycoSwitch plasmids 
pGlycoSwitch-ManII and pGlycoSwitch-GnTII 
 
The same procedure, detailed in section 3.2.1.3, was used for the co-transformation of 
linearised plasmids pGlycoSwitch-ManII and -GnTII into HyGal CFH, except that 
transformed cells were spread plated onto YPDS agar containing the antibiotic 350 µg/mL 
G418 (ThermoFisher Scientific, 10131035) and 150 µg/mL hygromycin B (Sigma) as well as 
Zeocin and nourseothricin as stated previously. A clone identified to contain all four 
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plasmids, by colony PCR, and shown to biosynthesise the target complex type galactose 
terminal glycan was called SuperGal CFH.  
 
3.2.2 Transformed clone selection by colony polymerase chain reaction (PCR) 
 
Two sets of colony PCR were carried out. The first set of colony PCR was used to identify 
clones of SuperMan 5 CFH, transformed as detailed in section 3.2.1.3, containing 
pGlycoSwitch-GnTI and -GalT. The second set of colony PCRs was used to identify clones of 
HyGal CFH, transformed as detailed in section 3.2.1.4, containing all four GlycoSwitch 
plasmids (-GnTI, -GalT, -ManII and -GnTII). The colony PCR procedure was as follows. 
Colonies of P. pastoris were picked from a fresh transformation plate and were used to 
inoculate 2 mL YPD (YPDS without sorbitol) media containing appropriate antibiotic. 
Inoculated media was incubated at 30 °C, 250 rpm for approximately 16 hours. 1mL of each 
culture was centrifuged (14,000 rpm, 5 minutes) and the supernatant was discarded. The 
remaining 1 mL culture was stored at 4 °C. 5 µL of each cell pellet was suspended in 10 µL 
SPZ buffer (75 U zymolase (Zymo Research), 1.2 M sorbitol, 81 mM sodium phosphate 
buffer, pH 7.5) and incubated at 37 °C for 1 hour. Zymolase was deactivated by heating to 
95 °C for 5 minutes. Samples were diluted with 90 µL ddH2O and then centrifuged (14,000 
rpm for 1 minute). The supernatant, containing crude genomic DNA, was transferred to a 
fresh 1.5 mL tube (Eppendorf) prior to PCR. 2 µL crude genomic DNA was mixed with 5 µL 
OneTaq Quick-Load Master mix (New England Biolabs) and 1.5 µL each of 10 µM forward 
primer and reverse primers (primers used for each colony PCR given below). PCR reactions 
were placed in a thermocycler (Eppendorf Mastercycler nexus X2) and PCR was carried out 
with the following parameters: the annealing temperature for all PCR reactions was 55 °C 
and the extension time used was 60 s per 1 kbp, rounded up to the nearest minute. 




3.i) For (5082): 5’-GAGGAAGCGGCCGCGCTCTTCGCAGGTGCGGTTATTGTTC-3’ 
3.ii) Rev (4048): 5’-CGATGATGGGGAATAGCTCAGCCGAGGGC-3’ 
PCR product size: 364 base pairs (bp) 
 
pGlycoSwitch-GalT 
3.iii) For (5088): 5’-GAGGAATCTAGAGCTCTTCGTAGTTTTGATATTGTGCGGGC-3’ 
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3.iv) Rev (4511): 5’- CAACGTCCCCTGCACGTCTAGGGGTGACC-3’ 
PCR product size: 1024 (bp) 
 
pGlycoSwitch-ManII 
3.v) For (5684): 5’-GGACACAGCTCTATTCACCCACATGATGC-3’ 
3.vi) Rev (5734): 5-TTAGATCTCGAGGCTCTTCGGGCTCAGCTTGAGTGACTGC-3’ 
PCR product size: 2376 (bp) 
 
pGlycoSwitch-GnTII 
3.vii) For (5680): 5’-ACTTTTCCTGGAAGAAGACCACTACTTAGC-3’ 
3.viii) Rev (5721): 5’-GAGGAAGCGGCCGCGCTCTTCGTCTCCCCACCCTCCATTTTTC-3’ 
PCR product size: 534 (bp) 
 
3.2.3 Test expression and selection of glycoengineered strains HyGal CFH and SuperGal CFH 
 
3.2.3.1 Shake-flask growth and expression 
 
Clones identified, by colony PCR, to contain pGlycoSwitch plasmids GnTI, ManII (for HyGal 
CFH), GnTII and Gal (for SuperGal CFH) were cultured in shake flasks and induced to express 
rFH. Colonies were picked and used to inoculate 5 mL BMGY media, containing appropriate 
antibiotics, and incubate overnight at 30 °C, 250 rpm shaking. Cultures were grown until an 
OD600 of between 0.8 – 1.5 was reached. 50 µL cell culture was used to inoculate 25 mL 
fresh BMGY media in 100 mL baffled shake flask, these were incubated at 30 °C, 250 rpm 
for approximately 60 hours. Glycerol stocks were made (200 µL 50 % (v/v) glycerol and 800 
µL cell culture) and stored frozen at -80 °C. Cell cultures were transferred to 50 mL conical 
tubes and centrifuged (1,600 rpm, 20 mins, 4 °C). The supernatants were discarded and the 
pellet suspended in 5 mL induction media BMMY (same as BMGY except glycerol replaced 
with 0.5% (v/v) methanol). Cultures were left to incubate in BMMY for approximately 96 
hours at 16 °C, 250 rpm shaking. Cultures were fed with 50 µL (1% culture volume) 
methanol 24, 48, 72 and 80 hours post-induction. Cultures were transferred to fresh 50 mL 
conical tubes and centrifuged (1,600 rpm, 20 minutes, 4 °C). Supernatant was transferred 
to fresh 50 mL conical tubes and 1% (v/v) 500 mM EDTA and 0.5% 100 mM PMSF was 
added. A 1 mL aliquot of each culture was taken for analysis, detailed below in section 




3.2.3.2 SDS-PAGE and Lectin Western blot 
 
SDS-PAGE and ECL lectin-based western blot were carried out as detailed in Chapter 2 
section 2.2.2.1. Specifically, for analysis of the HyGal CFH colonies, crude culture media, 10 
µL of supernatant was mixed with 40 µL reducing and non-reducing SDS-loading buffer, and 
10 µL of this was loaded onto 4-12% bis-tris polyacrylamide gels. For analysis of SuperGal 
CFH colonies crude culture media, 25 µL of supernatant was mixed with 25 µL of reducing 
and non-reducing SDS-loading buffer and 20 µL of this mix was loaded onto 4-12% bis-tris 
polyacrylamide gels. The reason the volumes used for SDS-PAGE and lectin-based western 
blot are different for HyGal CFH and SuperGal CFH is that the volumes used for HyGal CFH 
did not yield strong bands in either SDS-PAGE or lectin-based western blots, therefore, for 
SuperGal CFH analysis higher volumes of crude supernatant were used. 
Aliquots from the SuperGal colony culture media (after spinning out cells) were run on 
polyacrylamide gels before and after treatment with endo Hf. For endo Hf treatment, endo 
Hf (1 MU/mL) was added to crude culture supernatant at a volumetric ratio of 1:150 and 
incubated overnight at 37 °C 
 
3.2.4 Large-scale fermentation and purification of recombinant factor H expressed in 
glycoengineered strain SuperGal CFH 
 
Large scale fermentation of glycoengineered strain SuperGal CFH was carried out as in 
section 3.2.1.1 and purification by cation exchange chromatography as in section 3.2.1.2, 
except 10 mL fractions were collected, and anion exchange chromatography as in section 
3.2.1.3. However, 1 µL was mixed with reducing and non-reducing SDS loading buffer 
before application to gels for SDS-PAGE analysis of cation and anion exchange 
chromatography eluted fractions (figs. 3.15 and 3.16). 
 
3.2.5 Removal of endogenous yeast-type glycans from recombinant factor H expressed in 
glycoengineered P. pastoris strain SuperGal CFH catalysed by endoglycosidase Hf 
 
3.2.5.1 Endoglycosidase Hf catalysed yeast glycan removal  
 
Recombinant FH expressed and purified in glycoengineered strain SuperGal CFH, see 
section 3.2.4, is glycosylated with yeast glycans as well as the target diantennary, 
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diagalactosylated complex-type glycan, Gal2GlcNAc2Man3GlcNAc2. Yeast glycans were 
enzymatically removed using endo Hf, which has specificity for yeast and hybrid glycans, 
but cannot cleave complex-type glycans. 100 kU of endo Hf (New England Biolabs) was 
mixed with approximately 70 mg of purified recombinant FH expressed in glycoengineered 
strain SuperGal CFH and incubated at 37 °C for 2 hours. 
 
3.2.5.2 Purification of endoglycosidase Hf from recombinant factor H 
 
Endo Hf is tagged with maltose binding protein (MBP) which allows for efficient removal of 
endo Hf by MBP-tagged affinity chromatography. A 1 mL prepacked MBPTrap column (GE 
Healthcare Life Sciences) was equilibrated in 10 CV buffer A (PBS, pH 7.4). The recombinant 
FH endo Hf mix, in PBS, pH 7.4, was applied directly to the column at a flow-rate of 1 
mL/min. Flow-through was collected in 50 mL conical tubes. The column was washed with 
10 CV buffer A and protein was eluted by washing the column in 5 CV of buffer B (10 mM 
maltose in PBS, pH 7.4). 2 µL each of flow-through, wash and peak fractions, together with 
purified recombinant FH before endo Hf treatment and pure endo Hf, were mixed with 14 
µL reducing and non-reducing SDS-loading buffer and applied to 4-12% bis-tris 
polyacrylamide gels and run (200 V, 1 hour). The flow-through and wash fractions 
containing recombinant FH (fig. 3.17) were pooled, placed in 10 kDa molecular weight cut 
off dialysis tubing and dialysed against PBS, pH 7.4. 
 
3.2.6 Glycan release, purification and analysis by MALDI-TOF mass spectrometry of crude 
culture media and purified recombinant factor H 
 
Glycan release, purification and MALDI-TOF mass spectrometry analysis were the same as 
in chapter 2 section 2.2.3.2. However, for HyGal CFH and SuperGal CFH crude culture media 
analysis, 1.5 mL culture media was concentrated in a freeze dryer and the dried contents 
was suspended in 20 µL ddH2O before PNGase F deglycosylation and BlotGlyco glycan 
purification (figs. 3.9 and 3.13).  
 
3.3 Results  
 





Before attempts at glycoengineering using the GlycoSwitch technology, it was first 
important to assess whether the SuperMan 5 strain is capable of producing proteins 
decorated with five-mannose glycan, Man5GlcNAc2, since this lays the foundation for 
further efforts to humanise the glycosylation pathway in P. pastoris. 
 
To do this, recombinant human FH (rFH) was expressed in two strains of P. pastoris that 
were expected to produce two different patterns of glycosylation.  The strain KM71H CFH 
has no modifications to its glycosylation pathway, and therefore should produce what we 
can term wild – type glycosylation. The other strain, SuperMan 5 CFH, as outlined in 
Chapter 1 section 1.4.1, had its glycosylation pathway modified to produce a shortened five 
mannose yeast-type glycan, Man5GlcNAc2. A clone of each strain, taken from a freshly 
streaked YPD agar plate, was cultured in baffled shake flasks and induced to express rFH by 
the method outlined in section 3.2.3.1. Culture media was deglycosylated with PNGase F, 
glycans purified by BlotGlyco glycan purification and analysed by MALDI-TOF mass 
spectrometry as outlined in section 3.2.6 (fig 3.2). 
Figure 3.2: A) Schematic diagram of glycan processing in wild-type P. pastoris strain KM71H (left) and P. pastoris strain 
SuperMan5 (right) that has been glycoengineered to produce a five-mannose glycan by knock-out of the och1 gene 
and expression of the exogenous ManI gene from Trichoderma reesei. MADLI-TOF mass spectrums of glycans released 
and purified from crude supernatant after rFH expression in the P. pastoris strains KM71H CFH (B) and SuperMan5 
CFH (C). The glycan structures used here to annotate m/z peaks are archetypal isoforms thus, the structures 







The mass spectra (fig 3.2) represent the glycans in the extracellular environment that are 
sensitive to cleavage by PNGase F and, therefore, these mass spectra do not represent the 
glycans on exclusively rFH but they represent the entire N-linked extracellular glycome. The 
mass spectra show that there is substantial heterogeneity in the glycosylation of both 
strains. Additionally, both strains appear to incorporate phosphomannose into the 
glycosylation chain. The presence of phosphomannose in protein glycans is an important 
signal for targeting proteins to the lysosome (Sleat et al, 2006). However, why 
phosphomannosylation occurs in the extracellular environment is unknown, it could be the 
remnants of cell lysis during culturing.  
KM71H CFH shows the greater heterogeneity and its glycans tend to be 
hypermannosylated – structures containing upwards of 13 mannoses are present – with no 
particular species of glycan dominating. In comparison, the glycan mass spectrum for 
SuperMan 5 CFH has shifted to the left, relative to the KM71H CFH glycan mass spectrum. 
The glycans are, in general, substantially smaller, with a 10-mannose containing glycan 
being the largest detectable species in SuperMan 5 (the position of the 12- and 13-
mannose glycan species are included in the SuperMan 5 CFH spectrum to allow comparison 
with KM71H CFH however, these species are not detectable, above background levels, in 
the SuperMan 5 CFH spectra). 
A five-mannose glycan species is indeed present in the SuperMan 5 CFH strain and, in 
contrast to KM71H CFH, this appears to be the most abundant species. 
 
These experiments confirmed that that the SuperMan 5 CFH strain produces the five-
mannose glycan as expected. However, SuperMan 5 CFH also produced many other species 
that could not be developed into human glycans. Since the mass spectra in figure 3.2 were 
generated from crude supernatant, they represent the glycoprofile of all glycoconjugates in 
secreted proteins that are releasable by PNGase F. It was decided to purify rFH expressed in 
Superman 5 to analyse the glycoprofile specific to rFH. 
 
3.3.2 SuperMan 5 CFH expression and purification of recombinant factor H 
 
By methods outlined in section 3.2.1, a 10-litre fermentation of SuperMan 5 CFH was 
carried out and rFH was purified in a two-step purification process, cation exchange 
chromatography (fig. 3.3) followed by anion exchange (fig. 3.4) chromatography.  
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The cation exchange chromatography procedure exploits the basic, polyanion interacting 
CCPs (7 and 20) on FH that, at the slightly acidic pH of P. pastoris culture media, are 
positively charged. 10 L of culture supernatant, clarified by centrifugation and diluted 1:5 in 
ddH2O, was applied to a column containing 50 mL strong cation exchange resin (Toyopearl 
SP 650 M, XK 26 column) (fig. 3.3 A). 2 mL fractions were collected and select fractions 











Peak fractions (as shown in figure 3.3) were run on SDS-PAGE to assess purity. Fractions 
C11-D3 (elution volume 150.5 – 158.5 mL) were considered to have the highest 
concentration of rFH and relatively low levels of impurities. 
Figure 3.3: A) Cation-exchange chromatography purification from crude supernatant of rFH expressed in P. pastoris 
strain SuperMan 5. B) SDS-PAGE gel of rFH positive control, wash B10 (124.5 mL), peak fractions C9-D7 (146.5 – 166.5 
mL) and flow-through (FT) fractions. 2 µL of each fraction was mixed with 14 µL reducing SDS loading buffer. MW of 






After pooling the appropriate fractions and dialysis against 20 mM glycine, 80 mM NaCl, pH 
9.5, rFH was subjected to a second purification step by anion-exchange chromatography 
(fig. 3.4) as outlined in section 3.2.1.3. Approximately 25 mL of sample, purified by cation 
exchange chromatography and dialysed as described above, was applied to a column 
containing 6 mL strong anion exchange resin (Source 15Q, Resource Q column) (fig. 3.4 A). 








rFH eluted in a single, broad peak (fig 3.4 A). Fractions B10-C2 (79.4 – 87.4 mL) (fig 3.3 B) 
were pooled and dialysed against PBS, pH7.4. The concentration was measured by UV-VIS 
spectrophotometry to be 2.2 µM, purified rFH was aliquoted into 250 µL aliquots and 
stored frozen at -80 °C. Fraction C4, although having a high concentration of rFH, was not 
Figure 3.4: A) Anion exchange chromatography purification of rFH expressed in P. pastoris strain SuperMan 5. B) 
Reduced SDS-PAGE gel of rFH positive control, wash B3 (65.4 mL) and peak fractions B8-C2 (75.4 – 87.4 mL). 2 µL of 







pooled because it had a relatively high concentration of a cleavage product (a band just 
below the rFH main band at ~150 kDa) that presumably arises from the action of a P. 
pastoris protease. 
 
3.3.3 Characterising the glycosylation of purified recombinant factor H expressed in 
SuperMan 5 CFH 
 
After purification, the N-glycans were released from a 20 µg sample of rFH expressed in 
SuperMan 5 by incubating at 37 °C overnight with 0.5 U PNGase F and analysed by MALDI-

























The glycoprofile is dominated by five-mannose species, Man5GlcNAc2, but shows a degree 
of heterogeneity, with some glycans having 12 mannose residues, Man12GlcNAc2. This 
species is larger than the largest species detected in crude supernatant of SuperMan 5 (fig 
3.1), however, this difference could be due to the purity of the starting material and 
therefore produces less background allowing for detection of less abundant glycan species. 
In contrast to the glycoprofile of SuperMan 5 crude supernatant, there are no 
phosphomannose glycan species present on rFH expressed in this strain.  
Figure 3.5: MADLI-TOF mass spectrum of glycans released and purified from purified rFH expressed in P. pastoris 





The prominence of the five-mannose species, Man5GlcNAc2, suggest that the majority of 
glycans on rFH expressed in SuperMan 5 have the potential to be humanised.  
 
3.3.4 Glycoengineering P. pastoris to produce hybrid-type, galactose-terminated glycans 
 
The GlycoSwitch vector technology (fig 3.6) was then introduced into P. pastoris strain 
SuperMan5 to humanise the glycosylation of P. pastoris. This was achieved by a two-step 
process. In the first-step, the target was to engineer an intermediate, hybrid-type, 
galactose terminal glycan, Gal1GlcNAc1Man5GlcNAc2. To do this the GlycoSwitch vectors 
containing genes encoding GnTI and GalT (in fig. 3.6 A and B) were introduced together in a 
co-transformation procedure. Clones were screened by a combination of colony PCR, SDS-
PAGE and ECL lectin-based western blot to detect for rFH carrying the hybrid-type glycan.  
In the second-step, a clone identified to biosynthesise the intermediate, hybrid-type glycan 
was co-transformed with the final two GlycoSwitch plasmids (fig. 3.6 C and D). These two 
plasmids encode ManII and GnTII which catalyse the conversion of the intermediate, 
hybrid-type glycan, Gal1GlcNAc1Man5GlcNAc2, into a diantennary, digalactosylated 
complex-type glycan, Gal2GlcNAc2Man3GlcNAc2. 
The results for the production of the hybrid-type glycan are described in this section, and 
the results for production of the humanised, galactose terminal glycan are described in the 






















Initially, Jacobs et al. (2009) recommend that each plasmid is introduced sequentially.  In 
this way, selection for the target glycan could be done using lectin western blot, before 
introducing the next plasmid in the sequence.  
 
However, a caveat had to be applied to this process. Both candidates for the first plasmid 
to be introduced, i.e. those encoding N-acetylglucosamine transferase I (GnTI) (fig. 3.6 A) or 
Figure 3.6: GlycoSwitch plasmid maps. Each plasmid was linearised in the GAP promoter prior to transformation into 
P. pastoris. Marked on each plasmid is the restriction endonuclease used to linearise the plasmid. These plasmids 
were introduced pairwise in a two-step procedure. First, pGlycoSwitch-GnTI (A) and -GalT (B) were introduced. Clones 
that were identified to produce a galactose terminal hybrid glycan were then made competent and transformed with 













mannosidase II (ManII) (fig. 3.6 C), fail to produce products (GlcNAc1Man5GlcNAc2 or 
Man3GlcNAc2, respectively) that are distinguishable from the parental 5-mannose glycan, 
Man5GlcNAc2. Therefore, the lectin-based western detection method would not be able to 
report on success or otherwise of this first step. 
 
Therefore, an alternative method was devised in which the first GlycoSwitch plasmid, 
encoding N-acetylglucosamine transferase I, was introduce at the same time into P. 
pastoris SuperMan5 together with the second GlycoSwitch plasmid (co-introduced), 
encoding galactosyltransferase (fig. 3.6 A and B). Thus, the resulting glycan structure 
generated from the sequential action of N-acetylglucosamine transferase I and 
galactosyltransferase would incorporate galactose, a monosaccharide not naturally present 
in yeast glycans. This structure is a hybrid glycan intermediate between a yeast-type and 
human complex-type glycan, Gal1GlcNAc1Man5GlcNAc2. ECL, a lectin that requires galactose 
as a core competent for binding, could then be used in a western blot style assay to detect 
for clones of P. pastoris that had taken up and were expressing the glycosylation genes on 
the co-introduced plasmids. 
 
The second step in the process was to co-introduce the plasmids pGlycoSwitch-ManII and 
pGlycoSwitch-GnTII (fig. 3.6 C and D). Expression of ManII should cut back the two 
mannose residues linked to the α1,6-mannose of the trimannosyl-core of the hybrid-type 
glycan generated in the first step, converting Gal1GlcNAc2Man5GlcNAc2 to 
Gal1GlcNAc1Man3GlcNAc2. Not only does the enzymatic action of ManII generate the 
substrate for attachment of GlcNAc by GnTII, it also renders the glycan insensitive to 
cleavage by the endoglycosidase Endo Hf. This final point allowed for the selection of clones 
expressing the diantennary galactose-terminated complex-type glycan from the mono-
antennary galactose terminal hybrid-type glycan using the lectin ECL – i.e. to distinguish 
Gal1GlcNAc1Man5GlcNAc2 generated in the first step from Gal2GlcNAc2Man3GlcNAc2 
generated in the second step.  
 
Although P. pastoris autonomous replication sequences do exist (Cregg et al, 1985) their 
use is not routine due to stability issues. Therefore, the most common method for stable 
transformation of P. pastoris is genomic integration. This is done by linearising the plasmid 
(by restriction endonuclease digestion) in a stretch of DNA that is homologous to a region 
in the genome of P. pastoris. Genomic integration can then occur by single homologous 
97 
 
recombination using the cells endogenous recombination machinery. This additional need 
for genomic integration causes the success of transformation in P. pastoris to be low 
relative to E. coli.  
The strain SuperMan 5 was duly co-transformed with equivalent numbers of moles of the 
enzymatically linearised GlycoSwitch plasmids pGlycoSwitch-GnTI and pGlycoSwitch-GalT 
(fig. 3.6 A and B).  Because two plasmids were to be co-transformed, it was especially 
important to assess colonies, post-transformation, for the presence of both GlycoSwitch 
















Colony PCR analysis show that of the twenty-one colonies analysed only one does not 
contain pGlycoSwitch-GnTI (colony 5), and two do not contain pGlycoSwitch-GalT (colonies 
20 and 21) – this represents a transformation efficiency of ((18/21)*100=) 86%.  
 
Nine colonies, that had been shown to contain both pGlycoSwitch-GnTI and GlycoSwitch–
GalT, were cultured in 25 mL BMGY growth media in baffled shake flasks for 60 hours and 
induced to express rFH, by transfer of each culture to 5 mL BMMY induction media for 96 
hours, as outlined in section 3.2.3.1. After 96 hours, the OD600 had reached between 95 - 
120, and culture supernatants were harvested, and they were then subjected to SDS-PAGE 
and ECL lectin-based western analysis to detect for production of rFH and galactose-





Figure 3.7: Agarose electrophoresis gel images of colony PCR carried out using two sets of primers, one set was used 
to amplify a region in the GnTI gene (A) and the other set was used to amplify a region in the GalT gene (B). P is 
positive control – pGlycoSwitch-GnTI for A and pGlycoSwitch-GalT for B. N is negative control, this was the parental 
strain SuperMan 5 without either plasmid introduced. Molecular weight markers measured in kilobase pairs (kbp). 




























The lectin-based western blot (fig. 3.8 C) unexpectedly detected weak bands in the three 
negative controls, namely non-enzymatically treated human FH (lane 2), Endo Hf-
deglycosylated human FH (lane 3), and SuperMan 5-produced (untreated) rFH (lane 4). 
Critically, though, the signal for N-acetyllactosamine in the sialidase-treated human FH 
sample is substantially stronger than that for the untreated FH sample. These results 
suggest that, despite some background signals, this method can clearly distinguish between 
glycoproteins with and without N-acetyllactosamine-terminated glycans.  
 
All nine GlycoSwitch-engineered colonies produced detectable quantities of rFH (fig 3.8 B). 
However, only in colonies 2, 4 and 9 did the rFH band give a positive signal according to the 
ECL lectin-based N-acetyllactosamine analysis (fig 3.8 C). It seems therefore that only the 
Figure 3.8: A) Schematic diagram of the reaction catalysed by the genes encoded by the co-introduced plasmids 
pGlycoSwitch-GnTI and pGlycoSwitch-GalT. GnTI (GlcNAc transferase) converts a five mannose glycan into a hybdrid 
glycan with a single GlcNAc terminal antenna. GalT (Gal transferase) then catalyses the addition of galatose. The 
resulting LacNAc antennae (Gal-GlcNAc) can be bound by ECL lectin in a western blot assay.SDS-PAGE (B) and ECL 
lectin-based western blot for N-acetyllactosamine (C) analysis of the expression of rFH in P. pastoris strain SuperMan 5 
transformed with two GlycoSwitch plasmids pGlycoSwitch-GnTI and pGlycoSwitch-GalT. Left of the markers are 
different glycoforms of FH – in order from left to right, sialylated human FH, desialylated human FH, deglycosylated 
human FH and purified rFH expressed in SuperMan 5. Pa. is crude supernatant from SuperMan5 induced to express 
rFH. Black arrows on ECL lectin western blot indicate lanes that contain bands. Molecular weight markers are 






cells in these three colonies have co-expressed the GnT1 and GalT genes. The glycoprofile 
of supernatant from one of these – colony 9 – was analysed by MALDI-TOF mass 





















A peak corresponding to the mass (2,014 Da) of the hybrid galactose-terminated glycan is 
present in the mass spectrum of colony 9 following transformation with pGlycoSwitch-GnTI 
and -GalT (fig. 3.9 B). This peak is not present in SuperMan 5 crude supernatant before 
transformation with these plasmids (fig 3.9 A). Along with the western blot, these results 
confirm that colony 9 has been successfully genetically modified to biosynthesise hybrid-
type, galactose-terminated glycans, Gal1GlcNAc2Man5GlcNAc2 – this strain was named 
HyGal (for Hybrid-glycan, galactose terminal). Glycoanalysis of the supernatants from 
colonies 1 and 4, which also gave signals in ECL lectin western analysis, likewise featured a 
Figure 3.9: Glycoprofile based on MALDI-TOF mass spectrometry of crude supernatant from the parental strain 
of SuperMan 5 (A) and the glycoprofile based on MALDI-TOF crude supernatant from colony 9 after 






peak at 2,014 Da, but in this case, the relative peak intensities were much lower (data not 
shown). 
 
While very encouraging, these results also reveal some minor heterogeneity in the 
glycoprofiles. In addition to the target, hybrid glycan there are also high-mannose species. 
The most abundant of these high-mannose species is the five-mannose glycan, 
Man5GlcNAc2. 
 
3.3.5 Further glycoengineering of P. pastoris to produce complex-type, galactose terminal 
glycans 
 
HyGal colony 9 was used as the platform for further modifications to the glycosylation 
biosynthetic pathway of P. pastoris. The final two GlycoSwitch plasmids (fig. 3.6 C and D) 
encoding ManII and GnTII were introduced, together, into HyGal by transformation. 
Expression of these two enzymes, ManII and GnTII, should build a second N-
acetyllactosamine antennae on the hybrid-type glycan, Gal1GlcNAc1Man5GlcNAc2, 
facilitating the conversion to a galactose terminal, diantennary complex-type glycan, 
Gal2GlcNAc2Man3GlcNAc2.  
 
All four of the GlycoSwitch plasmids (fig. 3.6) contain the constitutive GAP promoter (GAPp) 
and all four GlycoSwitch plasmids were linearised in the GAPp for targeted genomic 
integration at the P. pastoris endogenous GAPp site (fig. 3.10). Therefore, for each plasmid-
genome integration event, an exogenous GAPp sequence will be introduced, resulting in 
multiple homologous repeat sequences. Spontaneous homologous recombination could 

















Consequently, it was necessary to not only detect for colonies which had taken up the new 
plasmids (pGlycoSwitch-ManII and -GnTII), but also to detect for the two GlycoSwitch 
plasmids which had previously been introduced (pGlycoSwitch-GnTI and -GalT) (fig. 3.11). 
Figure 3.11: Agarose electrophoresis gel images of colony PCRs carried out using four sets of primers, the first two are 
targeted toward amplifying parts of coding region of GnTI (A) and GalT (B), which had previously been integrated into 
the P. pastoris genome to generate the strain HyGal. The other two sets of primers are targeted toward amplifying 
parts of the coding regions of the genes ManII (C) and GnTII (D) on the newly introduced set of GlycoSwitch vectors. P 
is positive control – pGlycoSwitch-GnTI for A, -GalT for B, -ManII for C and –GnTII for D. N is negative control, this was 
the parental strain SuperMan 5 without any of the above four GlycoSwitch plasmids introduced. Molecular weight 
markers measured in kilobase pairs (kbp). Expected band sizes for PCR of GnTI is 364bp, GalT is 1024bp, ManII is 
2376bp and GnTII is 534bp. 
Figure 3.10: Schematic diagram of GlycoSwitch plasmid integration via homologous recombination between the 
exogenous GAPp in the plasmid and the endogenous GAPp in the P. pastoris genome. All four GlycoSwitch plasmids 
(encoding GnTI, GalT, ManII and GnTII) were linearised in the exogenous GAPp and directed for integration at the 
endogenous, genomic GAPp. Thus, for each plasmid, an additional GAPp sequence is introduced into the genome. The 
HyGal strain will have three GAPp sequences, the original endogenous GAPp and the two GAPp contained in 
pGlycoSwitch-GnTI and -GalT. SuperGal, which is transformed with all four GlycoSwitch plasmids, will have five GAPp 
sequences, the endogenous GAPp as well as the exogenous GAPp sequences contained in pGlycoSwitch-GntI, -GalT, -




Thus, ensuring that the colonies carried forward for rFH expression contain all 4 
GlycoSwitch plasmids. 
 
Colony PCRs of HyGal co-transformed with pGlycoSwitch-ManII and – GnTII show that, of 
twenty-nine colonies analysed, only one has lost the pGlycoSwitch-GalT plasmid. Just five 
colonies contained the introduced plasmid pGlycoSwitch-ManII and fifteen contained the 
other introduced plasmid pGlycoSwitch-GnTII. Of these fifteen, only four colonies contain 
all four plasmids i.e. the previously introduced plasmids pGlycoSwitch-GnTI and -GalT 
(responsible for producing the hybrid glycan) plus the two newly co-introduced plasmids. 
 
The four colonies which contain all four GlycoSwitch vectors were cultured in 25 mL BMGY 
growth media in baffled shake flasks for 60 hours and induced to express rFH, by transfer of 
each culture to 5 mL BMMY induction media for 96 hours, as outlined in section 3.2.3.1. 
After 96 hours, the OD600 had reached between 90 - 115, and culture supernatants were 
harvested, some of the culture supernatant from each of the four colonies was treated 
with the endoglycosidase Endo Hf and all culture supernatant was then subjected to SDS-
PAGE and ECL lectin-based western analysis to detect for production of rFH and galactose-
containing complex-type glycans, respectively (fig. 3.12). As outlined Chapter 1 section 
1.5.1, Endo Hf has substrate specificity for high-mannose glycans and, importantly, hybrid-
type glycans. But crucially, it cannot cleave complex-type glycans at an appreciable rate (fig. 
3.12 B). Therefore, our rFH, which has been modified to include complex-type 
glycosylation, should not be deglycosylated by endo Hf. Thus, we expect (i) that after Endo 
Hf treatment there will be no molecular weight shift by SDS-PAGE and (ii) that there will be 



















Figure 3.12: A) Schematic diagram of the reaction scheme catalysed by the co-introduced plasmids pGlycoSwitch-ManII 
and pGlycoSwitch-GnTII when transformed into P.pastoris strain HyGal. The gene encoded by pGlycoSwitch ManII, 
mannosidase II, cuts off two mannose from a hybrid glycan. GlcNAc transferase II, encoded by pGlycoSwitch-GnTII, then 
catalyses the addition of N-acetylglucosamine which can then be galactosylated by galactose transferase. B) Schematic 
diagram showing that Endo Hf can cleave the parental hybdrid glycan but not the engineered complex-type glycan. SDS-
PAGE (C) and ECL lectin western blot (D) analysis of the expression of rFH in P. pastoris strain HyGal CFH transformed 
with pGlycoSwitch-ManII and –GnTII. Left of the markers are different glycoforms of FH – in order from left to right, 
sialylated human FH, desialylated human FH, desialylated human FH treated with Endo Hf and desialylated human FH 
treated with PNGase F. Culture supernatant were either untreated or treated with Endo Hf prior to loading onto SDS-
PAGE gel. Molecular weight markers are measured in kDas. The molecular weight of α(2-3,6,8)-neuraminidase is 43kDa, 






Looking at the controls in figure 3.12 C and D, there is no molecular weight shift or loss of 
signal for neuraminidase-treated human FH after treatment with Endo Hf, as assessed by 
SDS-PAGE and ECL lectin-based western blot, respectively. This confirms that Endo Hf 
cannot cleave the complex-type glycans present on human FH. However, when treated 
with PNGase F there is a molecular-weight shift according to SDS-PAGE and a loss of signal 
in the ECL lectin-based western analysis. These results confirm that complex-type glycans 
are cleavable by PNGase F but that complex-glycans are not substrates of Endo Hf. 
 
Looking at the four strains of HyGal CFH transformed with pGlycoSwitch-ManII and 
pGlycoSwitch -GnTII, three show a reduction in molecular weight, by SDS-PAGE, and a loss 
of signal by ECL lectin-based western blot for N-acetyllactosamine. This suggests that, 
unfortunately, the glycosylation biosynthetic pathway has not been modified beyond the 
hybrid-type, galactose terminal glycan, Gal1GlcNAc1Man3GlcNAc2. The fourth colony, 
however, shows no loss of molecular weight according to SDS-PAGE, and no loss of signal in 
the western blot. Thus, in this one colony was the glycosylation pathway of HyGal CFH 
modified to go beyond the hybrid-type glycan. This strain is named SuperGal CFH from here 
on. 
 
To investigate the glycoprofile of SuperGal CFH colony 4 further, crude supernatant was 
enzymatically deglycosylated using PNGase F, the glycans purified from crude supernatant 
using BlotGlyco purification and analysed by MALDI-TOF mass spectrometry (fig. 3.13), as 




The mass spectrum for SuperGal CFH shows a peak corresponding to the mass, 2055.5 Da, 
of diantennary digalactosylated complex-type glycans, Gal2GlcNAc2Man3GlcNAc2. This, 
together with Endo Hf insensitivity, assessed by SDS-PAGE and western blot, suggest that 
the glycosylation pathway of P. pastoris has indeed been modified to biosynthesise 
humanised, complex-type glycosylation. However, as was observed with the HyGal CFH 
strain, there is some glycan heterogeneity present; the five-mannose glycan is probably as 
abundant as the complex-type, diantennary digalactosylated glycan. 
 
3.3.6 Scaled-up production of recombinant factor H with humanised glycosylation in P. 
pastoris glycoengineering strain SuperGal CFH 
Figure 3.13: Glycoprofile MALDI-TOF mass spectrum of crude supernatant from the glycoengineered P. pastoris strain 


















A 10 L batch fermentation of SuperGal CFH was carried out (fig. 3.14). The recombinant 
glycoprotein-producing strain was cultured, in two 5 L baffled shake flasks containing 1.5 L 
BMGY growth media, for 72 hours at 30°C. The shake flask cultures were then used to 
inoculate a 10 L BioFlow 4500 fermenter. The culture was grown by glycerol-fed batch 
fermentation and expression of recombinant FH was induced by switching to a 
methanol/glycerol continuous feed for four days. 8 L of culture supernatant was harvested 
by centrifugation (6,000 g, 30 minutes), diluted 1 in 5 with double distilled water and 
recombinant FH was purified from the dilute supernatant according to the same procedure 
used to purify recombinant FH from the P. pastoris strain SuperMan 5, i.e. using cation-
exchange chromatography followed by anion-exchange chromatography (figs 3.15 and 
3.16). 
 
Figure 3.14: Flow diagram of the purification process of recombinant FH expressed in glycoengineered strain SuperGal 
CFH. After 10 L fermentation of SuperGal CFH, the supernatant was harvested by centrifugation (6,000 g for 30 
minutes). The supernatant was diluted 1 in 5 with distilled water. In cation exchange run 1, approximately half of the 
diluted culture supernatant was applied to a cation exchange chromatography column and eluted. In cation exchange 
chromatography run 2, the second half of the diluted culture supernatant was applied to the same cation exchange 
column and eluted. Eluted fractions from cation exchange chromatography run 1 and run 2 were assessed for purity 
by SDS-PAGE, appropriate fractions were pooled and dialysed against buffer for a second purification step, anion 
exchange chromatography. Half of cation exchange chromatography run 1 and all of run 2 pooled and dialysed 
fractions were stored frozen. The other half of cation exchange chromatography run 1 was subjected to a further 
purification step, it was divided into five lots and each lot was applied separately to, and eluted from, an anion 
exchange chromatography column. The eluted fractions from the five anion exchange chromatography runs were 









































Due to the large volume of diluted culture supernatant, two successive cation-exchange 
runs were carried out. Figure 3.15 shows the first of these two runs. Less culture 
supernatant was used in the second run (this accounts for the lower protein concentration 
in run 2, see table 3.1). 
Recombinant FH eluted as a single peak at an elution volume of approximately 20.25 L, 
with a shoulder on the peak at elution volume approximately 20.1 L (fig 3.15 A). Avoiding 
the peak shoulder as much as possible, peak fractions B1-C1 (20,118.6 – 20,286.6 mL) were 
taken and run on SDS-PAGE to assess purity (fig 3.15 B and C). 
Fractions B3-B11 (20,146.6 – 20,258.6 mL), for both runs, were considered to have the 
highest concentration of rFH relative to impurities. So, these fractions were pooled, 
Figure 3.15: Cation-exchange chromatogram (A) and peak fractions run either non-reduced (B) or reduced (C) on SDS-
PAGE gel. hFH is human FH, FT is flow through, cFT is 10x concentrated flow through, A7 (20,034.6 mL) is a wash 
fraction and B1-C1 (20,118.6 – 20,286.6 mL) are cation-exchange chromatography peak fractions. Molecular weight 






separately, and dialysed against anion-exchange running buffer (pH 9.5) and the 
concentration and nucleic acid contamination was assessed by absorbance at 280 nm and 
the ratio of 260 nm to 280 nm (table 3.1). 
 
Half of the pooled and dialysed eluent from cation exchange chromatography run 1 and all 
of the pooled, dialysed eluent from cation exchange chromatography run 2 was stored 
frozen at - 80°C whilst the other half of run 1 pooled and dialysed eluent was further 
purified by anion-exchange chromatography (fig. 3.16). Five separate anion-exchange runs 
were carried out. In the first run, 6 mL of cation exchange purified protein was loaded onto 
a 6 mL Resource Q strong anion exchanger chromatography column. Protein was eluted in 
a linear gradient of 0 – 0.5 M NaCl and 1.5 mL fractions were collected and assessed for 
purity by SDS-PAGE (fig. 3.16). For the remaining four anion exchange chromatography runs 
12 mL of cation exchange purified protein was loaded onto the Resource Q column 
(chromatograms and SDS-PAGE gels not shown for anion exchange runs 2-5). Thus, a total 
volume of 55 mL eluent from cation exchange chromatography run 1 was subjected to 





































Recombinant FH eluted in a single peak (fig. 3.16) at approximately 100 mL elution volume; 
note, there is a slight shoulder at approximately 75 mL elution volume (fig 3.16 A). Avoiding 
the slight shoulder, peak fractions D1 – E3 (85.4 – 106.4 mL) were run on non-reducing (fig 
3.16 B) and reducing (fig 3.16 C) SDS-PAGE to assess for purity. Fractions D5-E1 (91.4 – 
103.4 mL) for run 1 (fig 3.16) and D3-E3 of runs 2-5 (data not shown) were considered to 
have the highest concentration and purity of rFH, these were pooled together and dialysed 




Figure 3.16: Anion exchange chromatogram (A) and peak fractions run non-reduced (B) and reduced (C) on SDS-PAGE 
gel. hFH is human FH, Cation Ex. is pooled fractions from cation exchange chromatography run, FT is flow through and 
D1-E3 (85.4 – 106.4 mL) are anion exchange chromatography peak fractions. 1.5 mL fractions were collected. 1 µL of 
every second fraction from D1 was mixed with 13 µL LDS loading buffer and loaded onto the gel. Molecular weight 





Table 3.1 shows that after cation-exchange chromatography the protein yield in run 1 
eluent is 560 mg. 55 mL (55 mL*5.12 mg/mL = 281.6 mg) of this was subjected to anion 
exchange chromatography and that after pooling peak fractions from all five anion-
exchange chromatography runs and dialysis against PBS (bottom row table 3.1) the yield of 
rFH is 165.4 mg. Hence ((165.4 mg / 281.6 mg)*100 = ) 58.7% of protein from cation-
exchange chromatography was recovered after anion-exchange chromatography. 
 
Protein from half of run 1 and all of run 2 of the cation-exchange chromatography was not 
further purified by anion-exchange chromatography and was instead stored frozen at -80 
°C for further purification later when stocks of high purity SuperGal CFH expressed 
recombinant FH are depleted. The protein content of the remaining pooled fractions from 
cation exchange chromatography run 1 was approximately 280 mg and after run 2 was 
approximately 310 mg. Assuming a similar yield would be obtained for a subsequent anion-
exchange step, it would produce 165.4 mg and 182.0 mg of purified rFH, respectively. Thus, 
it is fair to claim a total yield of (165.4 mg + 165.4 mg + 182.0 =) 512.8 mg purified rFH from 
this 10-L fermentation or about ~50 milligram per litre cell culture. This yield compares 
favourably with attempts by other groups to produce glycoengineered rFH, for example 
recently Michelfelder et al. (2017) report 1 milligram per litre cell culture of recombinant 
human FH with terminal GlcNac diantennary glycans, GlcNAc2Man3GlcNAc2, expressed in a 
glycoengineered strain of moss. 
 
Table 3.1: Absorbance readings at 280, 260 and 320 nm of fractions from cation exchange chromatography runs 1 and 2 
and anion-exchange chromatography runs 1-5 and runs 1-5 after pooling and dialysis against PBS. The absorbance 
reading at 280 nm was used to estimate protein concentration and the ratio of absorbance at 260 nm to 280 nm was 
























1 1 0.64 6.45 9.07 34.16 5.12 0.71 560




D5 - E1 (85.4 – 106.4 
mL)
0.01 0.31 0.49 9.89 1.48 0.62 12 17.8
2 0.00 0.42 0.72 14.61 2.19 0.58 39.4
3 0.01 0.43 0.73 14.57 2.18 0.59 39.3
4 0.00 0.43 0.72 14.40 2.16 0.60 38.9
5 0.01 0.41 0.67 13.37 2.01 0.61 36.1
150 246,800 0.2 0.026 0.039 0.674 3.240 1.969 0.577 84 165.4
Pooled anion run 1-5 















Additionally, there was a substantial amount of rFH in the flow through (~40 L) after cation-
exchange chromatography (fig 3.15 B and C) – suggesting that the capacity of the column 
was exceeded. Purification using a higher volume resin, or re-applying the flow through, 
could have increased yields of FH quite substantially.  
 
3.3.7 Further glycoengineering: Removing high-mannose glycans 
 
Figure 3.13 indicates that the glycoprofile of SuperGal CFH retains some heterogeneity and 
that the di-galactosyl species, Gal2GlcNAc2Man3GlcNAc2, is only about as abundant as the 
five-mannose species, Man5GlcNAc2, with other less abundant species corresponding to 
higher-mannose, yeast-type glycans. The ultimate aim of this work was to compare the 
function of recombinant human FH carrying human-like glycans on the one hand, with FH 
purified from blood plasma, on the other. The contaminating presence of five-mannose and 
high-mannose glycans would make this comparison difficult to interpret. It could have a 
particularly negative impact on in vivo studies in mouse models as mannose-rich glycans 
are highly immunogenic. 
 
It was therefore necessary to remove the mannose-rich glycans from the sample of purified 
rFH that had been produced in the P. pastoris strain SuperGal. This was attempted by first 
incubating a batch of this rFH (33 mL at 2 mg/mL) with MBP-tagged Endo Hf (100 kU at 37 
°C for 2 hours) to release mannose-rich glycans. Subsequently, mannose-rich glycans and 
MBP-tagged Endo Hf were removed by MBP-affinity chromatography (fig. 3.17). 


















The MBP-tag affinity chromatogram (fig 3.17 A) shows a large absorbance at 280 nm during 
sample application (flow through) and washing, with a small, sharp peak absorbance upon 
washing with 10 mM maltose (for elution). The SDS-PAGE gels (fig 3.17 B and C) show that 
the bulk of the protein content of the flow through and wash fractions A1-A6 (elution 
volume 35.8 – 38.3 mL) is rFH, and the small elution peak consists solely of Endo Hf. 
However, SDS-PAGE also show that there is a small amount of Endo Hf contaminating all 
fractions. FT1 and 2 had the lowest contaminating level of Endo Hf so were pooled, dialysed 
against PBS, pH 7.4, the concentration of protein assessed by UV-VIS spectrometry (table 
C) B) 
A) 
Figure 3.17: MBP-tag affinity chromatogram (A) and peak fractions run non-reduced (B) and reduced (C) on SDS-
PAGE gel. DiGal is purified rFH expressed in P. pastoris strain SuperGal CFH but not treated with Endo Hf, FT is flow 
through (elution volume 4 – 35 mL), A1-A7 (35.8 – 38.8 mL) are wash fractions, EHf is pure Endo Hf and B10 (45.9 – 
46.4 mL) and B11 (46.4 – 46.9 mL) are peak fractions. FT1 and FT2 were collected as 15 mL volumes and wash and 




3.2) and stored for future use. The remaining FH containing fractions were discarded 
because they had relatively high Endo Hf contamination and were only 0.5 mL in volume.  
 
 
Next the extent to which high-mannose (and hybrid) glycans had been removed from rFH 
expressed in SuperGal was assessed by glycan MALDI-TOF mass spectrometry (fig 3.18). 
 
 
Before treatment with Endo Hf the glycoprofile of purified rFH expressed in SuperGal CFH 
(fig 3.18 A) contains high-mannose and hybrid-type glycans as well as the target 
glycoengineered human complex-type diantennary digalactosylated glycan. After 
treatment with Endo Hf (fig 3.18 B) the glycoprofile is fairly homogenous, consisting almost 
exclusively of the diantennary digalactosylated complex-type glycan. There is also a small 
peak potentially corresponding to a six-mannose glycan – alternatively, this peak could be 
an artefact of the high background in the mass spectrum (compare backgrounds of fig 3.15 




Figure 3.18: Glycan MALDI-TOF mass spectra for glycans cleaved and purified from rFH expressed in P. pastoris 
strain SuperGal CFH before (A) and after (B) treatment with the endoglycosidase Endo Hf.  
 
Table 3.2: Absorbance readings at 280, 260 and 320 nm of rFH expressed in SuperGal CFH before and after endo Hf 
treatment and after application to MBPTrap affinity column. The absorbance reading at 280 nm was used to estimate 























SuperGal rFH 0.015 0.407 0.686 3.355 2.039 0.593 33 67.3
SuperGal rFH and Endo Hf 0.017 0.409 0.683 3.33 2.023 0.599 33 66.7
Pooled and dialysed FT1 
and FT2






By implementing a two-stage approach, and after first confirming that the SuperMan5 CFH 
does indeed express recombinant FH carrying five mannose N-linked glycans, this chapter 
has outlined the methodology used to humanise the glycan biosynthesis pathway of P. 
pastoris using GlycoSwitch technology. In the first stage, the glycosylation biosynthetic 
pathway of P. pastoris was modified to produce a hybrid-type, galactose terminal glycan, 
Gal1GlcNAc1Man5GlcNAc2. Building upon this, in the second stage, the hybrid-type glycan 
was converted to a diantennary galactose terminal complex-type glycan, 
Gal2GlcNAc2Man3GlcNAc2.  
However, the glycosylation profile of SuperMan 5 CFH was heterogenous and produced 
high-mannose glycans that could not be humanised. This heterogeneity carried through to 
the glycoengineered strain HyGal CFH and SuperGal CFH. 
Multiple studies in the literature report expression of glycoproteins in glycoengineered P. 
pastoris (Hamilton et al., 2006, Li et al., 2006, Jacobs et al., 2009, Ha et al., 2011, Jiang et 
al., 2011, Gomathinayagam et al., 2012, Cukan et al., 2012, Gong et al., 2013 and 
Gomathinayagam et al., 2015). However, just some of these report heterogeneity in the 
glycosylation profile of recombinant glycoproteins expressed in glycoengineered P. pastoris 
(Jacobs et al., 2009 and Ha et al., 2011). The others report homogenous glycosylation 
profiles composed exclusively of complex-type glycans (Hamilton et al., 2006, Li et al., 
2006, Jiang et al., 2011, Gomathinayagam et al., 2012, Cukan et al., 2012, Gong et al., 2013 
and Gomathinayagam et al., 2015). 
First introduced in the last paragraph of Chapter 1 section 1.4.1, GlycoFi Inc were the 
company that first developed in vivo sialylation technology in P. pastoris (Hamilton et al., 
2006) and were sold to Merck-Serono in 2008 (Roumeliotis, 2006). 
A common thread that links the literature that does not report glycosylation heterogeneity 
is that they are all in association with GlycoFi Inc. The GlycoFi Inc. glycoengineered P. 
pastoris platform differs in two key ways from the GlycoSwitch P. pastoris platform used in 
this study. Firstly, the GlycoFi Inc. platform is capable of in vivo sialylation. Secondly, the 
GlycoFi Inc. platform has incorporated more deletions of endogenous P. pastoris glycan 
modification enzymes. In addition to the Δoch1, common to both the GlycoSwitch and 
GlycoFi Inc. technology, GlycoFi Inc have also deleted the phosphomannosyltransferase 
gene PNO1 and the β-mannosyltransferase 2 gene BMT2. Both of these enzymes are 
responsible for catalysing the transfer of substrate monosaccharides onto the core N-linked 
glycan in yeast (Miura et al., 2004 and, Hopkins et al., 2011) and, therefore, deletion of 
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these two genes, together with Δoch1, appears to facilitate a strain of glycoengineered P. 
pastoris with a very homogenous glycosylation profile.  
The work in this study has, therefore, identified a limitation to the GlycoSwitch technology, 
revealing a significant contamination of high-mannose glycans on proteins produced by the 
engineered strain. The mannose-binding lectin pathway of the complement system in mice 
may lead to rapid clearance of rFH bearing high-mannose N-linked glycans, therefore Endo 
Hf enzymatic removal of high-mannose glycans was essential for further in vivo studies. 
 
Regardless of the limitations of the GlycoSwitch technology, the work in this study satisfies 
the two principle aims set out in chapter 1 section 1.7. Firstly, recombinant FH has been 
expressed in P. pastoris with humanised, complex-type diantennary digalactosylated 
glycans. Secondly, therapeutically useful quantities of recombinant FH were met by 


























In vitro sialylation of human recombinant factor H expressed in the 




4.1.1 Selecting a sialyltransferase 
 
The glycosylation of hFH and the need for sialylation of therapeutic glycoproteins in general 
were discussed in the Introduction (sections 1.1.3, 1.1.4 and 1.2.2). It was shown (Chapter 
2) that plasma-purified hFH is sialylated but, the nature of the glycosidic bond that links 
sialic acid to galactose is unknown. Up to 20 sialyltransferases exist in the golgi (Büll et al., 
2016). These attach sialic acid to galactose via two different glycosidic linkages, α(2,3) and 
α(2,6). Sialic acid linkages are known to influence the function of proteins to which they are 
conjugated, predominantly via interaction with immunomodulatory sialic acid-binding 
proteins including siglecs (Büll et al., 2016), and other lectins. For example, the human 
siglec, sialoadhesin, preferentially interacts with α(2,3)-linked sialic acid over α(2,6)-linked 
sialic acid (Hartnell et al., 2001). Conversely, α(2,6)-linked sialic acid, but not α(2,3)-linked 
sialic acid, protects T-cells from galectin 1-induced cell death (Toscano et al., 2007). These 
considerations made it difficult to choose the appropriate sialyltransferase for sialylation of 
SuperGal-expressed rFH. The key criteria that needed to be fulfilled when selecting a 
suitable sialyltransferase were that the enzyme must be sialylated with Neu5Ac and not the 
immunogenic mammalian Neu5Gc, the enzyme must also be expressed to high levels, 
active, soluble, stable and with a simple purification procedure. 
 
The majority of circulating hFH is expressed in the liver (Skerka et al., 2007 and, Scholl et 
al., 2008).  Within the liver, α(2,6)-sialyltransferase is the most highly expressed 
sialyltransferase. Although an α(2,3)-sialyltransferase is also highly expressed in the liver, 
α(2,6)-sialyltransferase was shown to have the higher activity (Paulson et al., 1989 and, 
Kitagawa and Paulson, 1994). Thus, it seems likely that the main sialic acid linkage on 
plasma derived hFH is α(2,6)-linked. Thus, it was decided to select a sialyltransferase that 




Mammals, and other eukaryotes, express a wide variety of sialyltransferase. However, 
recombinant production of these enzymes in mammalian cell lines is relatively slow, low 
yield, costly and often requires specialist equipment compared to an E. coli expression 
system. In contrast, bacterial expression is cheap, easy to do and fast. 
However, recombinant eukaryotic α(2,6)-sialyltransferases often express poorly in bacterial 
systems, due to low stability and solubility resulting in low activity, and this necessitates 
protein engineering protocols to enhance solubility and protein folding (Ortiz-Soto and 
Seibel, 2016). Taking all these factors into account, to achieve the criteria set out here, it 
was ultimately decided that a bacterial α(2,6)- sialyltransferase was the best enzyme for 
this purpose; bacterial proteins are generally produced in higher yields from bacterial 
expression systems and have  greater solubility, than eukaryotic proteins produced in 
bacterial expression systems. 
 
Although there are many bacterial sialyltransferase, there are only four known bacterial 
α(2,6)-sialyltransferases: one from Photobacterium damsela (Yamamoto et al., 1998), two 
from P. leiognathi (Yamamato et al., 2007 and Mine et al., 2010) and one from 
Photobacterium sp. (Tsukamoto et al., 2008). All four enzymes belong to the same 
glycosyltransferase family GT80 in the Carbohydrate-Active Enzyme Database (CAZy), and 
have been produced recombinantly in E. coli, to high levels (Mine et al., 2010), with affinity 
tags for ease of purification (Ding et al., 2011 and Kang et al., 2015). However, in addition 
to α(2,6)-sialyltransferase activity, all four enzymes have been shown to act reversibly and 
hence to have inherent sialidase activity (Cheng et al., 2010; Mine et al., 2010 and Kang et 
al, 2015). 
 
Interestingly, Photobacterium sp. α(2,6)-sialyltransferase (Ph-6ST) was reported to have 
significant sialidase activity when cultured at 30 °C for several hours  (Kang et al, 2015) but 
not when cultured at either 30 °C (Tsukamoto et al., 2008) or 20 °C (Ding et al., 2011), for 3 
minutes or 20 minutes, respectively. This indicates that sialidase activity may have a 
temperature- or incubation time- dependence. However, all reactions displayed a rapid 
initial α(2,6)-sialyltransferase activity. 
 
Taking all of this into account, Ph-6ST was selected as the best candidate. The aim was to 
produce it recombinantly in E. coli, purify it and optimise conditions for its sialylation of rFH 
carrying galactose-terminal diantennary glycans, Gal2GlcNAc2Man3GlcNAc2.  
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4.2 Materials and Methods 
 
4.2.1 InABLE plasmid assembly 
 
4.2.1.1 Ph6-ST PCR amplification 
 
All primers and oligonucleotide sequences were ordered from Sigma Genosys. 
The Ph-6ST gene sequence was synthesised and codon optimised for expression in E. coli by 
Invitrogen GeneArt gene synthesis service (DNA sequence in appendix). 
The Ph-6ST was amplified by PCR in a reaction containing 2 mM deoxynucleotide 
trisphosphate mix (New England Biolabs), 0.5 µM forward and reverse primers (see below), 
1x Q5 reaction buffer (New England Biolabs) and 0.5 U Q5 High-fidelity DNA polymerase 
(New England Biolabs). The cycling conditions were: denaturation at 98 °C for 30 seconds, 
30 cycles of: 98 °C for 10 seconds, 55 °C for 50 seconds and 72 °C for 45 seconds, followed 
by a final extension phase at 72 °C for 5 minutes. PCR reactions were carried out in a 
Mastercycler nexus X2 (Eppendorf). 
 
Ph-6ST PCR primers: 
4.i) Forward: 5’ – gaggaagcggccgcgctcttcgcatcaacaaaaccatcatcgac – 3’ 
4.ii) Reverse: 5’ – ttagatggatccgctcttcgggctcagtggtggtggtggtggtgtgcccaaaacaggacg – 3’ 
The PCR product was separated by 1.0% (w/v) agarose gel electrophoresis (100 V, 45 
minutes) and yielded a PCR product of 1,462 bp. The PCR product was gel extracted using 
Zymoclean gel DNA recovery kit (Zymo Research, D4002). The excised gel band was 
weighed and placed in three volumes of agarose-dissolving buffer (Zymo Research) per 
milligram of gel and the agarose was left to dissolve by heating to 55 °C for 15 minutes. 
Dissolved agarose was transferred to Zymo-Spin columns (Zymo Research) and centrifuged 
(15,000 g for 60 seconds). An aliquot of 200 µL DNA wash buffer (Zymo Research) was 
added and the column was centrifuged (15,000 g for 30 seconds). The extracted DNA was 
eluted by adding 10 µL ddH2O to the column and centrifuging (15,000 g for 30 seconds). 
 
The concentration of the gel-extracted PCR product and a plasmid containing the assembly 
vector back-bone part, P59, was measured using fluorimetry (Qubit, ThermoFisher 
Scientific). A sample of 1 µL of gel-purified DNA was added to 199 µL Qubit reagent (Qubit, 
ThermoFisher Scientific) and 10 µL Qubit double-stranded (ds) DNA broad-range standard 1 
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(Tris-EDTA (TE) buffer, Qubit, ThermoFisher Scientific) and standard 2 (100 ng/µL DNA in TE 
buffer) were added, separately, to 190 µL Qubit reagent. All samples were mixed and left to 
incubate for two minutes at room temperature (20 – 25 °C) before measuring DNA 
concentrations. Concentration measurements of Ph-6ST PCR product and P59 yielded 52.6 
ng/μL and 116 ng/μL, respectively. DNA molecular weights were calculated to be 1.59 MDa 
and 460 kDa, respectively, using online “Sequence Manipulation Suite: DNA Molecular 
Weight” software. 
 
4.2.1.2 Linker and Part Oligo phosphorylation and annealing 
 
In matched pairs, single-stranded oligonucleotides were subjected to a phosphorylation 
and annealing reaction to yield LO_730, LO_31, PO_730 and PO_31 (sequences listed 
below). Each phosphorylation and annealing reaction consisted of 1 µM of each matched 
pair of single-stranded oligonucleotides, 10 mU T4 polynucleotide kinase (New England 
Biolabs), 1 mM adenosine triphosphate (ATP), 5 µM dithiothreitol (DTT), 5 µL Polyethylene 
glycol 8,000 and 5 µL T4 polynucleotide kinase buffer (100mM MgCl2, 700 mM Tris-HCl, 50 
mM DTT, pH 7.6, New England Biolabs) and made up to 50 µL with ddH2O. Phosphorylation 
and annealing reactions were placed in a thermocycler (Mastercycler nexus X2, Eppendorf) 









Single-stranded oligonucleotide sequences: 























4.iii) LOlong_730: 5’ – gccatgtgtaataatagcgaagaaaatacccaga – 3’ 
4.iv) LOshort_730: 5’ – gctattattacacat – 3’ 
4.v) POlong_730: 5’ – atgtcgttcttgatgatgctctgggtattttcttc – 3’ 
4.vi) POshort_730: 5’ – gcatcatcaagaacga – 3’ 
4.iii) LOlong_31: 5’ – gcctgctaacaaagcccgaaaggaagctgagttg – 3’ 
4.iv) LOshort_31: 5’ – cgggctttgttagca – 3’ 
4.v) POlong_31: 5’ – ctcagcggtggcagcagccaactcagcttccttt – 3’ 
4.vi) POshort_31: 5’ – gctgctgccaccgct – 3’ 
 
4.2.1.3 Part-linker fusion reactions 
 
Two separate part-linker fusion reactions were set-up, containing PCR product, part oligo 
(PO)_730 and linker oligo (LO)_31 in one reaction and, the plasmid containing P59, PO_31 
and LO_730 in the other. The RE Ear I was used to liberate tPh-6ST and P59 in these two 
separate reactions. Standard part-linker fusion reactions conditions are as follows (final 
concentrations are given): a reaction mix consisting of 20 nM of truncated part (TP), 0.2 µM 
each of the LO and PO to be associated with the TP, 5 µL NEBuffer 4 (final concentrations of 
5 mM potassium acetate, 2 mM Tris-acetate, 1 mM magnesium acetate, 0.1 mM DTT, pH 
7.9, New England Biolabs), 1 mM ATP, 0.5 U T4 DNA ligase (New England Biolabs), 12.5 mU 
type II S restriction endonuclease (e.g. either Ear I or Sap I, New England Biolabs) and made 
up to 50 µL with ddH2O. Part-linker reactions were placed in a thermocycler and subjected 





























The part-linker fusion products, PO_730 – tPh-6ST – LO31 and PO_31 – P59 – LO_730, were 
separated by 1% (w/v) agarose gel electrophoresis (100 V, 45 minutes) (fig. 4.1 B) and gel 
extracted using Zymoclean gel-DNA recovery kit (Zymo Research). Subsequent 
measurement of DNA concentration by fluorimetry (Invitrogen, Qubit) gave 8.12 ng/μL and 
16 ng/μL, respectively (see section 4.2.1.1 for experimental details). The DNA molecular 
weight was calculated using the part-linker fusion DNA sequences and the online 
“Sequence Manipulation Suite: DNA Molecular Weight” software. 
 
4.2.1.4 inABLE assembly of Ph-6ST in a plasmid vector backbone for expression in E. coli 
 
The inABLE DNA assembly reaction was carried out by combining the two part-linker fusion 









 A sample of 1 µL of assembled plasmid was used to transform electrocompetent E. coli 
strain TOP10 (One Shot TOP10 Electrocomp E. coli, ThermoFisher Scientific, C404050) by 
electroporation (1.7 kV, 25 µF). Transformed cells were recovered in 1 mL SOC media for 
one hour at 37 °C with 250-rpm shaking.  Recovered cells were plated out onto LB agar 
containing 50 µg/mL kanamycin sulphate (ThermoFisher Scientific) and incubated at 37°C 
for approximately 16 hours. 
 
Transformation colonies, containing the assembled vector plasmid, were selected by colony 
PCR followed by 1.0% (w/v) agarose electrophoreses (100 V, 45 minutes) (data not shown). 
The colony PCR procedure was as follows: colonies were picked from the LB agar 
transformation plate and suspended in 10 µL sterile ddH2O. A 2 µL sample of suspended 
colony was added to a mix containing 5 µL OneTaq 2X Master mix (New England Biolabs) 
Table 4.3: inABLE assembly of part-linker fusion products to yield an E. coli expression vector plasmid containing a 




and 1.5 µL each of 10 µM stock of forward and reverse primers (see below for sequences). 
Colony PCR reactions were placed in a thermocycler and cycling conditions were as follows: 
DNA was denatured by heating to 94 °C for 30 seconds, then 30 temperature cycles of 94 °C 
for 30 seconds, 55 °C for 60 seconds and 68 °C for two minutes, were performed followed 
by a final extension at 68 °C for five minutes. The PCR reaction yielded a product of 2,276 
bp. The primers used were: forward primer 5.iii) LOlong_730 (sequence given above) and 
the reverse primer: 
 
4.vii) Reverse: 5’ – ctccttcattacagaaacgg – 3’ 
DNA, from clones identified by colony PCR, to contain the assembled plasmid, was 
prepared using a QIAprep Spin Miniprep plasmid-preparation kit (Qiagen). Colonies were 
used to inoculate 5 mL LB media, containing appropriate antibiotic, in 50 mL conical tubes 
(Falcon) and left to incubate for approximately 16 hours at 37 °C, with 250 rpm shaking. 
Cultures were centrifuged (5,000 g, 20 minutes), supernatant discarded and pellet 
resuspended in 250 µL buffer P1 (Qiagen) and transferred to a fresh 1.5-mL 
microcentrifuge tube (Eppendorf). A 250 µL aliquot of buffer P2 (Qiagen) was added before 
mixing and incubating for five minutes at room temperature (20 – 25 °C). Then, 350 µL 
buffer N3 (Qiagen) was added, the contents of the tube were agitated and then centrifuged 
(15,000 g for 10 minutes). The supernatant was applied to a QIAprep spin column and 
centrifuged (15,000 g, 60 seconds). A 0.5-mL aliquot of buffer PB (Qiagen) was added and 
the spin column was centrifuged (15,000 g, 60 seconds). Subsequently, 0.75 mL of buffer PE 
(Qiagen) was added and the spin column was centrifuged (15,000 g, 60 seconds). Finally, 50 
µL ddH2O was added and the spin column was centrifuged (15,000 g, 60 seconds) to 
collected purified plasmid. 
Restriction mapping of the purified plasmid was carried out to assess whether the plasmid 
was assembled correctly and with parts in the correct orientation. The restriction map was 
generated by restriction endonuclease digestion using the enzymes Age I and Sph I, and 
NEBuffer 1.1 (New England Biolabs). An aliquot containing 1 µg plasmid was incubated, at 
37 °C for one hour, with 0.5 µL each of Age I and Sph I (New England Biolabs), 2 L NEBuffer 
1.1 in a reaction volume made up to 20 µL with ddH2O. Correctly assembled plasmids were 
identified by bands at ~5300 bp and ~1300 bp (data not shown) by 1% (w/v) agarose 




4.2.2 Expression in E. coli strain BL21 (DE3) 
 
4.2.2.1 Transformation and selection 
 
A clone identified, by colony PCR and restriction mapping, to contain the correctly 
assembled plasmid was used to inoculate 100 mL LB media, containing 50 µg/mL 
kanamycin sulphate, in baffled shake flasks. The culture was left to incubate for 
approximately 16 hours at 37 °C, with 250-rpm shaking. The culture was centrifuged (5,000 
g, 20 minutes) and supernatant was discarded. The plasmid was isolated from the pelleted 
cells by Midi prep (Qiagen) standard procedure (Qiagen plasmid purification handbook, 
www.qiagen.com/handbooks). A 2-μL sample of pEcPh-6ST was mixed, by gentle flicking, 
with 50 μL E. coli BL21 (DE3) electro-competant cells (New England Biolabs) and 
transformation was carried out (1.7 kV, 25 µF). Transformed cells were transferred to 1 mL 
SOC media and incubated at 3.7 °C, with 250-rpm shaking for 1.5 hours. A sample of 50 μL 
of the recovered cells was spread plated onto LB agar containing 50 µg/mL kanamycin 
sulphate, and plates were then incubated for approximately 16 hours at 37 °C. 
 
Colonies containing pEcPh-6ST were identified by the same colony PCR used in section 
4.2.1.1 (fig. 4.3). PCR products were run on 4200 TapeStation 4200 (Agilent) using D5000 
DNA analysis screen tape. D5000 sample buffer (Agilent formulation) was equilibrated at 
room temperature (20 – 25 °C) for 30 minutes. A 1-µL D5000 ladder (Agilent formulation) 
and 1 µL of each PCR product were added, separately, to 10 µL D5000 sample buffer mixed 
and spun (3,000 g, one minute). Samples were loaded into the 4200 TapeStation 
instrument, and the run was started using Agilent TapeStation Analysis Software. 
 
4.2.2.2 Test expression of α(2,6)-sialyltransferase in E. coli 
 
A single colony, identified by colony PCR and restriction mapping to contain pEcPh-6ST, was 
used to inoculated 10 mL LB media containing 50 µg/mL kanamycin sulphate. This seed 
culture was incubated for ~16 hours at 37 °C and 250-rpm shaking. A glycerol stock was 
made by taking 800 μL and mixing with 200 μL 50% (v/v) glycerol before storing frozen at    
-80 °C. The culture was back-diluted to an OD600 of 0.1 into twelve 10-mL volumes of LB 
media and 50 µg/mL kanamycin sulphate. Cultures were incubated at 37 °C, and 250-rpm 
shaking until an OD600 of between 0.4 – 0.8 was reached. Expression of Ph-6ST was then 
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induced by the addition of 1 M isopropylthio-β-galactoside (IPTG) (ThermoFisher Scientific) 
to a final concentration of either 0.1 mM, 0.3 mM and 0.9 mM IPTG – yielding four cultures 
at each concentration of IPTG. One culture of each concentration of IPTG was incubated, 
with 250-rpm shaking, at either 10 °C, 20 °C, 30 °C or 37 °C (Table 4.2) for a total of 20 
hours. Samples of 600 μL were taken prior to induction, at four hours, and then at 20 hours 
post-induction. Aliquots of 100 μL were used to measure OD600 at each time point. The 
remaining 500 μL of each sample was placed in 1.5 mL micro-centrifuge tubes (Eppendorf) 
and centrifuged (16,000 g, 10 minutes). The supernatant was discarded and the pellet was 
used for expression analysis. 
 
4.2.2.3 Analysis of test expression: cell lysis, SDS-PAGE and western blot 
 
Cell lysis buffer was made up containing 124 μg/mL lysozyme (from chicken egg white, 
Sigma-aldrich) and >35 U of benzonase nuclease (EMD millipore) in BugBuster Protein 
Extraction Reagent (Novagen). Cell lysis buffer was added to cell pellets at a ratio of 32.2 μL 
per 1.0 unit OD600 (measured in section 4.2.2.2). Cells were incubated at room temperature 
(20 – 25 °C), with 40 rpm-rocking for 15 minutes followed by centrifugation (16,000 g, 20 
minutes, 4 °C). Supernatant was transferred into fresh 1.5-mL microcentrifuge tubes 
(Eppendorf) and the pellet was suspended in ddH2O at a ratio of 32.2 µL per 1.0 unit OD600 
(measured in section 4.2.2.2). An aliquot of 10 μL was mixed with 40 μL SDS-PAGE loading 
buffer and 10 μL of that was loaded onto 4-12% bis-tris plus polyacrylamide gels for 
electrophoresis (Invitrogen Mini Gel Tank, MES buffer, 200 V, 35 minutes). Gels were either 
stained with Coomassie InstantBlue or subjected to western blot. Western blot was used to 
detect the presence of the His6-tag on the bacterial α(2,6)-sialyltransferase. The western 
blot procedure was as follows: the polyacrylamide gel was placed in a western blot-transfer 
stack and transferred onto PVDF membrane as described in chapter 2 section 2.2.2.1. The 
membrane was placed in 50 mL blocking buffer (2.25% (w/v) milk powder (Sainsburys), 1% 
(v/v) tween-20, 10 mM phosphate buffer, 137 mM NaCl, 2.7 mM KCl, pH 7.4) and incubated 
at room temperature (20 – 25 °C), with 40 rpm rocking, for 1 hour. Blocking buffer was 
poured off and replaced with 20 mL of mouse monoclonal anti-His (poly) peroxidase 
conjugate antibody (Sigma-aldrich, A7058) diluted 1:2,000 in blocking buffer. After 
incubation at room temperature (20 – 25 °C), and 40-rpm rocking for one hour, the 
antibody solution was discarded and the membrane was washed thrice with wash buffer 
(TPBS, blocking buffer without milk powder), incubated at room temperature (20 – 25 °C) 
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with 40-rpm rocking for five minutes. Wash buffer was poured off and bands were 
developed by incubating membranes in 10 mL of metal-enhanced DAB (ThermoFisher 
Scientific, 34065) diluted 1:10 with stable peroxide buffer (ThermoFisher Scientific) until 
bands begin to appear, at room temperature (20 – 25 °C) and 40-rpm rocking. The reaction 
was stopped by dilution with ddH2O, before pouring off diluted DAB solution. 
 
4.2.2.4 Large-scale expression and nickel (II)-immobilised metal ion-affinity chromatography 
 
A 400-mL culture of E. coli containing pEcPh-6ST was incubated and expression of Ph-6ST 
induced with a final concentration of 0.9 mM IPTG and incubation at 20 °C, with 250-rpm 
shaking (optimal expression conditions determined in section 4.2.2.3). Cells were lysed 
according to the conditions in section 4.2.2.3, and the soluble protein fraction was 
subjected to nickel (II)-immobilised metal ion-affinity chromatography using a 1-mL HisTrap 
HP column (GE Healthcare Life Sciences, 29-0510-21). Prior to use, buffer A (0.5 M sodium 
chloride, 50 mM tris-HCl, pH 7.5) and buffer B (250 mM imidazole, 0.5 M NaCl, 50 mM tris-
HCl, pH 7.5) were filtered (0.2 μm filter) and degassed. The HisTrap column was 
equilibrated with 10 CV of 2% buffer B.  The sample was then applied at a rate of 1 mL per 
minute. After sample loading, the column was washed with 8 CV 2% buffer B followed by 
washing with 20% buffer B. Protein was then eluted over a linear gradient of 20% - 100% 
buffer B. The protein concentration of select fractions, was estimated by A280 and selected 
fractions analysed by SDS-PAGE on 4 – 12% bis-tris polyacrylamide gels and western blot 
(10 μL fraction added to 40 μL SDS-loading buffer, 10 μL loaded, 200 V, 35 minutes; 
western blot procedure outlined in section 4.2.2.3). Fractions determined, by SDS-PAGE, to 
have a high yield and purity of Ph-6ST were pooled, placed in 3.5 kDa molecular weight-cut 
off dialysis tubing (SnakeSkin, ThermoFisher Scientific) and dialysed against 2 L of 200 mM 
Tris-HCl, 50 mM NaCl, pH 8.0 for approximately 16 hours, with a buffer exchange after four 
hours, at 4 °C. Dialysed protein samples were aliquoted in 250 µL volumes and stored, 
frozen at -20 °C.  
 
4.2.2.5 Testing the activity of purified Ph-6ST 
 
To test the activity of purified Ph-6ST, a 10 µL reactions was set up containing 200 mM tris-
HCL, pH 8.0, 20 mM MgCl2, 500 μM CMP-N-acetylneuraminic acid sodium salt (Carbosynth, 
MC04391) (CMP-sialic acid), 3.125 µM rFH expressed in SuperGal and 0.3 µM purified Ph-
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6ST. Three control reactions were also set-up but omitting either CMP-sialic acid, rFH or Ph-
6ST. Reactions were left to proceed over night at 20 °C. Sialylation reactions were 
subjected to SNA and ECL lectin-based western blot analysis as detailed in Chapter 2 
section 2.2.2.1. 
 
4.2.3 Sialylation of recombinant factor H expressed in glycoengineered P. pastoris strain 
SuperGal 
 
4.2.3.1 Optimisation of sialylation reaction conditions 
 
Final concentrations of reagents for sialyltransferase reactions were as follows: 200 mM 
Trizma base, pH 8.0, 20 mM magnesium chloride, 500 μM CMP-N-acetylneuraminic acid 
sodium salt (Carbosynth, MC04391), 470 μg/mL rFH expressed in SuperGal and carrying 
Gal2GlcNAc2Man3GlcNAc2 glycans, 17 μg/mL Ph-6ST, made up to a defined volume with 
ddH2O. In the first round of optimisation, a single master stock was made up and separated 
into three equal volumes in 1.5-mL microfuge tubes and incubated at 10 °C, 20 °C or 30 °C. 
Samples were taken one hour, four hours and 20 hours after the start of the reaction. In 
the second round, all samples were incubated at 10 °C for 20 hours. A sample of 70 μM 
CMP-N-acetylneuraminic acid sodium salt or ~10 U alkaline phosphatase (calf intestine, 
Sigma-Aldrich) or both were added at 30 minutes, two hours and four hours after the start 
of the reaction. 
 
4.2.3.2 Lectin-based ELISA to detect sialylation of rFH expressed in SuperGal 
 
Plasma-derived hFH standards for lectin ELISA were prepared under native conditions as 
follows, 1.3 mg/mL plasma-purified hFH was combined, to a final concentration of 91 
ng/μL, with 5 μL 10x Glycobuffer 1 (New England Biolabs) and either 5 μL α(2-3,6,8)-
neuraminidase (New England Biolabs) for the desialylated standard, or ddH2O for the 
sialylated standard. Reactions were made up to 55 μL with ddH2O and left to incubate for 
approximately 16 hours at 37 °C. An 11 μL aliquot of each standard was combined with 39 
μL SDS loading buffer. To assess whether the standards were sialylated or desialylated, 200 
ng of α(2-3,6,8)-neuraminidase-treated and untreated FH standards were loaded onto 
three 4-12% bis-tris plus polyacrylamide gels (ThermoFisher Scientific) and electrophoresis 
was carried out (200 V, 35 minutes). One gel was stained with Coomassie InstantBlue. The 
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other two gels were placed in western blot-transfer stacks and subjected to the lectin-
based western blot procedure described in Section 2.2.2.1. 
 
Lectin-based ELISA, to detect the extent of sialylation, were carried out as follows. SUMO-
tagged PspCN (prepared in house by Dr Andrew Herbert) was mixed to a final 
concentration of 5 μg/mL in capture buffer (0.1 M sodium carbonate, pH 9.5), then 100 μL 
was added to wells in two 96-well plates (Falcon, 353072). One of these plates was 
designated for SNA lectin sialic acid detection, the other plate was designated for ECL lectin 
LacNAc detection. The two plates were incubated with gentle shaking at 40 rpm for 15 
minutes at room temperature (20 – 25 °C) followed by incubation for approximately 16 
hours at 4 °C. SUMO-PspCN in capture buffer was removed and 300 μL 1x carbo-free 
blocking buffer (Vector Laboratories, SP5040) was added before incubation with gentle 
shaking at 40 rpm for 30 minutes at room temperature. The sialylated and desialylated hFH 
standards, prepared as described above, were diluted to 10 μg/mL in 1x carbo-free 
blocking buffer. Aliquots of 100 μL of 10 μg/mL standard were loaded into wells A1 and B1 
of each plate. Blocking solution was removed and sialylated standard was added to the SNA 
lectin-designated plate, while desialylated standard was added to the ECL lectin-designated 
plate. A 1:2 serial dilution of each standard was created (in duplicate) from lanes A1-11 and 
from lanes B1-11. Aliquots of 100 μL of 1:1000 and 1:2000 dilutions (for time and 
temperature studies) or 1:1000 and 1:1500 dilutions (for CMP-sialic acid and alkaline 
phosphatase studies) from each reaction condition were loaded into selected wells. 
Controls and samples were incubated with gentle shaking at 40 rpm for one hour at room 
temperature.  
Subsequently, standards and samples were removed and the wells washed by the addition 
and removal of 300 μL wash buffer (0.05% (v/v) Tween-20 in PBS, pH 7.4). Washing was 
repeated five times. Separately, biotinylated SNA and biotinylated ECL lectins (Vector 
Laboratories, B-1305 and B-1145, respectively) were diluted to 10 μg/mL in carbo-free 
blocking buffer. An aliquot of 100 μL of diluted SNA was added to all wells in the SNA lectin-
designated plate and the same was done, but with diluted ECL to the ECL lectin-designated 
plate. Plates were incubated with gentle shaking at 40 rpm for 1 hour at room 
temperature, then SNA and ECL solutions were removed and the plates were washed as 
previously. NeutrAvidin Protein, HRP (ThermoFisher Scientific, 34028) was mixed to a final 
concentration of 0.5 μg/mL in carbo-free blocking buffer and 100 μL was added to each 
well. The plates were incubated with gentle shaking at 40 rpm for one hour at room 
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temperature, then NeutrAvidin Protein, HRP solutions were removed and the wells were 
washed as previously. Subsequently, 100 μL of 1-Step Ultra TMB (3,3’,5,5’-
Tetramethylbenzidine)-ELISA Substrate Solution (ThermoFisher Scientific, 34028) was 
added to each well and incubated for 15 minutes, and reactions were stopped by the 
addition of 100 μL 2 M sulphuric acid. Absorbance values (650 nm) were measured using a 
SpectraMax M5 Multimode plate reader. Standards were plotted on a four-parameter 
logistic curve plotted using MyAssays.com software that was used to quantify amounts of 
terminal sialic acid/ galactose in sialylation assay samples.  
 
4.2.3.3 Purification of sialylated rFH by cation-exchange chromatography 
 
Recombinant FH that had been expressed in SuperGal and previously treated with Endo Hf 
to remove yeast glycans (see Chapter 3 section 3.3.7), was sialylated according to the 
optimal conditions determined as described above (incubation at 10 °C, for 20 hours with 
one, two or three additions of CMP-sialic acid at 30 minutes, two hours and four hours 
after the start of the reaction). Sialylated rFH was placed in 10-kDa molecular weight cut-
off dialysis tubing (SnakeSkin, ThermoFisher Scientific, 88245) and dialysed overnight, at 4 
°C, against cation-exchange buffer A (20 mM potassium phosphate, pH 7.0), with the buffer 
changed after two hours. Dialysed sialylated rFH was purified by cation-exchange 
chromatography using a 6-mL Resource S column (GE Healthcare Life Sciences). The column 
was equilibrated with three CV of buffer A, approximately 35 milligrams sialylated rFH in a 
75 mL volume was loaded at 6 mL/min and the column was washed with three CV of buffer 
A before eluting with a 16-CV linear gradient from 0 – 50% buffer B (20 mM potassium 
phosphate, 1 M NaCl, pH 7.0), and a final high-salt wash with one CV from 50% - 100% 
buffer B. Fractions of 2 mL were collected. The protein concentration of selected fractions 
(flow through, first 80 mL of elution, and then every 2 mL from 150.5 to 182.5 mL) was 
estimated by A280 readings and then 2 μL of selected fractions were mixed with 14 μL of 
SDS-PAGE-loading buffer and subjected to PAGE (200 V, 1 hour) (fig. 4.9). Selected fractions 
(elution volume 158.5 – 174.5 mL) with high purity (fig. 4.5) and concentration of rFH were 
pooled, placed in 10-kDa molecular weight cut-off dialysis tubing (SnakeSkin, ThermoFisher 
Scientific) and dialysed against PBS, pH 7.4, for approximately 16 hours at 4 °C, with a 





4.2.3.4 Glycan release, purification and analysis by MALDI-TOF mass spectrometry 
 
Glycans were released, purified and analysed by MALDI-TOF mass spectrometry as detailed 
in Chapter 2 section 2.2.3.2. 
 
4.3 Results  
 
4.3.1 Ph-6ST gene synthesis and inABLE plasmid preparation  
 
The sequence for the gene encoding α(2,6)-sialyltransferase from Photobacterium sp. was 
obtained from the National Centre for Biotechnology Information (NCBI) (accession 
number: 2Z4T_A). A gene was designed with modifications in accordance with the method 
employed by Ding et al. (2011). Briefly, the gene was modified to yield a truncated, His-
tagged fusion protein with amino acid deletions at the N- and C-terminus (Δ2-14 and Δ502-
514, respectively). Removal of the N-terminal amino acids deletes a membrane-localisation 
domain, thus improving solubility and yield. Truncation of the C-terminal amino acids 
allowed for substitution with a polyhistidine (His6)-tag for ease of purification whilst not 
affecting enzymatic activity (Ding et al., 2011). The truncated His6-tagged gene was codon 
optimised for E. coli expression, synthesised and supplied by Invitrogen GeneArt gene 
synthesis. It is referred to as Ph-6ST and protein product Ph-6ST from here onwards.  
The Ph-6ST gene sequence (codon-optimised sequence in appendix), including the 3’ His6-


















The protparam-derived data indicates that the protein should be stable (from the instability 
and aliphatic indices) while the grand average of hydropathy score is slightly negative, 
indicating it is likely to be soluble. Overall, the sequence was judged to be suitable for 
production of a folded and well-behaved enzyme fit for the purpose of in vitro sialylation.    
 
The gene sequence was amplified using primers designed by Ingenza’s proprietary inABLE 
software. These primers were used to PCR amplify the Ph-6ST gene (fig 4.2 A) sequence to 
yield a truncated part (tPh-6ST) which was then inserted into the E. coli expression plasmid 
P59 – a plasmid made in house by inABLE-oriented modifications to the pET24 class of 
expression vectors – by restriction digestion (fig 4.2 B) and ligation according to inABLE 
plasmid-construction procedures. 
 
This generated an E. coli expression vector (pEcPh-6ST) containing the LacI gene (and 
associated promoter), the Ph-6ST gene under the control of the T7-promoter, for isopropyl 
β-D-1-thiogalactopyranoside (IPTG)-inducible expression in conjunction with LacI (process 
outlined in pET system manual 11th edition), and with a C-terminal His6-tag, and kanamycin 
Figure 4.1: Amino acid sequences, predicted from Ph-6ST gene sequence (A) and protein paramaters (B) 









































The assembled pEcPh-6ST was used to transform electrocompetent E. coli BL21 (DE3) cells 
as detailed below.  
 
4.3.2 Transformation, selection and optimisation of expression conditions 
After transformation, two colonies were selected for colony PCR analysis to identify 




Figure 4.2: DNA agarose gel electrophoresis images of A) PCR amplification of tPH-6ST and B) restriction endonuclease 
digestion of the backbone plasmid p59 and PCR amplified tPH-6ST. Expected band sizes for tPH-6ST PCR product was 
~1,462bp and, p59 and tPH-6ST after restriction digestion was 5150bp and 1438bp, respectively. And C), the plasmid map of 



















Both colonies analysed by colony PCR produced an amplification product of the expected 
size (2,276bp). Colony 1 was carried forward for test expression analysis. 
 
Twelve replicate cultures of colony 1 were used to inoculate lysogeny broth (LB) media.  
After an initial growth phase at 37 °C, each culture was subjected to a different set of 
induction conditions (table 4.4). 
 
 
Figure 4.3: Tapestation gel electrophoresis virtual image of the colony PCR analysis of BL21 (DE3) E. coli strains 
transformed with expression plasmid pEcPh-6ST. The expected PCR-amplified product size is 2,276 bp. P is the 
positive control – the pEcPh-6ST plasmid. N is the negative control – a colony of parental BL21 (DE3) E. coli before 



















Test expressions were carried out on colony 1 to test for the optimal temperature, 
incubation time and IPTG concentration for expression of Ph6-ST.  
 
The OD600 was measured before induction of protein expression and at four hours and 20 










Of the temperatures explored, 30 °C was best while 10 °C was worst, for growth of E. coli 
cells that have been transformed with pEcPH-6ST (i.e. E. coli Ph-6ST). But, the data does not 
help to select optimal conditions for gene expression or protein production per cell. 





















































Table 4.4: Ph-6ST expression induction condition for 12 cultures of colony 1 that had been confirmed to have been 
successfully transformed with plasmid pEcPh-6ST. Three cultures were cultured at one of four temperatures during 
expression induction, each of these three were induced with one of three IPTG concentrations, and samples of each 
culture were taken at four hours and 20 hours post-induction to assess for the presence and levels of the Ph-6ST. 
enzyme. 




To address this, OD600 readings were used to normalise cell density across the different 
cultures and then normalised protein expression levels were assessed by SDS-PAGE and 
western blot (fig 4.4).  
 
 
From the SDS-PAGE and anti-His-tag western blot images (fig. 4.4), expression appears 
tightly controlled since no Ph-6ST (~56.5 kDa) was detected in the non-induced culture. 
Post induction, Ph-6ST is expressed under all conditions. However, there is a tendency for 
the protein to form insoluble inclusion bodies, especially at higher incubation 
temperatures. For example, at 30 °C and 37 °C most of the protein appears to form 
inclusion bodies, while at 20 °C there is an approximately equal distribution of protein in 
the soluble and inclusion body samples.  At 10 °C the protein seems more soluble – 
especially at higher IPTG concentrations. For this reason, inductions at 30 °C and 37 °C were 
deemed unsuitable for expression of Ph-6ST. 
 
Even though there is a similar distribution of Ph-6ST in the soluble and inclusion body 
samples at 20 °C, incubation at 20 °C yields more total protein in the soluble samples 
compared to the soluble samples following incubation at 10 °C. Therefore, 20 °C was 
Figure 4.4: SDS-PAGE (top row) and anti-His-tag antibody western blot (bottom row) showing the results of test 
expression for E. coli BL21 (DE3) cells transformed with plasmid pEcPh-6ST containing Ph-6ST. The black triangles 
represent an increasing concentration gradient of IPTG (0.3 mM, 0.6 mM and 0.9 mM). For each time point, soluble 
(left) and inclusion body-containing samples (right) were run on SDS-PAGE – each time point is demarcated by short 




judged to be the optimal incubation temperature for Ph-6ST expression and Ph-6ST 
production. 
 
Additionally, slightly more protein was present in the soluble samples at 20 hours post-
induction compared to four hours post-induction.  Higher IPTG concentrations also yielded 
higher amounts of soluble protein. Therefore, the optimal conditions defined for 
expression of recombinant Ph-6ST were as follows: 20 °C, 0.9 mM IPTG and cells harvested 
at 20 hours post-induction. 
 
4.3.3 Ph-6ST expression and purification 
 
Next, E. coli Ph-6ST was cultured and Ph-6ST expressed according to the experimentally 
determined optimal conditions. Ph-6ST was then purified from 400 mL lysed E. coli Ph-6ST 










The chromatogram (fig. 4.5 A) shows that the majority of protein in E. coli Ph-6ST cell lysate 
did not bind to the affinity resin. However, the SDS-PAGE and lectin western (fig. 4.5 B and 
C, respectively) show that a high proportion of Ph-6ST had eluted in the flow through – this 
suggests that the amount of Ph-6ST in the lysed E. coli PH-6ST cells exceeded the capacity 
of the 1-mL HisTrap column (the column capacity is reported to be 40 milligram His-tagged 
protein /mL resin, GE lifesciences). The chromatogram shows two peaks (T2, T3 and T4) 
A) 
B) C) 
Figure 4.5: Chromatogram (A) of the nickel (II)-immobilised metal-affinity chromatography purification of His6-tagged 
recombinant Ph-6ST from lysed E. coli PH-6ST cells. SDS-PAGE (B) and anti-His antibody western blot analysis (C) of 
selected fractions from the nickel (II)-affinity purification. CFE – is cell free extract (lysed E. coli PH-6ST cells prior to 
purification). BT5 and BT9 factions are from the flow-through; T2, T3 and T4 fractions are associated with peaks 




during the wash step of the chromatographic run but these two contain very little Ph-6ST 
protein according to western blot. The chromatogram also shows a peak with a shoulder 
during the elution gradient (T16 – 24) which, when analysed by SDS-PAGE and western 
blot, contains Ph-6ST as well as other contaminating proteins of varying molecular weights. 
Fractions T17-T24 were subsequently pooled, (along with a pool of equivalent fractions 
from a second pass of crude material through the column) and dialysed against Tris buffer. 
The absorbance at 280 nm, 260 nm and 320 nm was measured before and after dialysis 
(Table 4.6). 
 
The volume post-dialysis was approximately 12 mL and the amount of protein purified was 
extimated, using the ExPASy protparam derived molar extinction coefficient of 69,790 M-
1cm-1 (fig. 4.1), to be ~5.3 mg protein. As the initial culture volume was 400 mL, this would 
have corresponded to a yield of ~13 mg of purified protein per litre of cell culture. 
However, from SDS-PAGE (fig 4.5 B) the sample contains other contaminating proteins at 
low levels. Additionally, the purity measurement (last column Table 4.6) is >0.6 (0.75) 
indicating that there is some nucleic acid contamination. 
 
However, achieving high purity of Ph-6ST was not the primary objective – the purpose of 
the exercise was to produce enough functional enzyme to catalyse the sialylation of 
galactose terminal diantennary complex-glycans on rFH expressed in glycoengineered P. 
pastoris strain SuperGal. To test the activity of purified Ph-6ST, a 10 µL reaction was set up 
containing 200 mM tris-HCL, pH 8.0, 20 mM MgCl2, 50 µM CMP-N-acetylneuraminic acid 
(CMP-sialic acid), 3.125 µM rFH expressed in SuperGal and 0.3 µM purified Ph-6ST. Three 
control reactions were also set-up but omitting either CMP-sialic acid, rFH or Ph-6ST. 
Reactions were left to proceed over night at 20 °C. Sialylation reactions were subjected to 
SNA and ECL lectin-based western blot analysis to detect for the presence of sialic acid (fig. 
4.6). 















16.30 27.67 2.63 233.14 13189.1 1.7 400 5276 
Purified Ph-6ST 0.55 0.41 0.09 7.87 445 0.75 12 5.3 
Table 4.6: Absorbance readings at 280 nm, 260 nm and 320 nm and calculated concentrations of pooled fractions from 















A band present in the SNA lectin-based western for the sample that contains CMP-sialic 
acid, Ph-6ST and SuperGal-rFH (lane on far right of figure 4.6) indicates that Ph-6ST is active 
and is catalysing the sialylation of rFH. In the ECL lectin-based western, ECL cannot bind to 
glycans if sialic acid is present on the glycan. The presence of a strong band in the lane on 
the far right of the ECL lectin-based western blot indicates that there is still a substantial 
proportion of glycans on SuperGal-expressed rFH that have not been sialylated. Therefore, 
the next step was to optimise the reaction conditions for sialylation of rFH expressed in P. 
pastoris strain SuperGal. 
 
4.3.4 Optimisation of sialylation of complex galactose terminal glycans by Ph-6ST 
 
To assess sialylation of the galactose-terminating complex glycans carried by rFH, two lectin 
ELISA procedures were implemented. The first used SNA lectin to detect for the presence 
of sialic acid, while the second used ECL to detect for the presence of terminal N-
acetyllactosamine. These two ELISAs together would show the relative proportion of 
sialylated to non-sialylated (terminal N-acetyllactosamine) glycans. 
 
For standard curve production in the SNA ELISA, human plasma-purified FH was used. For 
the ECL ELISA standard curve, human plasma-purified FH that had been desialylated under 
native conditions (i.e. not denatured) was used. The extent of sialylation of both standards 
was confirmed by SDS-PAGE and lectin-based western blot (fig. 4.7). 
Figure 4.6: ECL and SNA lectin-based western blot analysis of SuperGal expressed rFH subjected to sialylation catalysed 
by purified Ph-6ST. Top is the ECL LacNAc binding lectin-based western blot. Bottom is the SNA sialic acid binding lectin-














Inspection of the SDS-PAGE (fig 4.7) lanes to the left of the MW markers, reveals the 
expected small reduction in MW for desialylated hFH compared to sialylated. The ECL 
lectin-based western confirms that ECL lectin binds to desialylated hFH but not to sialylated 
hFH. Conversely, the SNA lectin-based western blot shows that SNA lectin binds to hFH but 
not to desialylated hFH. This confirms that hFH, to be used for SNA ELISA standard curve, is 
sialylated and that desialylated hFH, to be used for ECL ELISA standard curve, is largely 
desialylated. 
 
Two separate previous studies explored conditions needed for Photobacterium sp. α(2,6)-
sialyltranferase activity. Tsukamoto et al. (2008) studied full-length α(2,6)-sialyltransferase 
and a truncated version with deletion of the N-terminal amino acids 2-17 (Δ2-17α(2,6)-
sialyltransferase).  The other study (Ding et al. (2011)) used Ph-6ST (that is N- and C-
terminally deleted Photobacterium sp. α(2,6)-sialyltransferase with a C-terminal His6 tag), 
as used in the current study. In Tsukamoto et al. (2008), sialylation was carried out at 
between 25 - 30° C and reactions were allowed to proceed for up to 48 hrs. In Ding et al., 
sialylation reactions were carried out at 20 °C for 20 minutes. Neither study used 
glycoproteins as substrate and the substrates that were used were mono- and 
disaccharides of lactose or N-acetylgalactosamine conjugated to various tags. Sialylation 
was observed by HPLC analysis in both studies on all of the substrates tested. Due to this 
lack of previous reports for glycoproteins as substrates for this enzyme, it was necessary to 
optimise conditions for sialylation of galactose-terminal glycans on rFH, from scratch. 
 
Figure 4.7: SDS-PAGE (top) and lectin-based western blots to detect for N-acetyllactosamie (middle) and sialic acid 
(bottom) of sialylated and enzymatically desialylated human plasma-purified FH (hFH). The standards to the left of 
the MW markers were prepared under optimal, denaturing conditions whilst test samples (standards for ELISA) 
were prepared under non-denaturing conditions. Molecular weight markers are measured in kDa. Desialyl-hFH is 
hFH desialylated with α(2-3,6,8)-neuraminidase. Deglycolyl-hFH is hFH deglycosylated with PNGase F. + and – 




Importantly, because of inherent heterogeneity in the hFH glycoprofile, these ELISAs were 
not able to provide absolute quantitative information on sialic acid/galactose content for 
rFH. Instead, they gave an approximation of the relative amounts of sialic acid/galactose on 
Ph-6ST-treated rFH carrying humanised galactose-terminal glycans, under the different 
conditions tested. The temperatures and incubation times for the sialylation reactions were 
varied, and the extent of sialylation was measured using lectin ELISA (fig. 4.8). 
For all sialylation reactions a ten-molar excess of CMP-sialic acid, relative to rFH, was used. 
The molar excess was based upon a prediction of the number of potential sialylation sites 
(LacNAc antennae) on the glycans carried by rFH. All eight N-linked glycosylation sites of 
rFH were assumed to be occupied by diantennary, digalactosylated, complex-type glycans. 
This would yield 16 LacNAc motifs (two per glycan) that could potentially be sialylated. 




















Figure 4.8: Standard curves for terminal N-acetyllactosamine (A) and for terminal sialic acid (B) detection by ECL 
lectin-based and SNA lectin-based ELISAs, respectively. Both standard curves were a 1:2 dilution series, starting at 
10 µg/mL, of desialylated hFH and untreated hFH, respectively.  Measurement of relative amounts of terminal N-
acetyllactosamine (C) and terminal sialic acid (D), by ECL lectin-based or SNA lectin-based ELISA, on rFH treated with 
Ph-6ST at different incubation temperatures and reaction times. SiaT- is the reaction without Ph-6ST, hr is hours, 
hFH is human plasma-purified FH and hFH LI is hFH exposed to lectin incubated with the lectins inhibitory sugar (0.5 




The data for ECL ELISA (fig. 4.8 C) show that, as expected,  in the absence of Ph-6ST 
galactose terminal rFH is not sialylated. The data also show that the positive control, 
desialylated hFH, is bound by ECL lectin and that, when ECL is incubated with an inhibiting 
sugar (0.5 M galactose), binding by ECL to desialylated hFH is abolished. 
At all incubation times, at 30°C, there is still some glycan antennae that have not been 
sialylated. This was also the case for one hour and four hours incubation times at 20 °C and 
one hour incubationtion time at 10 °C. At four hours and 20 hours incubation times at 10 °C 
there is no detectable terminal N-acetyllactosamine on rFH, indicating that at an incubation 
temperature of 10 °C all available N-acetyllactosamine sites are sialylated by four hours. 
 
Equally, the data from the SNA ELISA (fig. 4.8 D) confirmed that in the absence of Ph-6ST, 
rFH is not sialylated. The SNA lectin binds to the positive control hFH and, when SNA is 
incubated with an inhibitory sugar (0.5 M galactose), binding by SNA to hFH is almost 
completely abolished. The data show that at all incubation temperatures, rFH is sialylated 
after one hour and that incubation at 10 °C results in the highest level of sialylation.  
Sialylation continues to increase from four to 20 hours incubation at 10 °C. Conversely, 
after an initial increase in sialylation from one to 4 hours at 20°C, and after one hour at 30 
°C, the level of sialylation decreases. This indicates that at the higher temperatures of 20 
and 30 °C there is detectable sialidase activity. However, at 10 °C, there is no detectable 
sialidase activity and the forward, sialylation reaction is dominating. These data further 
indicate that the optimal temperature to maximise sialyltransferase activity is 10 °C; and 
that the optimal length of incubation, of these tested herein, is 20 hours. 
 
Incomplete sialylation of rFH could lead to reduced circulatory half-life in vivo due to 
recognition and clearance by asialoglycoprotein receptors. Thus, the inherent sialidase 
activity of Ph-6ST could negatively affect in vivo half-life of rFH. Kang et al. (2015) 
investigated methods to reduce the sialidase activity of three α(2,6)-sialyltransferases, 
including Ph-6ST. Kang et al. (2015) employed two methods to bias the reaction in favour of 
the sialyltransferase reaction. In the first instance, Kang et al. (2015) hypothesised that as 
the sialyltransferase reaction proceeds the pool of CMP-sialic acid is depleted. Over time 
this then allows the sialidase reaction to dominate. Kang et al. (2015) showed that multiple 
additions of CMP-sialic acid, at various time points after the start of the reaction, helped 
improve the level of sialylated product. 
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For the second method, Cheng et al. (2010) show that the cytidine monophosphate (CMP) 
product of a sialyltransferase catalysed reaction, released when sialic acid is transferred 
from CMP-sialic acid to the exposed LacNAc motif at the glycan non-reducing terminus, 
enhances sialidase activity of the Ph-6ST related α(2,6)-sialyltransferase from P. damsela. 
Kang et al. (2015) tested the effect of different nucleotides on sialidase activity of three 
α(2,6)-sialyltransferases (including Ph-6ST). The authors found that CMP increased sialidase 
activity of all three α(2,6)-sialyltransferases, whilst CDP, CTP and cytidine slightly reduced 
sialidase activity. Therefore, Kang et al. (2015) hypothesised that the addition of alkaline 
phosphatase to the reaction would dephosphorylate CMP evolved in the sialylation step 
and thus, ameliorate sialidase activity. Kang et al. (2015) were subsequently able to show 
that alkaline phosphatase did indeed reduce sialidase activity of the three α(2,6)-
sialyltransferases tested. 
 
However, the temperature and time of incubation for sialyltransferase assays, conducted 
by Kang et al. (2015), were 30 °C for 30 minutes. These conditions are different from the 
optimal conditions for Ph-6ST determined in this study. Therefore, the effects of multiple 
additions of the substrate CMP-sialic and alkaline phosphatase, separately and together, 
throughout the reaction were explored and assessed by ECL and SNA ELISA. Three sets of 
nine sialyltransferase reactions were carried out with either one, two or three ‘feeds’ with 
either CMP-sialic acid (in addition to the CMP-sialic acid included in the reaction mixture at 
the start of the reaction) or alkaline phosphatase - on their own - or CMP-sialic acid plus 
alkaline phosphatase at 30 minutes, two hours and four hours from the start of each 
















Figure 4.9: Standard curves for terminal N-acetyllactosamine (A) and for terminal sialic acid (B) detection by ECL and 
SNA lectin ELISA, respectively. Measurement of relative amounts of terminal N-acetyllactosamine (C) and terminal 
sialic acid (D), by ECL and SNA lectin ELISA, on rFH treated with Ph-6ST incubated at 10 °C for 20 hours. The numbers 
1, 2 and 3 refer to the number of feeds with either CMP-sialic acid, alkaline phosphatase or both. Feeds were at 30 
minutes, two hours and four hours from the start of the reaction. SiaT- is the reaction without Ph-6ST, SiaT+ is the 
reaction with Ph-6ST at 10 °C for 20 hours but with no additional feeds, hr is hours, hFH is human plasma-purified 
FH and hFH LI is hFH exposed to lectin incubated with the lectins-inhibitory sugar (0.5 M galactose). DeSia hFH is 




Alkaline phosphatase does not appear to enhance sialylation of rFH and instead multiple 
additions of alkaline phosphatase may actually enhance sialidase activity of Ph-6ST. There is 
no detectable N-acetyllactosamine after a single addition of alkaline phosphatase (fig. 4.9 
C) but after two or three additions, the amount of N-acetyllactosamine detected on rFH 
increases slightly. Supporting this finding, the SNA-lectin ELISA (fig. 4.9 D) shows that 
sialylation is highest after a single addition of alkaline phosphatase, but the amount of sialic 
acid on rFH falls after a second and third addition of alkaline phosphatase. 
 
Multiple additions of CMP-sialic acid improves the sialic acid content of rFH compared to 
no additions (SiaT+ reaction) (fig. 4.9 D). Three additions of CMP-sialic acid confers the 
greatest enhancement to sialylation of rFH by Ph-6ST. Addition of CMP-sialic acid and 
alkaline phosphatase together does not enhance sialylation of rFH beyond that seen with 
three additions of CMP-sialic acid alone. These data suggest that three ‘feeds’ of CMP-sialic 
acid, but not alkaline phosphatase, over the course of the reaction enhances sialylation of 
rFH. 
 
Taken together, these studies suggested that suitable reactions conditions for Ph-6ST-
catalysed sialylation of galactose-terminating diantennary complex glycans on rFH, 
containing 3.125 µM rFH (approximately 50 µM LacNAc), 500 µM CMP-sialic acid, 20 mM 
MgCl2 in Tris buffer at pH 8.0, are as follows: incubation at 10 °C for 20 hours with up to 
three ‘feeds’ of ~1.6 nmol CMP-sialic acid (at 30 minutes, two hours and four hours after 
the start of the reaction). 
 
4.3.5 Purification of Ph-6ST sialylated rFH  
 
In Chapter 3 section 3.3.7, rFH expressed in glycoengineered P. pastoris strain SuperGal 
was purified, and yeast and hybrid-type glycans were enzymatically removed by treatment 
with Endo Hf. After Endo Hf treatment, rFH was purified and confirmed to carry exclusively 
diantennary digalactosylated complex-type glycans by MALDI-TOF mass spectrometry. 
Using the optimal conditions determined in this Chapter, this rFH was then sialylated and 
contaminants were purified away from sialylated rFH by cation-exchange chromatography 












The chromatogram (fig. 4.10 A) for purification of sialylated rFH shows a single peak eluting 
early on in the elution phase (at an elution volume of 150-200 mL). The SDS-PAGE gels 
show a band corresponding to the MW of Ph-6ST in the ten-times concentrated flow-
through (figs. 4.10 B and C). Importantly, no Ph-6ST was detected in the elution peak 
fractions containing rFH. Fractions D6 – E2 (elution volume of 158.5 – 174.5 mL) were 
deemed to contain the highest concentrations of rFH and so were pooled and dialysed into 




Figure 4.10: Cation-exchange chromatogram (A) of the purification of sialylated rFH expressed in glycoengineered P. 
pastoris strain SuperGal and after yeast glycan removal with Endo Hf. SDS-PAGE of human factor H (hFH), purified 
recombinant Ph-6ST expressed in E. coli, flow-through (FT, cFT is 10x concentrated flow through), wash fraction A2 
(elution volume = 80 mL) and peak fractions D2-E6 (elution volumes 150.5 – 182.5 mL) (every second fraction run on 




Measurement of absorbance readings and assessment of purity of cation-exchange purified 
sialylated rFH was hampered by the fact that the nucleoside cytidine (present in the 
substate CMP-sialic acid and the product CMP) absorbs wavelengths of 280 nm and 260 
nm. These cytidine derivatives elevate the A260/A280 ratio of non-purified sialylated rFH (row 
two and three of table 4.7) preventing accurate quantification of protein content. But after 





An approximate total of 34.5 milligrams rFH was sialylated and loaded onto the cation-
exchange chromatography column. After purification and dialysis against PBS, pH 7.4, 19 
milligrams of rFH was recovered. Purified Ph-6ST-treated rFH was then assessed for the 
extent of sialylation by MALDI-TOF mass spectrometry. 
 
4.3.6 Glycan analysis by MALDI-TOF MS of Ph-6ST sialylated rFH  
 
Kang et al. (2015) report that sialylation of diantennary glycans, catalysed by Ph-6ST, can 
yield both monosialylated and disialylated glycans. Binding of ECL lectin to N-
acetyllactosamine is blocked upon sialylation. While complete loss of detectable binding by 
ECL lectin occurred under optimal conditions for Ph-6ST (fig. 4.9 C) it is not known whether 
both antennae of a diantennary complex glycan need to be sialylated to abolish ECL 
binding. Put simply, after treatment of rFH with Ph-6ST, are the glycans monosialylated, 
disialylated or a mixture of the two? 
 
To test this, the glycans were enzymatically liberated from sialylated, purified rFH by 
incubation with PNGase F. The glycans were then purified and analysed by MALDI-TOF 
mass spectrometry to assess the extent of sialylation. 
A260 A280 A260/A280 (μM) (mg/mL)
DiGal rFH 0.329 0.546 0.603 11.06 1.66 20.8
Nonpurified DiSia rFH 0.935 0.917 1.020 18.58 2.79 75.6
Nonpurified DiSia rFH post dialysis 0.497 0.519 0.958 10.51 1.58 83
Purified DiSia rFH pst dialysis 0.210 0.358 0.587 7.25 1.09 17.5
Concentration Absorbance
Sample Volume (mL)
Table 4.7: Absorbance readings at wavelengths of 280 nm and 260 nm for samples of rFH before sialylation, after 
sialylation before and after dialysis and after purification of sialylated rFH by cation-exchange chromatography. DiGal rFH is 






















The mass spectra show that before sialylation (fig. 4.11 A) the glycans on rFH are almost 
exclusively digalactosylated diantennary complex-type glycans. After sialylation (fig. 4.11 B) 
however, the glycoprofile consists of mono- and disialylated diantennary complex-type 
glycans. The disialylated species has the higher relative abundance. Also, there is no 




Figure 4.11: MALDI-TOF mass spectra of the glycoprofile of rFH before (A) and after (B) enzymatic sialylation 








This chapter has demonstrated the successful production of catalytically active, 
recombinant α(2,6)-sialyltransferase from Photobacterium sp. in E. coli and, that this 
sialyltransferase can be used to sialylated rFH expressed in glycoengineered P. pastoris 
strain SuperGal, to yield a protein glycoprofile consisting of mono- and disialylated species. 
What effect the terminal galactose moieties of monosialylated glycans might have on the 
half-life of rFH is unknown. But, due to accelerated clearance of non-sialylated 
glycoproteins from circulation by the asialoglycoprotein receptor (Ashwell and Harford, 
1982 and, Schwartz, 1984 and discussed in Chapter 1 section 1.1.3), it is likely that 
complete sialylation – that is, all glycans in the disialylated form – will be necessary to 
maximise half-life and thus therapeutic efficacy, so this remains an unmet goal. 
 
Kang et al. (2015) first reported sialidase activity of Ph-6ST and, in addition, they compared 
sialidase activity of Ph-6ST with two other bacterial α(2,6)-sialyltransferases and found 
that, under the conditions they used, Ph-6ST has the highest sialidase activity. 
In light of this, with the view to improving the disialylated glycan content of rFH it will be 
necessary to test a range of α(2,6)-sialyltransferases under different experimental 
conditions.  
 
As demonstrated in this chapter, in vitro sialylation hinders downstream processing – this 
would add significant cost to manufacturing processes if rFH expressed in SuperGal were to 
be developed as a biotherapeutic. With this in mind, a strain of P. pastoris glycoengineered 














Consolidation of the humanised glycan biosynthetic pathway onto a single 




The aim of this work was to engineer P. pastoris to biosynthesis a fully humanised terminal 
sialylated complex-glycan in vivo. This was achieved in Chapter 3. However, the 
GlycoSwitch technology, as well as stopping short of the fully humanised sialylated glycan, 
had additional draw backs: i) it used all available dominant, antibiotic resistant selectable 
markers available for use in P. pastoris, ii) potential for plasmid integrant instability due to 
repeated use of the same, limited set of regulatory gene sequences and, iii) potential for 
bottle necks in the biosynthetic pathway due to this same limited set of regulatory 
elements. Each draw-back will be discussed below. 
 
i) Dominant, antibiotic resistant selectable markers 
Antibiotic selectable markers present several advantages over selection by auxotrophic 
gene complementation in that they offer straightforward dominant selection without the 
need for production of auxotrophic strains by gene knockout, this is especially 
inconveniencing for instances where multiple genes are introduced for biosynthetic 
pathway manipulation. An additional advantage of selection by antibiotic resistance is that 
strains that contain multiple copies of a target plasmid can be selected for by increasing 
concentrations of antibiotic (Sunga et al., 2008 and, Gong et al., 2013b) – a useful tool for 
increasing protein titres or overcoming biosynthetic pathway bottlenecks by increasing 
expression of low efficiency enzymes. 
However, P. pastoris lacks antibiotic resistant selectable markers, just five have been 
reported. These confer resistance to the antibiotics blasticidin S (Drocourt et al, 1990 and, 
Kimura et al, 1994), Zeocin™ (Chen et al., 2012), hygromycin (Yang et al., 2014), G418 
(Scorer et al., 1994) and nourseothricin (Chen et al., 2012).  The glycoengineering 
technology platform, GlycoSwitch (including the starting glycoengineered strain SuperMan 
5), uses all five antibiotic selectable markers available for use in P. pastoris (Jacobs et al., 
2009). To demonstrate the lack of P. pastoris antibiotic selectable markers available, in this 
study the Zeocin™ selectable marker was used twice. This marker was present in both the 
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pPICZα plasmid containing the CFH gene, as well as on the pGlycoSwitch-GnTI plasmid 
containing the gene GnTI encoding GlcNAc transferase I. In this regard, as SuperMan5 CFH 
was already Zeocin resistant, GnTI expressing strains could not be selected for on the basis 
of Zeocin resistance. So, careful selection methods were required, based on identification 
of the GlcNAc transferase I modification to the glycosylation pathway, to select for strains 
that expressed both CFH and GnTI. 
One of the principal aims of this study was to attempt the ambitious step of sialylation of 
rFH in vivo. This procedure would involve the introduction into P. pastoris of the six genes 
responsible for biosynthesis of Neu5Ac, charging with cytidine monophosphate (CMP), 
transport of CMP-Neu5Ac into the golgi and transfer of Neu5Ac onto LacNAc glycan 
termini. Therefore, making available antibiotic resistant selectable markers would reduce 
the number of genetic manipulation steps involved for bioengineering in the fully 
humanised glycan biosynthetic pathway. 
 
ii) Plasmid integrant stability 
Demonstration of genetic stability of strains produced by recombinant DNA technology is a 
key requirement as outlined by the World Health Organisation (WHO, 2013) and is an 
important factor in ensuring the quality of a recombinant biotherapeutic (Burns, 1993). Lim 
et al. (2000) produced a multi-copy integrant strain of P. pastoris, expressing the 
recombinant protein Gaurmerin, and was able to show that this strain was stable up to 70 
generations, exceeding the approximately 20 generations P. pastoris goes through in a 
standard high-cell density, large scale fermentation process. However, Lim et al. (2000) 
showed that the multi-copy integrant strain held just two copies of the expression cassette. 
In comparison, the SuperGal CFH strain produced in this study (Chapter 3) contains 5 copies 
of the Glyceraldhyde-3-phosphate promoter (GAPp), 4 exogenous and 1 endogenous (the 
site of integration), 4 exogenous alchohol oxidase I terminator sequences (AOXIt), 3 
exogenous translation elongation factor 1-α promoters (TEFp), 3 exogenous terminator 
sequences from Ashbya gossypii and 4 pUC vector plasmid backbone sequences (for 
plasmid amplification in E. coli). Assuming all plasmids integrated in neighbouring genomic 
GAPp sites, these homologous sequences will be near each other in the genome. Thus, 
there is a real risk that the SuperGal CFH strain could be genetically unstable and that loss 
of one or more integrated pGlycoSwitch plasmids by homologous recombination could 
occur during long-term storage and fermentation. Indeed, in confirmation of the 
significance of ensuring genetic stability, efforts have been made in the literature to 
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develop novel promoter sequences with the specific intention to reduce the number of 
repeat sequences in extensively genetically engineered P. pastoris (Vogl et al., 2015). 
 
iii) Potential for bottlenecks in the engineered glycan biosynthetic pathway 
Unlike DNA/RNA or protein synthesis, glycan synthesis is a non-template driven process 
and the glycan sequences is dependent on the spatial-temporal localisation and relative 
activities of the glycan biosynthetic enzymes in the secretory pathway. The GlycoSwitch 
technology incorporates peptide localisation sequences into the exogenous glycan 
modification enzymes to ensure the spatial-temporal demand for correct glycan sequence 
is met. For example, the early acting ManI is localised to the ER – golgi by fusion to the 
HDEL ER retention signal sequence (Callewaert et al., 2001). Conversely fusion of GnTI with 
the transmembrane domain from the S.cerevisae α(1,2)-mannose transferase Kre2p 
localises the enzyme to the cis-medial golgi (Lussier et al., 1995 and, Vervecken et al., 
2004). This is a necessary process to avoid missed steps in the glycan biosynthetic process. 
However, low enzyme activity in the biosynthetic pathway could also be a cause of missed 
steps in glycan biosynthesis. For example, a particular enzyme at a specific point in the 
glycan biosynthetic pathway with low activity may not be able to catalyse the formation of 
its product as efficiently as an enzyme which acts before it in the pathway. The result will 
be a build-up of substrate for the low activity enzyme. 
 
Efforts have been made to fully characterise promoter libraries with the aim of fine control 
of gene expression to optimise protein expression or to manipulate flux of biosynthetic 
pathways. Most of these libraries have focused on E. coli (Alper et al., 2005 and, Nevoigt et 
al., 2007), however, a few have sort to develop promoter libraries in P. pastoris 
(Stadlymayr et al., 2010; Qin et al., 2011; and, Vogl and Glieder, 2013). These libraries have 
identified promoters of strengths varying from weak to strong, and present a useful tool kit 
for the intelligent design for the remodelling of the GlycoSwitch glycan biosynthetic 
pathway. Jacobs et al. (2009) noted that the doubling time of the P. pastoris strain with 
humanised glycosylation was double that of the SuperMan 5 strain. It is likely that repeat 
use of the high expression strength GAPp has burdened the cell with high level gene 
expression compromising its growth potential. Therefore, consolidation of the GlycoSwitch 
technology onto a single expression plasmid presented the opportunity to identify genes 
encoding biosynthetic glycosyltransferases with low activity and to couple these genes to 
promoters with strong expression profiles, and vice versa, with the aim of predicting and 
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overcoming potential bottlenecks in the glycan biosynthetic pathway to reduce glycan 
heterogeneity and to ease the protein expression burden of the cells. 
 
5.1.1 OCH1 encodes α(1,6)-mannosyltransferase 
 
OCH1 encodes α(1,6)-mannosyltransferase in yeast (Nakayama et al., 1992). During yeast 
glycan biosynthesis, covered in Chapter 1 section 1.4.1, the gene product of OCH1 (OCH1) 
catalyses the transfer of a single Man onto the 8 Man glycan as it leaves the ER (Nakayama 
et al., 1997). The 9 Man product is the substrate for further mannosyltransferases which 
lead to the formation of hypermannosylated glycans in yeasts. 
 
Vervecken et al. (2004) hypothesised that deletion of the P. pastoris OCH1 gene would 
prevent hypermannosylation and that the subsequent 8 Man glycan could serve as a 
platform for further in vivo glycoengineering. Vervecken et al. (2004) achieved an Δoch1 
knockout strain by incorporating a truncated version of the och1 gene into a vector plasmid 
(fig. 5.1). RE digestion at a site within the truncated och1 gene and transformation into P. 
pastoris allowed for single site homologous recombination to occur between the 
endogenous OCH1 gene and the truncated och1 sequence. This resulted in a plasmid 
































The aim of this study was initially to consolidate the first half of the GlycoSwitch technology 
onto a single plasmid with a view to glycoengineering a P. pastoris strain with an 
unmodified glycosylation pathway, KM71H, to produce a hybrid-type glycan with a single 
LacNAc antenna, Gal1GlcNAc1Man5GlcNAC2. Included in this plasmid was a truncated och1 
sequence that, when linearised, would direct plasmid integration at the endogenous 
genomic OCH1 locus whilst simultaneously deleting the OCH1 gene. In addition, this 
plasmid was generated with unique promoter-gene-terminator pairs with a view to predict 
and overcome bottlenecks in the biosynthetic pathway by coupling promoter strength to 
enzymatic activity and to reduce potential genetic instability from repeated use of the 
same promoter and terminator sequences. 
 
 
Figure 5.1: Schematic diagram of the simultaneous plasmid integration and OCH1 gene deletion. The truncated 
och1 sequence (purple striped rectangle) has on the 5’ end an in frame stop codon (small yellow rectangle) and in 
frame at the 3’ end is the TPS1t terminator sequence (red rectangle). Linearisation in the truncated och1 by RE 
digest using the RE MfeI, prior to transformation into P. pastoris, facilitates single homologous recombination 
between the plasmid truncated och1 sequence and the P. pastoris genomic OCH1 gene. After homologous 
recombination, the genomic OCH1 gene is divided into two halves, with the plasmid inserted in the centre. The 5’ 
end of the plasmid places a premature stop codon in frame and downstream of the 5’ half of the OCH1 sequence. 
The 3’ end of the plasmid places the TPS1t terminator sequence upstream and in frame of the 3’ end of the OCH1 
gene to prevent transcriptional readthrough from the plasmid to the 3’ end of OCH1.  
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5.2 Materials and Methods 
 
5.2.1 InABLE plasmid assembly 
 
5.2.1.1 Truncated part PCR amplification 
 
All primers and oligonucleotide sequences were ordered from Sigma Genosys. P. pastoris 
codon optimised ManI and truncated och1 gene sequences were synthesised by Invitrogen 
GeneArt gene synthesis service (sequences in the appendix). ManI and och1 were designed 
as readily useable parts for inABLE assembly and flanked by type II S RE recognition sites for 
liberation of the part from the vector plasmid backbone. The type II S RE will bind at the 
recognition site, move along the DNA strand and cut at a defined distance from the 
recognition site. In silico design ensures the type II S RE cuts the TP to generate the 5’ and 
3’ TP overhangs necessary for ligation with PO and LO sequences. For use in inABLE the 
following DNA sequence had to be PCR amplified using primers designed to incorporate 
type II S RE sites at either end of the DNA sequence: GnTI, GalT (including shuttle vector 
plasmid backbone), AODt and ILV5p. PCR reactions were carried out using KOD Hot Start 
DNA Polymerase (Merck Millipore) (och1, GnTI, AODt and ILV5p) or Q5 Hot Start High-




Table 5.1: Reaction components and PCR cycle conditions for PCR amplification of inABLE truncated parts using 
either KOD Hot Start DNA polymerase or Q5 Hot Start High-Fidelity (HF) DNA polymerase.  
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The following primers were used for PCR amplification, type II S RE recognition sites are 
capitalised: 
 
5.i) GnTI_For: 5’ – gagagaagcggccgcGCTCTTCgcaggtgcggttattgttc – 3’ 
5.ii) GnTI_Rev: 5’ – ttagatctcgagGCTCTTCgggcctaattccagtaggatcatag – 3’ 
5.iii) GalT_bb_For: 5’ –  gaggaatctagaGCTCTTCgtagttttgatattgtgcgggc – 3’ 
5.iv) GalT_bb_Rev: 5’ – ttagatttaattaaGCTCTTCgggcttgagatcctttttttctgcg – 3’ 
5.v) AODt_For: 5’ – gaggaagcggccgcGCTCTTCgaaccaattcaggcaatgtg – 3’ 
5.vi) AODt_Rev: 5’ – ttagatctcgagGCTCTTCgggcatgtatacggatgttttattatctatttatgc – 3’ 
5.vii) ILV5p_For: 5’ – gaggaagcggccgcGCTCTTCgttgacttcgtgaaagtttctttag – 3’ 
5.viii) ILV5p_Rev: 5’ – ttttttcggataattttttaaagcgttagatctcgagGCTCTTCgggcaaaa – 3’ 
 
The PCR products were separated by 1.0% (w/v) agarose gel electrophoresis (100 V, 45 
minutes) (fig. 5.1 A) and gel extracted using Zymoclean gel DNA recovery kit (Zymo 
Research), procedure in Chapter 4 section 4.2.1.1. The remaining parts ADH1p, GAPp, 
GAL7t, and TPS1t existed as pre-generated parts, flanked by type II S RE recognition sites 
and cloned into plasmids for selection and amplification in E. coli. 
 
5.2.1.2 Linker and Part Oligonucleotide phosphorylation and annealing: first round 
 
In matched pairs, single-stranded oligonucleotides were subjected to a phosphorylation 
and annealing reaction, procedure in Chapter 4 section 4.2.1.2, to yield LO/PO_X.1, 
LO/PO_A.2, LO/PO_A.3, LO/PO_X.2, LO/PO_X.3, LO/PO_B.2, LO/PO_B.3, LO/PO_X.4, 





5.2.1.3 Part-linker fusion reactions: A1-3, B1-3 and C1-3 
 
Twelve separate part-linker fusion reactions were set up, conditions in Chapter 4 section 










Part-linkers were isolated by 1% (w/v) agarose gel electrophoresis (100 V, 45 minutes) (fig. 
6.2), gel extracted and purified using a Zymoclean gel DNA recovery kit (Zymo Research) 
according to conditions in Chapter 4 section 4.2.1.1. DNA concentration of gel extract part-
Table 5.2: Pairs of oligonucleotide sequences annealed and phosphorylated to produce LO and POs associated with 
truncated parts A.1-4, B.1-4 and C.1-4 required for the assembly of “nested” parts A, B and C. 
Oligo length LO strands Sequence 5' - 3' PO strands Sequence 5' - 3' 
Long A.2 gccatgagatttccttctagttccgtcttggcac A.2 ctggtccaatcaatccaagtgccaagacggaact
Short A.2 agaaggaaatctcat A.2 ttggattgattggac
Long A.3 gcctgcagctaaggtaatcagatccaagtttccc A.3 gtttgccccggaagattggggaaacttggatctg
Short A.3 attaccttagctgca A.3 caatcttccggggca
Long B.2 gccatggccctctttctcagtaagagactgttga B.2 ctgcaatgacggtaaatctcaacagtctcttact
Short B.2 gagaaagagggccat B.2 gatttaccgtcattg
Long B.3 gccaaagaaagtggaatattcattcatatcatat B.3 aggcagctaatagaaaaaatatgatatgaatgaa
Short B.3 tattccactttcttt B.3 tttttctattagctg
Short C.2 gccatgctgcttaccaaaaggttttcaaagctgt C.2 ctatgaacgtcagcttgaacagctttgaaaacct
Short C.2 tttggtaagcagcat C.2 tcaagctgacgttca
Long C.3 gcctggtaagctatattcgccgtttctgtcattt C.3 agggtccgtacaaaacgcaaatgacagaaacggc
Short C.3 gaatatagcttacca C.3 gcgttttgtacggac
Long X.1/3/5 gccatgaaacattcttccgatatctgcattgttg X.1 gtacgaagagaccagcaccaacaatgcagatatc
Short X.1/3/5 ggaagaatgtttcat X.1 gtgctggtctcttcg
Long X.2/4/6 gcccgaagagacaggtggcacttttcggggaaatgtgcgcggaa X.3 agacgaagagaccagcaccaacaatgcagatatc





Table 5.3: Twelve part-linker fusion reactions were set up. Each PO and LO associates with a truncated part via 
overhanging complementary triplet sequences at the 3’ end of PO, 5’ end of LO and 5’ and 3’ ends of the part. Part-







1 PO_X.1 A.1 LO_A.2 7.60
2 PO_A.2 A.2 LO_A.3 18.50
3 PO_A.3 A.3 LO_X.2 12.20
4 PO_X.2 A.4 LO_X.1 12.20
5 PO_X.3 B.1 LO_B.2 2.40
6 PO_B.2 B.2 LO_B.3 16.10
7 PO_B.3 B.3 LO_X.4 2.30
8 PO_X.4 B.4 LO_X.3 12.20
9 PO_X.5 C.1 LO_C.2 8.50
10 PO_C.2 C.2 LO_C.3 2.24
11 PO_C.3 C.3 LO_X.6 3.20
12 PO_X.6 B.4 LO_X.5 58.60
158 
 
linkers was measured by fluorimetry (Invitrogen, Qubit) (fig. 5.3) and DNA molecular 
weights were calculated using the part-linker fusion DNA sequences and the online 
“Sequence Manipulation Suite: DNA Molecular Weight” software. 
 
5.2.1.4 inABLE assembly of “nested” parts A, B and C 
 
The inABLE DNA assembly reaction was carried out by combining the part-linker fusion 
products in the proportions outlined in table 6.4 and incubating at 37 °C for 30 minutes. 
 
 
The assembled plasmids A, B and C were transformed into E. coli electrocompetent TOP10 
(One Shot TOP10 Electrocomp E. coli, ThermoFisher Scientific, C404050) by electroporation 
(1.7 kV, 25 µF) and transformed cells were spread plated onto LB agar containing 100 
µg/mL ampicillin (ThermoFisher Scientific) (A and B) or 50 µg/mL nourseothricin sulphate 
(Carbosynth) (C) and incubated at 37°C for approximately 16 hours. 
Transformation colonies, containing the assembled vector plasmids, were selected by 
colony PCR followed by DNA agarose electrophoresis (data not shown), procedure in 











PO_X.1-A.1-LO_A.2 2.6 PO_X.3-B.1-LO_B.2 5.6 PO_X.5-C.1-LO_C.2 1.3
PO_A.2-A.2-LO_A.3 2.6 PO_B.2-B.2-LO_B.3 2.5 PO_C.2-C.2-LO_C.3 2.8
PO_A.3-A.3-LO_X.2 1.0 PO_B.3-B.3-LO_X.4 6.1 PO_C.3-C.3-LO_X.6 4.9
PO_X.2-A.4-LO_X.1 4.5 PO_X.4-B.4-LO_X.3 4.5 PO_X.6-C.4-LO_X.5 4.3
Buffer 2 (10x) 1.5 Buffer 2 (10x) 2.5 Buffer 2 (10x) 1.8
PEG 8000 (50%[w/v]) 1.5 PEG 8000 (50%[w/v]) 2.5 PEG 8000 (50%[w/v]) 1.8
SapI 1.0 SapI 1.0 SapI 1.0
Total Volume 14.6 Total Volume 24.6 Total Volume 17.9
A  B C
Table 5.4: Three assembly reactions were set up, using the part-linkers generated previously (table 5.3), to yield 
three “nested” parts A, B and C. Each assembly reaction contained a backbone plasmid part-linker encoding an 










DNA, from two clones each identified by colony PCR to contain the assembled plasmids A, B 
or C, was prepared using Mini-prep (Qaigen) plasmid preparation kit, procedure in chapter 
4 section 4.2.1.4. Correct assembly of plasmids was further confirmed by restriction 
mapping of purified plasmids A, B and C using the REs Alwn I, BsaB I and Cla I (plasmid A), 
Xba I and Xcm I (plasmid B) and, Mfe I, Pvu I and Sph I (plasmid C) (fig. 5.3). The RE mapping 
reaction was as follows, 500 ng plasmid was combined with 0.5 µL of each RE and 2 µL 
Cutsmart buffer and reactions were made up to 20 µL with ddH2O. RE and Cutsmart buffer 
are from New England Biolabs. RE map DNA fragments were isolated and visualised by DNA 
1% (w/v) agarose electrophoresis (100 V, 45 minutes). 
 
5.2.1.5 Linker and Part Oligonucleotide phosphorylation and annealing: second round 
 
For the second step in the “nested” assembly, oligonucleotides, in matched pairs, were 
annealed and phosphorylated, procedure in Chapter 4 section 4.2.1.2, to yield the LO and 





Oligo length LO strands Sequence 5' - 3' PO strands Sequence 5' - 3' 
Long A.1 gcctagggggtgtacaatatggacttcctctttt A.1 gtatgggtttggttgccagaaaagaggaagtccat
Short A.1 attgtacacccccta A.1 ctggcaaccaaaccca
Long B.1 gcctttttgtagaaatgtcttggtgtcctcgtcc B.1 agagatggctacctgattggacgaggacaccaag
Short B.1 acatttctacaaaaa B.1 aatcaggtagccatc
Long C.1 gccgatccttcagtaatgtcttgtttcttttgtt C.1 caaaatggctcaccactgcaacaaaagaaacaaga
Short C.1 cattactgaaggatc C.1 gcagtggtgagccatt
Table 5.6: Pairs of oligonucleotide sequences annealed and phosphorylated to produce LO and POs associated with 
truncated parts A.1, B.1 and C.1 required for the assembly of pPpGalHy from “nested” parts A, B and C. 
Table 5.5: PCR primers and extension times of colony PCRs carried out on colonies of E. coli TOP10 electocompetant 
cells transformed with either plasmid A, B or C. 

















5.2.1.6 Part-linker fusion reactions: A, B and C 
 
Three separate part-linker fusion reactions were set up, according to conditions in Chapter 
4 section 4.2.1.3. PO, LO and parts were combined according to table 5.7 to yield “nested” 






Part-linkers were isolated by 1% (w/v) agarose gel electrophoresis (fig. 5.5), gel extracted 
and purified using a Zymoclean gel DNA recovery kit (Zymo Research) according to 
conditions in Chapter 4 section 4.2.1.1. DNA concentration of gel extract part-linkers was 
measured by fluorimetry (Invitrogen, Qubit) and DNA molecular weights were calculated 
using the part-linker fusion DNA sequences and the online “Sequence Manipulation Suite: 
DNA Molecular Weight” software. 
 
5.2.1.7 inABLE assembly of pPpGalHy 
 
The inABLE DNA assembly reaction was carried out by combining the part-linker fusion 
















1 PO_A.1 A LO_B.1 366
2 PO_B.1 B LO_C.1 924
3 PO_C.1 C LO_A.1 924
Table 5.7: Three part-linker fusion reactions were set up to generate “nested” part-linkers for the assembly of 







Buffer 2 (10x) 1.5




Table 5.8: An assembly reaction was set up, using the “nested” part-linkers generated previously (table 5.7), to yield 
the plasmid pPpGalHy.  
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The assembled plasmid pPpGalHy was transformed into E. coli electrocompetent TOP10 
(1.7 kV, 25 µF) and transformed cells were spread plated onto LB agar containing 50 µg/mL 
nourseothricin and incubated at 37°C for approximately 16 hours. 
Transformation colonies, containing the assembled vector plasmid, were selected by colony 
PCR followed by DNA 1% (w/v) agarose electrophoresis (100 V, 45 minutes) (data not 
shown), colony PCR procedure in chapter 4 section 4.2.1.4. Primers and extension times for 





DNA, from two clones identified by colony PCR to contain the assembled plasmid 
pPpGalHy, was purified using Mini-prep (Qaigen) plasmid preparation kit, procedure in 
chapter 4 section 4.2.1.4. Correct assembly of the plasmid was further confirmed by 
restriction mapping using the REs EcoR V and Xba I in Cutsmart buffer (New England 
Biolabs) (fig 5.6), procedure in section 5.2.1.4. RE map DNA fragments were isolated and 
visualised by DNA 1% (w/v) agarose electrophoresis (100 V, 45 minutes). 
 
5.2.2 pPpGalHy transformation, selection and shake-flask culture of P. pastoris KM71H CFH 
 
5.2.2.1 pPpGalHy transformation of P. pastoris KM71H CFH 
 
Purified pPpGalHy was sequenced using Edinburgh genomics gene sequencing service. 
After analysis of sequencing data and confirmation of correct assembly, 40 μg of purified 
pPpGalHy (40 ng/μL) was linearised by digestion with the RE MfeI-HF (7.5 µL, 20kU/mL), 
cutsmart buffer (75 µL) and made up to 1.5 mL with ddH2O and incubated at 37 °C for 
approximately 16 hours. Linearisation of pPpGalHy was assessed by separation of an 
aliquot by 1% (w/v) agarose gel electrophoresis (100 V, 45 minutes). Linear pPpGalHy was 
concentrated by isopropanol precipitation, procedure in Chapter 3 section 3.2.1.2, and 4 
µg, in a 10 µL volume of H2O, was used to transform electocompetant P. pastoris strain 
KM71H CFH, competency procedure in Chapter 3 section 3.2.1.3. Transformed cells were 






Table 5.9: PCR primers and extension times for the colony PCR carried out on colonies of E. coli TOP10 
electocompetant cells transformed with pPpGalHy. 
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plated on YPD agar containing nourseothricin (100 µg/mL) and incubated at 30 °C for 6 
days. 
 
5.2.2.2 Selection of transformed P. pastoris by colony PCR 
 
Approximately 150 colonies grew on the nutrient agar plates. 46 of these were analysed by 
two different colony PCRs to detect for the present of the pPpGalHy plasmid. Colonies were 
culture and crude genomic DNA prepared and subjected to PCR using OneTaq DNA 
polymerase (New England Biolabs) using the primers and extension times in table 5.10 and 







DNA products of PCR reactions were visualised by 1% (w/v) agarose gel electrophoresis 
(100 V, 45 minutes) (fig. 5.7 and 5.8). 
 
5.2.2.3 Shake-flask culture and expression of FH in P. pastoris transformed with pPpGalHy 
 
Nine colonies of KM71H CFH transformed with pPpGalHy were randomly selected for shake 
flask fermentation and expression of FH. The nine colonies, and a tenth taken from a 
glycerol stock of parental strain KM71H CFH (not transformed with pPpGalHy), were used 
to inoculate 5 mL BMGY media containing 100 µg/mL nourseothricin sulphate in 50 mL 
conical tubes (Falcon). These starter cultures were left to incubate at 30 °C, 250 rpm 
shaking for approximately 16 hours. OD600 of the starter cultures was monitored and when 
it reached 0.8 – 1.5 25 mL BMGY media in 100 mL baffled shake flasks was inoculated with 
50 μL of the starter cultures and left to incubate at 30 °C, 250 rpm for approximately 60 
hours. Cell cultures were transferred to 50 mL conical tubes (falcon) and centrifuged at 4 
°C, 1600 rpm for 20 minutes. The supernatant was removed and discarded and the pellet 
was resuspended in 5 mL induction media (BMMY). Cultures were transferred to fresh 50 










Table 5.10: PCR primers and extension times for the colony PCR carried out on colonies of P. pastoris KM71H CFH 
cells transformed with pPpGalHy. 
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mL baffled flask and incubated at 16 °C, 250 rpm for approximately 96 hours. Cultures were 
fed with 50 μL pure methanol at 24 hours, 48 hours, 72 hours and 80 hours post induction. 
Cultures were transferred to 50 mL conical tubes and centrifuged at 4 °C, 1600 rpm for 20 
minutes. Supernatant was removed and transferred to fresh 50 mL conical tubes on ice and 
1% (v/v) EDTA (250 mM stock) and 0.5% (v/v) PMSF (100 mM stock) protease inhibitors 
were added. 1 mL aliquot of each culture supernatant was removed for SDS-PAGE and 
western blot analysis, the remainder was stored frozen at -20 °C. 10 μL of each culture 
supernatant was added to 40 μL SDS loading buffer and 10 μL of this was loaded onto three 
4-12% bis-tris polyacrylamide gels (Bolt Plus, 15-well, ThermoFisher Scientific) along with 
FH protein standards and the gel was run (200 V, 35 minutes). One gel was stained with 
Coomasie InstantBlue stain (Expedeon) the other two gels were subjected to lectin-based 
western blot procedure in chapter 2 section 2.2.2.1. One western blot was exposed to DAB 
substrate (metal enhanced, ThermoFisher Scientific) for 1 minute 30 seconds, the other to 
substrate for 8 minutes. 
 
5.3 Results  
 
5.3.1 Promoter-gene pairing 
 
There are 3 genes involved in the GlycoSwitch hybrid glycan biosynthesis pathway. The 
specific activities of these enzymes were compared to identify if any have a significantly 
low specific activity (Table 5.11). 
 
 
Using the MW of the enzymes and the specific activities per unit mass enzyme, the molar 
specific activity of each enzyme was calculated (last row table 5.2). Consideration of 
differences in MW allowed for a fairer comparison of specific activity. GnTI has the lowest 
enzymatic activity (Chen et al., 2008) whilst ManI (Maras et al., 2000) and GalT (Krezdorn et 
al., 1993 and, Malissard et al., 1996) have similar activities. 
 
Table 5.11: Specific activities of enzymes used in humanising the glycosylation biosynthetic pathway in P. pastoris. 
U (μmol/min) is the enzyme activity as measured by the amount of substrate used in the enzymatic reaction per 
minute. 
Enzyme Specific Activity (U/mg) Molecular Weight (kDa) Specific Activity per Mole (U/nmol)
Mannosidase I (ManI) 6.70 56.2 0.38
N-acetylglucosamine transferase I (GnTI) 0.48 50.9 0.03
Galactose transferase (GalT) 4.7 - 8.4 44.1 0.21 - 0.37
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The P. pastoris TEFp is a high-level expression, constitutive promoter (Ahn et al., 2007) that 
has routinely been used as the standard for comparison of P. pastoris promoter controlled 
gene expression levels (promoter strength or activity). Literature data for the promoter 




 All promoters in table 5.12 are constitutive promoters. The GAPp has the highest activity 
with an activity equal to the TEFp promoter (Partow et al., 2010 and, Stadlmyer et al., 
2010), the alcohol dehydrogenase 1 promoter (ADH1p) has an activity approximately one 
quarter of TEFp (Partow et al., 2010) whilst the acetohydroxy acid isomeroreductase 
promoter (ILV5p) had the lowest relative activity (Vogl and Glieder, 2013).  
 
The low activity of GnTI compared to the other enzymes (table 5.11) could cause a 
bottleneck in the glycan biosynthetic pathway. Therefore, to overcome this potential 
bottleneck, the GnTI encoding gene was placed under the control of GAPp, the strongest 
available promoter. The remaining promoters were randomly assigned to the other genes. 
 
5.3.2 “Nested” inABLE assembly: incorporating the hybrid glycan biosynthetic pathway 
onto a single plasmid 
 
The vector plasmid (pPpGalHy) (fig. 5.2), encoding the hybrid glycan biosynthetic pathway, 
contains a total of 9 DNA sequences, or parts. However, due to the inefficiency of 
assembling plasmids containing greater than 6-7 parts, a “nested” approach was employed 
to construct this plasmid. 
Table 5.12: Strength of the influence of gene expression of three P. pastoris promoters. Promoter strength 
(activity) is measured as a percentage relative to the activity of the strong constitutive P. pastoris promoter TEFp. 
Promoter Activity relative to TEF1 promoter
GAPp 100%


















In the first round of the “nested” approach the 9 DNA sequences were divided into groups 
of three (Table 5.13). Each group of three was assembled into a single contiguous part, 
yielding three “nested” parts.  
Figure 5.2: The shuttle vector plasmid, pPpGalHy, containing genes for the biosynthesis of a hybrid-type glycan in P. 
pastoris and the truncated och1 sequence (purple) for simultaneous integration of the plasmid in to the P. pastoris 
genome at the OCH1 gene locus. Marked on the och1 sequence is the RE Mfe I recognition site for linearisation of 
the plasmid and the in frame stop codon is marked at the 5’ end of the och1 sequence. Also encoded in the plasmid 
is a gene encoding nourseothricin resistance (NrsR, light green arrow) for selection in E. coli and P. pastoris and, an 
origin of replication for plasmid amplification in E. coli (yellow arrow). Green arrows are promoters, maroon arrows 
are gene sequences, red rectangles are terminators and clear arrows and rectangles are E. coli regulatory elements. 
PCR primers (NrsR_For and _Rev and, ADH1p_ For and _Rev) are in purple writing and positions of annealing to 
plasmid are marked by purple lines. Positions of recognition sites are marked for RE EcoR V and Xba I, these RE 




Each part was either synthesised (ManI (A.2) and truncated och1 (C.3)), PCR amplified 
(AODt (A.3), GnTI (B.2), ILV5p (C.1) and GalT containing backbone plasmid (C.2)) or, existed 
as a pre-generated part cloned into a plasmid for selection and amplification in E. coli. In all 
cases the parts were produced such that they were flanked by the same type II S RE 
recognition site, one site was in the reverse orientation (fig. 1.17 Chapter 1 section 1.6.2). 
The parts were then digested with the type II S RE which liberated the truncated part 
sequence. In independent, separate part-linker fusion reactions each truncated part was 
ligated to the truncated parts associated PO and the LO of the next part in the sequence to 
generate part-linkers (fig. 5.3). For example, the truncated part A.1 was ligated to PO_A.1 
at the 5’ end and LO_A.2 at the 3’ end; truncated part A.2 was ligated to PO_A.2 at the 5’ 
end and LO_A.3 at the 3’ end; etc. Once the truncated part is fused to an LO and a PO it is 
referred to as a part-linker. 
 
 
Table 5.13: The plasmid pPpGalHy was made up of three “nested” parts (A, B and C). Each “nested” part was made 
up of four parts (A.1-4, B.1-4 and C.1-4). In “nested” parts A and B the fourth part (A.4 and B.4) is a vector plasmid 
backbone for selection and amplification in E. coli. “Nested” part C contains part C.2 which encodes a shuttle 
backbone vector plasmid for selection in P. pastoris as well as E. coli, and an origin of replication of amplification in 
E. coli. 
"Nested" Part Part Sequence contained in part 
A.1 S.cerevisiae Alcohol dehydrogenase I promoter (ADH1p)
A.2 C-terminal HDEL- tagged α(1,2)-mannosidase from Trichoderma reesei
A.3 S.cerevisiae Alcohol oxidase terminator (AODt)
A.4
Backbone vector containing ampicillin resistance selectable marker and 
origin of replication for selection and amplification in E.coli
B.1 P.pastoris Glyceraldehyde-3-phosphate dehydrogenase promoter (GAPp)
B.2
N-acetylglucosamine transferase I (GnTI) from H.sapiens with N-terminal 
S.cerevisiae  Kre2p membrane localisation domain
B.3 Galactose-1-phosphate uridylyltransferase terminator (GAL7t)
B.4
Backbone vector containing ampicillin resistance selectable marker and 
origin of replication for selection and amplification in E.coli
C.1 Acetohydroxy acid isomeroreductase promoter (ILV5p)
C.2
DNA sequence containing S.pombe  Galactose epimerase/H.sapiens 
Galactose transferase fusion construct (GalT) in frame with Alcohol 
oxidase I terminator (AOXIt) as well as a backbone shuttle vector 
containing a gene encoding nourseothricin resistance for selection in 
P.pastoris  and  E.coli  and, an origin of replication for amplification in 
E.coli
C.3
Truncated och1  sequence for targeted intregration into P.pastoris 
genome























Agarose electrophoresis of part-linkers was carried out to separate part-linkers from other 
contaminating DNA sequences (fig. 5.3) e.g. backbone plasmids or free LO and PO 
sequences. Part-linkers were then gel extracted using Zymoclean DNA recovery kit. 
All part-linkers are visible as bands at expected base pair positions except for C.4. However, 
gel extraction of the region between 200 and 400 bp yielded a measurable DNA 
concentration. It was therefore assumed that this contained part-linker C.4 and was used in 
the assembly of “nested” part C. DNA sequencing analysis of pPpGalHy (data not shown) 
later confirmed the presence of C.1 in the plasmid. 
 
Part-linkers A.1-4, B.1-4 and C.1-4 were incubated, separately in a one-pot reaction to 
produce the plasmids A, B and C (see plasmid maps in figure 5.5). In this procedure, the 16 
bp complimentary sequences of associated LO and POs anneal by base pairing. This joined 
the part-linkers into a single, contiguous sequence. For example, in the part-linker fusion 
process for A the part-linkers LO_A.4-TP_A.1-PO_A.1 and LO_A.1-TP_A.2-PO_A.2 were 
Figure 5.3: Products of part-linker fusion reactions. The expected band positions of part-linker fusion products are 
as follows: A.1 (ADH1p) ~700 bp, A.2 (ManI) ~1.6 kbp, A.3 (AODt) ~400 bp, A.4 (plasmid backbone) ~1.8 kbp, B.1 
(GAPp) ~500 bp, B.2 (GnTI) ~1.3kbp, B.3 (GAL7t) ~500 bp, B.4 (plasmid backbone) ~1.8 kbp, C.1 (ILV5p) ~550 bp, C.2 
(GalT and shuttle vector plasmid backbone) ~5.2 kbp, C.3 (och1) ~500 bp and C.4 (TPS1t) ~250 bp.  
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formed. In the assembly process PO_A.1 and LO_A.1 can join to each other by 
complimentary base pairing between the 16 bp 5’ overhand of LO_A.1 and 16 bp 3’ 
overhang on PO_A.1. The result is that ADH1p (A.1) is joined, in frame, with ManI (A.2).  
 
Plasmids A, B and C (see plasmid maps in figure 5.5) were used to transform E. coli TOP10 
electrocompetent cells by electroporation. Transformed E. coli was selected for on nutrient 
agar containing the appropriate selection antibiotic (for plasmid A and B ampicillin and, for 
plasmid B nourseothricin). Colonies containing plasmid A, B and C were selected for by 
colony PCR (data not shown) and 2 colonies containing each plasmid were cultured in 
shake flasks. Plasmids were extracted and purified using a plasmid extraction procedure 
(Qaigen, plasmid mini-prep kit) and correct assembly of plasmids A, B and C was confirmed 












Purified plasmids A, B and C were subjected to restriction mapping (fig. 5.4) to confirm that 
all part-linkers were assembled into each plasmid in the correct order and orientation. The 
REs and associated positions of recognition sites are labelled on plasmids A, B and C (fig. 
5.5). The restriction maps show that all plasmids were assembled correctly. For example, 
digestion of plasmid A with AlwN I, BsaB I and Cla I was expected to yield three DNA 
fragments 2379 bp, 1524 bp and 647 bp in length. The agarose gel electrophoresis image of 
the restriction map of plasmid A, from both E. coli colonies transformed with this plasmid, 
Figure 5.4: Restriction mapping of plasmids isolated from 2 colonies of E. coli transformed with either plasmid A, B 
or C. Plasmid A (4550 bp) was digested with the REs AlwN I, BsaB I and Cla I to yield three DNA fragments of 2379 
bp, 1524 bp and 647 bp. Plasmid B (4156 bp) was digested with the REs Xba I and Cla I to yield DNA fragments of 
3291 bp and 865 bp. Plasmid C (6467 bp) was digested with the REs Mfe I, Pvu I and Sph I to yield DNA fragments of 
3926 bp, 1710 bp, 575 bp and 256 bp. 
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show three bands of lengths approximately 2500 bp, 1500 bp and 650 bp confirming the 






















The “nested” parts A, B and C are contained within plasmids A, B and C. The “nested” parts 
were liberated from the plasmids by RE digest with the type II S RE Ear I. The RE sites flank 
the “nested” part in opposite orientation (or mirror images) and create an overhanging 
Figure 5.5: Plasmids A, B and C containing “nested” parts A, B and C. The GCC triplet sequence marks the 
intersection between each part. The recognition site for the type II S RE Ear I is marker on each map. 
Digestion of each plasmid with Ear I liberates the “nested” parts to allow for production of part-linkers of 
A, B and C for the second round of inABLE assembly. Also marked on the plasmid maps are the RE sites use 
for confirmation of correct plasmid assembly by restriction mapping (fig. 5.4). The exact base pair position 
of the RE cut site is labelled in brackets next to the RE. 
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triplet sequence for the attachment of LOs and POs in part-linker fusion reactions (fig. 1.17 
Chapter 1 section 1.6.2). The Ear I digested parts A, B and C were isolated by agarose gel 
electrophoresis (data not shown) and gel extracted and purified (zymoclean gel extraction 
kit). Part-linker fusion reactions were carried out on “nested” parts A, B and C (fig. 5.6). In 
contrast to the part-linker fusion reactions for parts A.1-4, B.1-4 and C.1-4, in which 
“nested” LOs and POs were used for parts A.1 and A.4, B1. and B.4 and, C.1 and C.4, for this 
set of part-linker fusion reactions the true LOs and POs for parts A.1, B.1 and C.1 were used 










After part-linker fusion reactions were carried out, “nested” part linkers A, B and C were 
isolated by agarose gel electrophoresis (fig. 5.6), gel extracted and purified (zymoclean gel 
extraction kit). Figure 5.6 shows that there are bands at the expected sizes for part-linkers 
A, B and C. The lowest band in lanes A and B is the digest plasmid backbone (band at 
approximately 2 kbp). Considering the lengths of plasmid A and B are 4550 bp and 4156 bp, 
respectively (fig. 5.5), then the highest band at approximately 5 kbp is likely to be 
undigested plasmid A and B. Digestion of plasmid C with Ear I (sites marked on plasmid map 
in figure 5.5) produces two DNA sequences, a long sequence comprising och1, GalT as well 
as a nourseothricin resistance selectable marker gene and origin of replication in E. coli, the 
second sequence is very short (the gap between the two Ear I sites on the plasmid map) 
and does not show on the agarose gel images (fig. 5.6 lane C). 
 
Purified “nested” part-linkers were place together in a one-pot assembly reaction. 
Associated LOs and POs joined neighbouring parts together by base pair annealing between 
the 16 bp complimentary overhand sequences. The assembled plasmid, pPpGalHy, was 
Figure 5.6: Products of part-linker fusion reactions carried out on “nested” parts A, B and C, previously digested with 
Ear I type II S RE. The expected band for A is ~2700 bp, for B is ~2300 bp and for C is ~6400 bp. 
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transformed into TOP10 electrocompetent E. coli by electroporation. Transformed colonies 
were selected for on agar containing the antibiotic nourseothricin and colony PCR was 
carried out to identify colonies that contained pPpGalHy (data not shown). 2 colonies, 
identified to contain pPpGalHy, were cultured in shake flasks and the pPpGalHy plasmid 
was isolated and purified using a plasmid extraction procedure (Qaigen, plasmid mini-prep 











Restriction mapping, of the two purified plasmids from two colonies transformed with 
pPpGalHy, was expected to yield three DNA fragments of lengths 5009 bp, 3948 bp and 
2552 bp. Digestion of pPpGalHy with the REs EcoR V and Xba I (RE recognition sites are 
marked the plasmid map in figure 5.2) did yield three DNA fragments of approximate 
lengths 5000 bp, 4000 bp and 3000 bp which fits with the expected DNA fragment lengths. 
Restriction mapping confirmed the correct assembly of pPpGalHy, this was further 








Figure 5.7: Restriction mapping of plasmids isolated from 2 colonies of E. coli transformed with pPpGalHy. Purified 
plasmid pPpGalHy (11509 bp) was digested with the REs EcoR V and Xba I. There were two RE sites for EcoR V and one 
for XbaI in pPpGalHy. Digestion with these RE yielded three DNA fragments at positions approximately 3000 bp, 4000 
bp and 5000 bp. 
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5.3.3 Transformation and expression of pPpGalHy in P. pastoris 
 
The purified pPpGalHy plasmid was linearised by digestion with the RE Mfe I. 
Approximately 10 μg linear pPpGalHy was used to transform P. pastoris strain KM71H CFH. 
This strain has not been glycoengineered, and therefore has a wild-type glycosylation 
profile and an intact, full length OCH1 gene in the genome. Additionally, KM71H CFH had 
previously been transformed with a plasmid encoding human FH (CFH). 
After transformation clones containing pPpGalHy were selected for on yeast nutrient agar 
containing the antibiotic nourseothricin. Colony PCR was carried out using PCR primers that 
bind either side of the ADH1p and amplify across this promoter (ADH1p_For and 









None of the 14 colonies analysed by colony PCR gave a PCR product of the expected length 
(fig. 5.8). The lack of PCR product cannot be explained by a failure in PCR as the positive 
control, purified pPpGalHy (first lane in figure 6.7), yielded a product of the expected 
length. There is a band in all 14 colonies at approximately 300bp and at 100 bp. The 100 bp 
band is likely due to dimerisation of PCR primers (this has been observed in other, 
unrelated, PCR reactions). The 300 bp product is also present in the negative control, 
KM71H CFH without pPpGalHy. Therefore, this band is due to off target binding of the PCR 
primers to a site within the genome of P. pastoris strain KM71H.   
 
Figure 5.8: Colony PCR of P. pastoris KM71H CFH colonies transformed with pPpGalHy and selected for on yeast 
nutrient agar containing the antibiotic nourseothricin. PCR primers ADH1p_For and _Rev were designed to amplify 
across the ADH1p in pPpGalHy to yield a 722 bp product. The lane labelled pPpGalHy is the positive control and 
contains the product from PCR amplification of the purified plasmid pPpGalHy, KM71H CFH is the negative control as it 
was not transformed with pPpGalHy and does not contain the S. cerevisiae ADH1 promoter. To the right of the DNA 
ladder are colonies 1 – 14 of KM71H CFH transformed with pPpGalHy. 
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However, the transformed cells were plated onto nutrient agar containing the antibiotic 
nourseothricin. If colonies were to grow on this media they must contain a gene conferring 
resistance to nourseothricin. Therefore, a second round of colony PCR (fig. 5.9) was 
performed on the 14 selected colonies. In this PCR, primers were designed (NrsR_For and 
_Rev) to bind the pPpGalHy plasmid at sites that flanked, and would amplify across, the 
gene conferring nourseothricin resistance (NrsR) (see figure 5.2 for sites of primer binding) 
to yield a 1249 bp product. The aim here was to determine if P. pastoris transformed with 










A band is present at ~1200 bp in the positive control lanes pPpGalHy and, although faint, 
SuperGal CFH (which was transformed with the plasmid pGlycoSwitch-Galt and contains 
the NrsR gene) and there is no band at ~1200 bp in the negative control lane KM71H CFH. 
To the right of the DNA ladder, colony PCR using NrsR_For and _Rev yields a band at ~1200 
bp for 11 out of 14 of the colonies analysed. This shows that these colonies contain the 
NrsR gene. The colony PCRs shown in figure 5.8 and 5.9 are samples of a much larger 
colony screening procedure. Approximately 150 colonies were present on nutrient agar 
plates after transformation with pPpGalHy, 46 of these were screened by colony PCR. The 
data in figures 5.8 and 5.9 reflects a trend that was seen across all 46 colonies analysed. 
 
Figure 5.9: Colony PCR of P. pastoris KM71H CFH colonies transformed with pPpGalHy and selected for on yeast 
nutrient agar containing the antibiotic nourseothricin. PCR primers NrsR_For and _Rev were designed to amplify across 
the NrsR gene in the pPpGalHy plasmid to yield a 1249 bp product. The lane labelled pPpGalHy is a positive control and 
contains the product from PCR amplification of the purified plasmid pPpGalHy, SuperGal PDI CFH is also a positive 
control as it had been transformed with the plasmid pGlycoSwitch-GalT, a plasmid that contains the NrsR gene. KM71H 
CFH is the negative control as it was not transformed with pPpGalHy and does not contain the NrsR gene. To the right 
of the DNA ladder are colonies 1 – 14 of KM71H CFH transformed with pPpGalHy. 
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The results in figure 5.8 and 5.9 from both colony PCRs show that colonies of P. pastoris 
KM71H transformed with pPpGalHy do not contain the ADH1 promoter but 11 of these 
colonies do contain the NrsR gene. Taken together, this would suggest that the cells were 
successfully transformed with pPpGalHy but, however, part of the pPpGalHy plasmid 
containing the ADH1p promoter was lost at some point between transformation and 
selection for PCR analysis. As selection occurred in the presence of nourseothricin, 
complete loss of pPpGalHy did not occur as it was advantageous to retain part of the 
plasmid that conferred resistance to the antibiotic. 
 
However, there was still the possibility that other parts of the pPpGalHy plasmid were 
present in the transformed colonies. Therefore, to test to see if the glycan biosynthesis 
genes on pPpGalHy were present and active in P. pastoris KM71H CFH transformed with 
pPpGalHy, nine colonies were cultured in shake flasks, expression of FH was induced and 
the supernatants of these cultures was analysed for the presence of FH by SDS-PAGE and 
the presence of LacNAc terminal hybrid glycans on FH by ECL western blot (fig. 5.10). 
 
 
SDS-PAGE analysis (fig. 5.10 A) shows that all 10 colonies expressed rFH. However, there 
are no bands indicating the presence of galactose according to the ECL lectin western blot 
images (fig. 5.10 B). The faint bands on SDS-PAGE indicates a low concentration of FH in the 
samples loaded onto the gels, therefore a second, duplicate ECL western blot was carried 
Figure 5.10: SDS-PAGE (A) and ECL lectin western blots (B) of FH expression in nine colonies of P. pastoris strain KM71H 
CFH transformed with pPpGalHy. The ECL lectin western blots are duplicates, the western blot on the right was 
incubated in metal enhanced DAB substrate for an extended time period to enhance low level signal – i.e. to detect any 
low abundance galactose in the rFH samples. To the left of the molecular weight ladder are control samples. hFH is FH 
purified from human blood plasma, desialylated hFH is hFH desialylated with α(2-3,6,8)-neuraminidase (desialylated 
hFH is the positive control for the ECL western blots), deglycosylated hFH is hFH deglycosylated with PNGase F. 
SuperMan 5 rFH is purified recombinant FH expressed in P. pastoris strain SuperMan 5 CFH. KM71H CFH is the parental 




out with an extended incubation time with the detection substrate (1 min 30s incubation 
time for left image in fig. 6.9 B compared to 8 min incubation time for the right image). This 
was done to try and enhance any low-level signal from any galactose that may be present 
on rFH. However, galactose was still not detectable on rFH expressed in any of the 10 




The aim of this study was to consolidate the hybrid glycan biosynthetic pathway onto a 
single plasmid in order to make available antibiotic selectable markers for in vivo glycan 
sialylation. Additional aims were to reduce the potential for genetic instability by replacing 
the repeatedly used regulatory elements for unique sequences and, in doing so, to couple 
promoter activity to the specific activity of the enzyme gene product. However, although 
the genes could be consolidated onto a single plasmid, pPpGalHy (fig. 5.2), this plasmid was 
not retained within P. pastoris. The detection of the NrsR gene in P. pastoris KM71H CFH 
transformed with pPpGalHy, but absence of this gene in KM71H CFH not transformed with 
the plasmid, suggests that (at least part of) the plasmid had integrated into the genome of 
this strain. However, ADH1p was not detectable by colony PCR in this strain. This suggests 
that at some point before or after genome integration recombination occurred resulting in 
the loss of part of the plasmid that contained ADH1p but, retention in the genome of part 
of the plasmid bearing the NrsR gene. 
 
Efforts were made in this study to replace the regulatory elements used in the GlycoSwitch 
technology, GAP promoter and AOX1 terminator, with alternative regulatory elements in 
an attempt to reduce the number of homologous sequences in close proximity – potentially 
reducing genetic instability caused by homologous recombination. Homologous 
recombination is a process that has been exploited in P. pastoris to generate strains with 
plasmids integrated into the genome (Cregg et al., 1985). However, non-homologous end 
joining (NHEJ) is also known to occur in P. pastoris and deletion of the P. pastoris KU70 
homologue, the protein product of which facilitates NHEJ, was shown to improve plasmid-
genome targeting efficiency in P. pastoris (Näätsaari et al., 2012). There is the possibility 
that loss of the pPpGalHy plasmid, but retention of the NrsR gene, could have occurred by 
homologous recombination between two homologous sites within the plasmid. However, 
as care was taken to ensure no large homologous sites were present in pPpGalHy it 
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therefore seems more likely that plasmid loss was due to NHEJ. DNA sequencing of the site 
of insertion of pPpGalHy into the genome would allow for identification of the DNA 
sequence at the 5’ end and 3’ end of the fragment of pPpGalHy that was retained in the 
genome. This would allow for identification of any homologous sequence present in the 
plasmid which could then be removed to improve stability. Additionally, DNA sequencing 
may identify that plasmid loss occurred by NHEJ in which case retention of genomically 
integrated pPpGalHy may be achieved by using a P. pastoris Δku70 knockout strain with 
reduced NHEJ activity (Näätsaari et al., 2012). 
 
Since the development of the GlycoSwitch technology efforts have been made to expand 
the molecular toolbox of P. pastoris. As well as the development of novel promoters (Vogl 
et al., 2015) other efforts to improve the molecular toolbox include: investigation into 
promoter strengths to produce natural promoter libraries (Partow et al., 2010, Stadlmyer 
et al., 2010, Vogl and Glieder, 2013 and Love et al., 2016), as well as short synthetic 
promoter libraries for fine-tuned gene expression (Hartner et al., 2008 and, Vogl et al., 
2014), the importance and effect of terminators in gene expression has been demonstrated 
in yeast (Curran et al., 2013  and, Vogl et al., 2016), the development of recyclable 
selectable markers (Nett and Gerngross, 2003), genome editing techniques such as the Cre-
loxP system (Marx et al., 2008) and CRISPR/Cas9 (Weninger et al., 2016) and, finally, the full 
genome sequence of the background host P.pastoris strain GS115 has been reported (De 
Schutter et al., 2009). This study was a small exploration of the potential for using more 
modern techniques to improve upon the existing GlycoSwitch P. pastoris glycoengineering 
technology. However, utilisation of some of the recent advances in the molecular toolbox 
listed above it may now be possible to generate a stable glycoengineered strain of P. 
pastoris with precisely controlled, site specific plasmid-genome integration, a normal 












Investigating the function of sialylated and non-sialylated recombinant 
factor H in vitro and in vivo 
6.1 Overview 
 
The overarching aim of this study was to engineer P. pastoris to produce recombinant FH 
with humanised glycosylation that would be suitable for therapeutic trials. It was important 
to characterise the resulting material, and in so doing compare the activity of sialylated 
(Sia-) and non-sialylated, terminal galactosylated (Gal-) IYD variant rFH, with human 
plasma-derived FH (hFH) and deglycosylated (DeGly-) VYE variant rFH 
 
In previous chapters of this study different glycoforms of FH had been produced. Firstly, 
human plasma derived FH (hFH) carrying, predominantly disialylated diantennary complex-
type glycans, Sia2Gal2GlcNAc2Man3GlcNAc2. Secondly, recombinant FH expressed in P. 
pastoris strain SuperMan 5 and subsequently deglycosylated (DeGly-rFH). Thirdly, 
recombinant FH expressed in the glycoengineering strain SuperGal and carrying 
diantennary digalactosylated complex-type glycans, Gal2GlcNAc2Man3GlcNAc2 (Gal-rFH). 
Fourthly, Gal-rFH sialylated with the α(2,6)-sialyltransferase from the bacterium 
Photobacterium sp. to yield rFH carrying diantennary disialylated, 
Sia2Gal2GlcNAc2Man3GlcNAc2, as well as monosialylated, Sia1Gal2GlcNAc2Man3GlcNAc2, 
complex-type glycans (Sia-rFH). 
 
As discussed in Chapter 1 section 1.2.2, the role of FH is to regulate complement activation 
in fluid-phase and on self-surface by binding to and suppressing C3b amplification. FH 
destabilises the C3bBb complex; this is its DAA. FH also has CA for cleavage of C3b by the 
serine protease FI. Cleavage of C3b by FI sets off a chain of proteolytic events converting 
C3b to iC3b then to C3dg and, eventually, to C3d.  
 
In vitro function of different glycoforms of FH produced either recombinantly (DeGly-, Gal- 
and Sia-rFH) or purified from human blood plasma (hFH) were compared. SPR Biacore 
based assays were used to compare the ability of these different glycoforms to bind to C3b 
and C3d and to compare the DAA activity. In solution assays were used to compare the CA 




Complement is an ancient, evolutionarily conserved, crucial part of the immune system. As 
such, the general features of complement are conserved in mice and humans and, like in 
humans, mice rely upon regulators of complement activation to protect host cells from 
complement. FH is structurally and functionally conserved in mice and humans (Pouw et 
al., 2015) as the key regulator of the alternative pathway of complement.  
A FH knockout (cfh-/-) mouse model mimics the disease phenotype observed in factor H 
deficient humans and pigs (Høgåsen et al., 1995, Rougier et al., 1998 and, Pickering et al., 
2002). Lack of FH allows unhindered activation of fluid-phase C3 causing depletion of 
plasma C3, as it is converted to C3b and deposits on surfaces, and leads to spontaneous 
membranoproliferative glomerulonephritis in both pigs, humans and, crucially, cfh-/- mice. 
Supplementation of cfh-/- mice with either human (Fakhouri et al., 2010, Nichols et al., 2015 
and, Michelfelder et al., 2017) or mouse FH (Paixão-Cavalcante et al., 2009) successfully 
restores complement regulation which can be observed by either an increase in plasma C3 
levels and / or reduction in C3b staining of kidney sections. 
In this study, comparison of in vivo function of rFH with humanised glycosylation was 
carried out in mice. The focus of these assays was two-fold. Firstly, the four glycoforms 
(hFH, DeGly-rFH, Gal-rFH and Sia-rFH) were compared for the ability to recover plasma C3 
levels and, thus, regulate complement in vivo. Secondly, due to the known effects of 
differential glycosylation on circulatory half-life of glycoproteins (Morell et al., 1971 and, 
Fukuda et al., 1989), the clearance rate of the four glycoforms of FH were compared in 
mice.  
 
In the first of the two in vivo mice assays, the mice used were wild-type, i.e. with no genetic 
modifications. Wild-type mice were used as the assay was designed to analyse exclusively 
the plasma half-life of FH independently of the role of FH as a complement regulator.  
In the second mouse assay the aim was to evaluate the ability of the four glycoforms to 
regulate complement. Therefore, for this assay, cfh-/- mice were used.  
 
6.2 Materials and Methods 
 
6.2.1 Production of deglycosylated recombinant factor H 
 




A sample of 54.6 mg of rFH expressed in P. pastoris strain SuperMan 5 and partially purified 
by cation exchange chromatography before dialysis against PBS, pH 7.4 (see methods in 
Chapter 3 sections 3.2.1.1 and 3.2.1.2), was deglycosylated by incubating with 1 kU Endo Hf 
per milligram of rFH at 37 °C for 45 minutes. Deglycosylation was assessed using samples of 
approximately 2.5 µg protein by SDS-PAGE analysis on 4-12% bis-tris polyacrylamide gels 
(NuPAGE 4-12% bis-tris, ThermoFisher Scientific, NP03222) and run (200 V, 1 hour) before 
staining with Coomasie Brilliant Blue G250. 
 
6.2.1.2 Concanavalin A resin chromatography 
 
A 5-mL concanavalin A (ConA) sepharose (Sigma-aldrich, C9017) resin gravity-flow column 
was washed with 5 CV of a solution containing 1 M NaCL, 5 mM MgCl2 and 5 mM CaCl2. The 
resin was equilibrated with 5 CV of PBS, pH 7.4, before loading the deglycosylated rFH 
sample (DeGly-rFH). Flow-through fractions were collected, and then the column was 
washed with 2 CV of PBS and wash fractions were collected. The protein concentration of 
flow-through and wash fractions was estimated from absorbance at 280 nm.  SDS-PAGE 
analysis of approximately 1 µg protein samples from flow-through and wash fractions was 
carried out on 4-12% bis-tris polyacrylamide gels (200 V, 1 hour). 
 
6.2.1.3 Anion-exchange chromatography of deglycosylated recombinant factor H 
 
Flow-through and wash fractions were pooled, placed in dialysis tubing (10 kDa molecular 
weight cut off, 35 mm dry internal diameter, Snakeskin, ThermoFisher Scientific, 88245) 
and dialysed against anion-exchange chromatography buffer A (20 mM glycine, 80 mM 
NaCl, pH 9.5) for 2 hours at 4 °C followed by transfer into fresh buffer and dialysis for 16 
hours at 4 °C.  
 
Anion-exchange chromatography was performed using a 6 mL Resource Q column (GE 
Healthcare Life Sciences, 17117901) according to the conditions in Chapter 3 section 
3.2.1.3. Briefly, at a flow-rate of 6 mL/min, the column was equilibrated with 6 CV of buffer 
A, protein sample was loaded onto the column and washed with 5 CV buffer A. Protein was 
eluted in a linear gradient from 0-50 % buffer B (20 mM glycine, 1 M NaCl, pH 9.5). 
Fractions of 2 mL were collected and 2 µL samples from various fraction were analysed by 
180 
 
SDS-PAGE. Peak rFH-containing fractions were pooled, placed in dialysis tubing (10 kDa 
molecular weight cut off, 35 mm dry internal diameter, Snakeskin, ThermoFisher Scientific, 
88245) and dialysed against PBS for 2 hours at 4 °C followed by transfer into fresh buffer 
and dialysis for 16 hours at 4 °C. Protein concentration and purity was assessed by 
absorbance at 280 and 260 nm. The purified sample of ~14 mg DeGly-rFH was aliquoted 
and stored frozen at -80 °C. 
 
6.2.2 In vitro functional characterisation of four glycoforms of factor H 
 
6.2.2.1 SPR-based C3b and C3d-binding assays 
 
Protein samples were assessed for purity by SDS-PAGE prior to SPR-based binding assays. 
Samples of 3 µg of each glycoform of FH, C3b (CompTech, A114) and C3d (CompTech, 
A117) were prepared under reducing and non-reducing conditions, applied to 4-12% bis-
tris polyacrylamide gels and polyacrylamide gel electrophoresis was carried out (200 V, 1 
hour) and stained with Coomasie Brialliant blue G250. 
 
C3b- and C3d-binding assays were performed using a Biacore T200 instrument at 25 °C. For 
these studies, 150 RUs of C3b or 50 RUs of C3d were attached by standard amine coupling 
to the flow cells of a C1 sensor-chip (GE Healthcare Life Sciences), the other two available 
flow cells were left blank for background subtraction.  A two-fold dilution series of each 
glycoform of FH was performed in 10 mM HEPES, 150 mM NaCl, 0.05% (v/v) surfactant P20 
(HBS-P+ buffer, GE Healthcare Life Sciences). Glycoform dilutions were injected for 150 s at 
a flow rate of 50 µL/min followed by a dissociation time of 600 s. For each dilution series, a 
negative control sample containing PBS diluted in HBS-P+ buffer was also injected. The 
sensor-chip was regenerated by three injections of 1 M NaCl for 30 s at a flow-rate of 50 
µL/min. Data were analysed using the Biacore Evaluation software and a 1:1 steady state 
binding model. 
 
6.2.2.2 SPR-based decay acceleration assay 
 
Decay-accelerating activity was measured in an SPR-based assay performed using a Biacore 
T200 instrument at 25 °C. 1000 RUs of C3b was attached to a single flow-cell of a Biacore 
CM5-sensor chip (GE Healthcare Life Sciences) using standard amine coupling. A second 
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flow-cell was left blank for background subtraction. C3bBb was assembled on the chip by a 
180 s 10 µL/min injection of a solution containing 500 nM Factor B (CompTech, A135) and 
50 nM Factor D (CompTech, A136). The formation of the C3 convertase complex C3bBb 
was monitored (~150 RUs), and then allowed to decay naturally, during a dissociation 
phase lasting 240 s, to observe intrinsic convertase decay. Glycoforms of FH (20 nM), or 
PBS, were injected for 180 s at a flow-rate of 10 µL/min and a further dissociation phase 
was monitored. The sensor-chip was regenerated between cycles by a single 30 s injection 
of 0.1 M hFH followed by three 30 s injections of 1 M NaCl at a flow rate of 10 µL/min.  
 
6.2.2.3 Cofactor assay 
 
The activity of FH as a cofactor for C3b cleavage, catalysed by FI, was measured by 
detection of C3b 63 and 39 kDa α′-chain proteolytic products following SDS-PAGE. The 
non-cleaved β-chain served as an internal control. The 16 μl reaction mixture contained 1.7 
μM C3b, 14 nM FI (CompTech, A138), and a range of concentrations (80, 40, 20, 10 nM) of 
each glycoform of FH. The reaction mixture was incubated for 30 minutes at 37°C, then 
stopped by addition of SDS-PAGE loading buffer. The mixture was boiled for 5 minutes and 
subjected to polyacrylamide gel electrophoresis on 4-12% bis-tris polyacrylamide gels (200 
V, 1 hour) and stained with Coomasie Brilliant Blue G250. Densitometry values were 
obtained using ImageJ software. 
 
6.2.3 In vivo characterisation of four glycoforms of factor H in mice 
 
6.2.3.1 Endotoxin removal 
 
Endotoxin was removed from 10 mg samples of each glycoform of FH using Pierce High-
Capacity Endotoxin Removal 0.5 mL Spin Columns (ThermoFisher Scientific, 88274). Briefly, 
columns were regenerated overnight in 0.2 M NaOH followed by washing once each with 2 
M NaCl (Sigma-aldrich, 71386-1L), endotoxin-free ultra-purified H2O (Merck, TMS-011-A) 
and endo-toxin free PBS (Merck, TMS-012-A) before adding sample and end-over-end 
mixing at 4 °C for 1 hour. The columns were centrifuged at 500 g for 1 minute after each 
wash step and for sample collection the columns were centrifuged at 500 g for 1 minute in 




6.2.3.2 Factor H half-life assay  
 
Wild-type and cfh-/- mice were injected intraperitoneally with 1 mg of each glycoform of FH 
in identical volumes of PBS, or PBS alone. Three mice per glycoform of FH were used, and 
two mice for administration of PBS. Blood was collected into EDTA, via tail venesection 
before injection and at 2, 24, 48, 72 and 96 hours post-injection.  Plasma was separated by 
centrifugation before storage of plasma samples at −80 °C.  
 
Sandwich enzyme-linked immunosorbent assays (ELISA) were carried out on plasma 
samples from mice injected with glycoforms of FH. Each well of a 96-well plate was 
incubated in 100 µL 2 µg/mL Ox24 monoclonal anti-FH antibody in carbonate buffer. Wells 
were washed thrice with wash buffer (PBS containing 0.1% (v/v) tween-20) and then 
blocked with 200 µL blocking buffer (1% (v/v) bovine serum albumin (BSA) in wash buffer) 
for 1 hour at room temperature. Plates were washed with wash buffer and then plasma 
samples from mice were diluted 1:1000 and 1:5000 with blocking buffer and 100 µL added 
to wells in the 96-well plate. For calibration, a 1:2 dilution series for each sample was set-
up with a starting concentration of 100 ng/mL and containing a total of seven dilutions. 
Then 100 µL of each dilution (plus a zero FH sample) were added to the 96-well plate 
before incubation for 1 hour at room temperature. The plates were washed thrice with 
wash buffer. Then 100 µL Sheep anti-FH antibody diluted 1:20,000 in blocking buffer was 
added to each well in the 96 well-plate and left to incubate for 1 hour at room 
temperature. The plate was washed thrice with wash buffer. 100 µL Donkey anti-sheep 
horseradish-peroxidase conjugate antibody diluted 1:20,000 in blocking buffer was added 
to each well in the 96-well plate and left to incubate for 1 hour at room temperature. The 
plate was developed by the addition of 100 µL of TMB HRP Microwell Substrate (Leinco 
Technologies, T118). The reaction was stopped after 5 minutes by the addition of 100 µL 
10% (v/v) H2SO4. Spectrophotometry was performed at a wavelength of 450 nm. 
 
6.2.3.3 Plasma C3 concentration in cfh-/- mice 
 
Three mice per glycoform of FH were administered with 1 mg intraperitoneal injections of 
FH and plasma harvested in a process identical to that detailed for FH half-life analysis in 
wild-type mice, except two additional injections of 1 mg of each glycoform were 
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performed at 48 hours and 96 hours and mice were sacrificed at 144 hours after the first 
injection.  
 
The plasma concentration of C3 was measured by sandwich ELISA in a procedure similar to 
the sandwich ELISA for measurement of FH concentration detailed in section 6.2.3.2., 
except, plates were pre-coated with 1:250 dilution anti-C3 11H9 antibody, the blocking 
buffer used was 2% (w/v) BSA plus 2 mM EDTA in wash buffer, the 1:2 serial dilution used 
C3 (CompTech), plasma was diluted 1:1,000 and 1:2,000, samples, dilution series, control, 
antibody and TMB volumes used were all 50 µL, and detection was with 1:25,000 dilution 




6.3.1 Deglycosylation and purification of partially purified recombinant FH 
 
To prepare DeGly-rFH, a stock of rFH, previously produced in the P. pastoris strain 
SuperMan5 CFH and partly purified from crude supernatant by cation-exchange 
chromatography, was used as starting material. This was deglycosylated with Endo Hf and 
then subjected to a two-step purification procedure.  
 
Partially purified rFH (54.6 mg) was enzymatically deglycosylated by incubating with endo 










Figure 6.1: SDS-PAGE of rFH that had been produced in P. pastoris strain SuperMan5 CFH before and after 
deglycosylation with endo Hf. Approximately 2.5 µg of protein from each sample of rFH was loaded onto the 





SDS-PAGE analysis of rFH after incubation with Endo Hf shows a significant loss in MW. For 
example, prior to the addition of Endo Hf reduced rFH migrates to a position just above the 
150 kDa MW marker and non-reduced rFH migrates to a position equivalent to 
approximately 125 kDa. After the addition of Endo Hf, reduced rFH migrates to a position 
equivalent to approximately 140 kDa and non-reduced rFH migrates to a position 
equivalent to approximately 110 kDa. The ExPASy predicted MW of the amino acid 
sequence of human FH is approximately 137 kDa. Deglycosylation with Endo Hf leaves a 
GlcNAc (MW= 203 Da) at each of eight N-linked glycosylation sites. Therefore, the 
predicted MW of Endo Hf-deglycosylated rFH is 138.6 kDa. Thus, under reduced conditions, 
the Endo Hf-treated rFH is migrating at the expected MW. In addition, the band for Endo Hf-
treated rFH appears less smeared. Smearing of the untreated sample is likely the result of 
variation in MW caused by heterogeneity in the P. pastoris glycans, as shown by MALDI-
TOF mass spectrometry (Chapter 3 section 3.3.3 figure 3.5).  Thus, the shift in MW and 
reduction in band smearing suggest that rFH has been successfully deglycosylated by Endo 
Hf. In support of this, the MW loss of approximately 10 kDa after treatment with Endo Hf is 
consistent with the loss of 8 five mannose glycans released from rFH by Endo Hf cleavage 
between the two GlcNAc residues of the N-linked glycan chitobiose core. The released 
glycans, Man5GlcNAc1, would have a molecular weight of approximately 1 kDa each. 
 
Following deglycosylation, DeGly-rFH was applied to a gravity-flow chromatography column 
containing concanavalin A (ConA) sepharose resin. As discussed in Chapter 1 section 1.5.2, 
concanavalin A is a lectin which binds to the mannose residues in the trimannosyl core of 
N-linked glycans. Application of DeGly-rFH to this resin resulted in the removal of free 
glycans and any rFH that had not been deglycosylated. After application of Endo Hf treated 
rFH to the ConA column, flow-through and wash fractions were collected and SDS-PAGE 












As expected, rFH was eluting both in the flow-through and the wash fractions (fig. 6.2), 
suggesting that rFH was either not interacting, or interacting weakly, with the Con A resin. 
Flow-through and wash fractions were pooled together, dialysed against anion-exchange 
buffer A (20 mM glycine, 80 mM NaCl, pH 9.5) and the concentration was measured by UV-
Vis spectroscopy absorbance at 280 nm wavelength. Approximately 55 mg of rFH was 
applied to the column but only 28.7 mg (table 6.1) of protein was collected in the pooled 
and dialysed flow-through and wash fractions, yielding a 48% loss of protein.  
To maximise enzymatic deglycosylation of rFH an extended incubation time with Endo Hf 
was needed (> 1 hour to overnight to ensure complete deglycosylation).  
However, P. pastoris is known to secrete proteases (Sinha et al., 2005 and, Salamin et al., 
2010) and, as rFH used in the enzymatic deglycosylation reaction is only partially purified, 
there was a risk of contamination from P. pastoris secreted proteases. So, the incubation 
time used for deglycosylation of rFH (45 – 60 minutes) was a trade-off between achieving 
deglycosylation whilst reducing proteolysis. Therefore, the loss of protein could be 
attributed to incomplete deglycosylation and retention of glycosylated rFH on the ConA 
resin.  
 
DeGly-rFH was then purified by anion-exchange chromatography (6 mL resource Q column) 
and peak fractions were analysed by SDS-PAGE (fig. 6.3). 
 
Figure 6.2: SDS-PAGE of flow-through (FT) and wash (W) fractions of Endo Hf treated rFH after application to a ConA 
chromatography column. Approximately 1 μg of protein of each sample was loaded. +/– signifies whether or not 


























A total of 28.5 mg of deglycosylated rFH was loaded onto the anion-exchange column and 
fractions were collected in 2 mL volumes. The chromatogram shows a large A280 peak 
eluting at 120 – 150 mL with a shoulder at ~110 – 120 mL (fig. 6.3 A). Fractions were 
analysed by SDS-PAGE (fig. 6.3 B and C). This showed that there is undetectable rFH in the 
flow-through or wash fractions, even when concentrated ten times (cFT1, cFT2 and cW in 
figure 6.3 B and C) and the peak shoulder also appear devoid of rFH (C7). Instead, rFH 
eluted within the main peak (fraction C10 – D10, 122 mL – 146 mL elution volume) 
evidenced by intense bands at ~140 kDa for reduced samples and 120 kDa for non-reduced 
B) C) 
A) 
Figure 6.3: Chromatogram (A) and SDS-PAGE analysis of reduced (B) and non-reduced (C) samples of flow-through 
fractions 1 (FT1) and 2 (FT), ten-times concentrated flow-through fractions (cFT1 and cFT2), ten-times 
concentrated wash fraction (cW) and peak fractions C7 (elution volume 116 mL) and C10 – D10 (elution volume 
122 mL – 146 mL).  Fractions were collected in 2 mL volumes. Every second fraction is loaded onto the gel. 2 μL of 
each fraction was diluted in 14 μL SDS loading buffer, and all 16 µL of each sample was loaded onto SDS-PAGE gel. 




samples. However, rFH appears to be co-eluting with a protein with a MW ~30 kDa. There 
is also a band just below the main rFH band, ~120 kDa in the reduced samples and 
approximately 90 kDa in the non-reduced samples. These are likely to be proteolytically 
“clipped” rFH. Fractions C12 – D6 (elution volume 126 – 138 mL) had the highest 
concentration of purified rFH, assessed by SDS-PAGE (fig. 6.3 B and C), and were pooled 
and dialysed against PBS, pH 7.4. 
 
After dialysis, the nucleic acid contamination and concentration of protein was measured 
(table 6.1), by absorbance at 260 nm and 280 nm, to yield 13.9 mg protein of low nucleic 
acid contamination (A260/A280 of 0.6). 
 
6.3.2 SDS-PAGE analysis of factor H glycoforms and C3b and C3d 
 
Prior to functional characterisation, the four samples of FH glycoforms prepared in this 
study, together with the commercially produced samples of C3b and C3d, were evaluated 










Table 6.1: Table containing protein absorbance readings, concentrations, volumes, protein yields and purity at each 














Samples were prepared under reducing (left lane) and non-reducing (right lane) conditions 
to assess for partial protein degradation by protease “clipping” (fig. 6.4). Under reducing 
conditions all samples of FH display evidence of a small amount of “clipping” as there is a 
faint band just below the main FH band at ~150 kDa. This band is not present in the non-
reduced samples hFH, Sia-rFH and Gal-rFH but is present in the non-reduced samples of 
DeGly-rFH. This may be the result of DeGly-rFH having undergone deglycosylation in only a 
partially purified state and, therefore, was exposed to P. pastoris secreted proteases. 
Additionally, DeGly-rFH had been stored frozen after the initial cation-exchange 
purification from crude P. pastoris culture media, and it underwent a freeze-thaw cycle 
which may have contributed to increased degradation. All three groups of protein display a 
mobility shift on SDS-PAGE (fig. 6.4) when reduced consistent with the presence of the 
numerous (40) disulfides expected to form in FH.  
 
C3b (177 kDa) migrates as a single band when not reduced (fig 6.4), but as two bands when 
reduced. This is expected, as C3b is composed of two subunits, an α’-chain and a β-chain, 
which are covalently linked via a disulphide bond (Janssen et al., 2006). Reducing agent 
results in the appearance of two bands corresponding to these two chains. The C3 
fragment C3d (35 kDa) also has a disulphide bond (Nagar et al., 1998) that could explain the 
shift in mobility on SDS-PAGE following reduction (fig. 6.4).  
 
Figure 6.4: SDS-PAGE analysis of five glycoforms of FH, C3b and C3d to evaluated purity. Replicate samples were 
prepared. The first replicate was prepared under reducing conditions (left) and the other replicate prepared 
under non-reducing conditions (right). 3 µg of protein was applied to a 4-12% bis-tris polyacrylamide gel. MW 




Overall, it appears from SDS-PAGE that all of the samples are of acceptable purity. 
Approximately 3 µg of each protein was loaded and the detection limit of the Coomassie 
G250 stain used is in the region of 30 ng (although this is protein sequence dependent) 
therefore any protein contaminants are likely to be less than 1% of the total protein 
content. 
 
6.3.3 in vitro functional characterisation of sialylated and non-sialylated recombinant 
factor H: Binding to C3b and C3d 
 
The interactions of the four different glycoforms of FH with C3b and with C3d, a breakdown 
product of C3b that remains surface bound after degradation of C3b, were assessed using 
SPR-based binding assays. Duplicate concentrations of each FH glycoform were flowed over 
either C3b (150 RUs) or C3d (50 RUs), that had been fixed to a C1 sensor-chip by standard 


















Figure 6.5: C3b binding sensorgrams (A), B), C) and D)) and affinity curves (E), F) G) and H)) of recombinant 
deglycosylated FH (hFH) ( A) and E)), humanised terminally galactosylated rFH (Gal-rFH) ( B) and F)), humanised 
terminally sialylated rFH (Sia-rFH) ( C) and G)) and, human plasma derived FH (hFH) (D) and  H)) binding to 150 RUs of 
C3b. Sensograms were generated from duplicate injections of eight concentrations of each glycoform of FH and a 
blank for 150 s at 50 μL/min followed by dissociation for 600 s. Sensorgrams were referenced and blank subtracted, 




















The dissociation phase of the sensorgrams for all glycoforms of FH binding to C3b, including 
FH purified from plasma, does not return to base line. This has been observed previously by 
colleagues in the Barlow group and is thought to be due to “stickiness” of the sensor-chip 
surface i.e. FH is pulled down to the sensor-chip surface by binding to C3b, but when FH 
dissociates from C3b it interacts with and sticks to the sensor-chip surface. The 
sensorgrams, however, show that steady-state has been reached for all glycoforms of FH-
C3b interactions. This allowed for the production of affinity curves and calculation of KD 









































Figure 6.6: C3d binding sensorgrams (A), B), C) and D)) and affinity curves (E), F) G) and H)) of recombinant deglycosylated FH 
(hFH) ( A) and E)), humanised terminally galactosylated rFH (Gal-rFH) ( B) and F)), humanised terminally sialylated rFH (Sia-
rFH) ( C) and G)) and, human plasma derived FH (hFH) (D) and  H)) binding to 50 RUs of C3d. Sensograms were generated 
from duplicate injections of eight concentrations of each glycoform of FH and a blank for 150 s at 50 μL/min followed by 
dissociation for 600 s. Sensograms were referenced and blank subtracted, and 1:1 steady state kinetic model was fitted to 
sensograms to generate the affinity curves. Rmax and χ2 values in table 6.2. 
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The sensograms for C3d binding (fig. 6.6) also show that the trace is not returning to 
baseline during FH dissociation. This is not surprising because C3d and C3b binding assays 
were conducted in different flow-cells of the same sensor-chip. 
 
The affinities displayed in Table 6.2 were calculated by fitting the steady-state sensograms 
to a simple 1:1 interaction model. As well as the calculated affinities (dissociation constant, 
KD), theoretical maximum response (Rmax) and chi-squared (χ2) values are also displayed in 
table 6.2.  
 
An immediately striking feature of the data is the variation in the values of Rmax for both 
C3b and C3d. The Rmax vales are in line with expectations for hFH, but they are higher than 
expected for the other versions. C3b and FH have similar molecular weights so it would be 
expected that the Rmax for FH binding to a chip with 150 RUs of C3b would not exceed 150 
RUs. A value of 68.5 for hFH seems quite low, for example in Chapter 2 section 2.3.5 table 
2.2 the Rmax for hFH binding 150 RUs C3b was 76.5, but could be explained if some C3b 
molecules are immobilised in a way that renders the FH-binding site(s) inaccessible. The 
other glycoforms clearly behave differently. One explanation, consistent with the non-
return of baseline to zero, is that FH molecules first bind C3b then migrate on to the 
surface from where they are hard to dislodge. Thus, more than one FH molecule could be 
present per C3b, e.g. one bound to the C3b and a second bound to the surface nearby 
producing an Rmax that exceeds expectations. Another possibility – more consistent with the 
acceptable fit obtained when assuming a 1:1 interaction is that these non-native FH 
molecules may self-associate (Nan et al., 2008) and bind to C3b and C3d as dimers.  
 
 
The data in table 6.2 suggest that all four glycoforms bind to surface-bound C3b with 
similar affinities, in the approximate range of 0.3-0.9 M. hFH has a slightly higher affinity 
Table 6.2: Summary of the parameters fitted for the SPR-based binding studies of four different glycoforms of FH to 
the ligands C3b and C3d. Binding to 150 RUs of C3b and, 50 RUs of C3d was measured. SE = standard error. 
194 
 
for C3b (KD of ~0.29 µM) than the others (the mean KD for all four is 0.5 M) but this 
interaction has a markedly lower value of Rmax (69 RUs compared to a mean of 225 RUs). A 
similar picture emerges for binding to C3d except that the Rmax is even lower, relative to the 
others, (for hFH 25 RUs compared to an average for all four of 160 RUs). Of the four, Sia-
rFH has the weakest binding for both C3b and C3d. Indeed, the ratio of C3b-binding affinity 
to C3d-binding affinity is remarkably consistent for all four FH glycoforms. In all cases the χ2 
values are less than 10% of the Rmax values indicating an acceptable fit of the data to 1:1 
steady state kinetics. 
 
Taken together, hFH is behaving as expected but with a slightly lower response and KD for 
C3b seen previously in this study and by others (Herbert et al., 2015 and, Kerr et al., 2017) 
and a higher than expected response for C3d has yielded a measurable KD for C3d. The 
recombinant glycoforms all behave similarly, with similar responses and KDs for C3b and 
C3d binding. However, the assay needs repeating to determine if any individual differences 
between the recombinant glycoforms is statistically significant. The key finding is that 
humanisation of the glycosylation of recombinant FH does not appear to make rFH behave 
more like hFH. 
 
6.3.4 in vitro functional characterisation of sialylated and non-sialylated recombinant 
factor H: decay acceleration activity 
 
The ability of hFH and the three different glycoforms of recombinant FH to accelerate the 
decay of the bimolecular C3-convertase complex, C3bBb, was investigated using an SPR-
based decay-acceleration activity (DAA) assay. In these experiments, 1000 RUs of C3b was 
immobilised on the surface of a CM5 sensor-chip by standard amine coupling. Then the 
C3bBb complex, C3-convertase, was generated by the addition of complement factors B 
and D. Formation of the C3-convertase complex was monitored (~ 150 RUs) and then 
allowed to decay naturally (in the absence of FB and FD) for a short time to observe 
intrinsic convertase decay, prior to addition, in duplicate, of the different glycoforms of FH 
to be tested. Plotting several such experiments on the same graph allowed a direct 
comparison of the dissociation rate of the C3-convertase complex on its own and in the 
presence of the different glycoforms of FH (fig. 6.7). Each glycoform DAA assay was carried 














A rising response occurs over the range of ~20 s – 200 s (fig. 6.7), which is consistent with 
the binding of Factor B to surface immobilised C3b, and the subsequent cleavage of Factor 
B by Factor D to form the C3-convertase complex, C3bBb. An exponential decline in 
response units between ~200 s – 450 s represents the natural dissociation of the C3bBb 
complex. At ~460 s, the FH samples (20 nM) were injected, resulting in an accelerated 
decline in RU. This corresponds to a more rapid decay of the complex catalysed by the 
presence of FH – its DAA.  
 
Figure 6.7: Sensorgram showing the results of a decay acceleration activity (DAA) assay of various glycoforms of FH 
on the C3-convertase complex, C3bBb. Approximately 1000 RUs C3b was amine coupled to the surface of a CM5 
sensor-chip, C3bBb was assembled by an injection of 500 nM and FB 50 nM FD lasting 180 s. After formation of 
C3bBb, the complex was allowed to naturally decay for 240 s followed by the addition of  FH glycoforms, in 
duplicate, at 10 μL/min for 180 s. Duplicate traces have been omitted for clarity. hFH is human plasma derived FH, 
Sia-rFH is terminal sialylated recombinant FH, Gal-rFH is terminal galactosylated recombinant FH and DeGly-rFH is 



















Duplicates of each glycoform were assessed for DAA of C3bBb and decay half-life of the 
C3bBb complex was calculated before and after the addition of each glycoform. Averages 
of each duplicate were taken to find the mean half-life for each glycoform (Table 6.3). 
Changes in half-life were calculated for each sample relative to the initial natural decay of 
the C3bBb complex. All glycoforms of FH accelerate the decay of the C3bBb complex (fig. 
6.7). However, hFH induces the smallest reduction in half-life (table 6.3) whilst the 
recombinant glycoforms all induce similar, but larger (then hFH) reductions in half-life (1.3 
and 2-fold less than that of the C3bBb complex, respectively). This study previously found 
(see Chapter 2 section 2.3.5 table 2.3) that hFH had a 1.5-fold, DeGly-rFH a 2.5-fold and 
desialylated hFH a 2-fold decrease in half-life compared to natural C3bBb complex decay 
and this indicated that deglycosylation significantly improves DAA and that desialylation of 
hFH slightly improves DAA of FH. In comparison, this study (table 2.3) suggests that there is 
no difference between the DAA of the recombinant glycoforms of FH, whether sialylated or 
not, and that all three recombinant glycoforms have greater DAA compared to hFH. 
 
6.3.5 in vitro functional characterisation of sialylated and non-sialylated recombinant 








































Table 6.3: Calculated half-life (s) for decay of the C3bBb complex before and after the addition of FH. The change in half-




The ability for the different glycoforms of FH to act as a cofactor for FI-mediated proteolysis 
of the α’chain of C3b was investigated. Four concentrations (80, 40, 20 and 10 nM) of each 
glycoform of FH were incubated with C3b (1.9 μM) and FI (1.6 nM), and the extent of 
cleavage of the α’-chain of C3b was assessed by SDS-PAGE (fig. 6.8 A). Each reaction was 
carried out as independent duplicates. ImageJ software densitometry function was used to 
measure density of each band. The β-chain was used as an internal standard against which 
band intensities for the α’-chain-derived 63-kDa and 39-kDa fragments were normalised. 
The mean of normalised duplicate band intensities were plotted against concentration of 












































Inspection of the SDS-PAGE gels (fig 6.12 A) shows that, as expected, in the presence of FH, 
FI cleaves the α’-chain of C3b to form two products of molecular weight 63 kDa and 39 kDa 









Figure 6.8: A) SDS-PAGE of the cofactor assay of four glycoforms of FH incubated with C3b and Factor I. B) 
Band intensity of the α’-chain, C) band intensity of the 63k-Da chain, D) band intensity of the 39-kDa chain. 
Band intensities were measured using ImageJ software and normalised against the β-chain in the same 
lane as the measured band. Each sample was run in duplicate (duplicates not shown in A)). Error bars are 
standard deviation. hFH is human plasma derived FH, Sia-rFH is terminally sialylated recombinant (r)FH 
with complex-type glycosylation, Gal-rFH is terminally galactosylated rFH with complex-type glycosylation, 
DeGly-rFH is deglycosylated rFH and the negative control is C3b and FI incubated in the absence of FH. MW 




FI. Densitometry performed on the gels (fig 6.8) suggests that Sia-rFH, Gal-rFH and hFH 
facilitate cleavage of the α’-chain to similar extents and, in comparison, DeGly-rFH has a 
slightly reduced cofactor activity. However, overlap of error bars, e.g. between hFH, Sia-rFH 
and DeGly-rFH in figure 6.8 D, indicate that any difference observed may not be significant.  
 
6.3.6 in vivo functional characterisation of sialylated and non-sialylated recombinant 
factor H: circulatory half-life in wild-type mice 
 
The four glycoforms of FH were assessed for retention in blood circulation of wild-type 
mice, capable of producing endogenous mouse FH (fig. 6.9). Blood circulation retention 
times of endotoxin-free glycoforms were assessed in triplicate, with three mice per 
glycoform of FH. A sample of 1 milligram of each glycoform was injected into wild-type 
mice and blood samples were taken pre-injection (zero-time point), and at 2, 24, 48, 72 and 
96 hours post-injection. The concentration of human FH was measured in blood plasma 
samples by sandwich enzyme-linked immunosorbent assay (ELISA) in which FH was 
captured on the surface of a 96-well plate using the human FH-specific OX-24 monoclonal 



































The plots of concentration of FH as a function of time (fig 6.9 A) show a steep increase two 
hours post-injection; the hFH injections yielded the highest plasma concentration of FH 
(71.2 ± 7.0 µg/mL), Sia-rFH the next highest (57.5 ± 3.7 µg/mL), then DeGly-rFH (46.8 ± 0.5 
µg/mL) and Gal-rFH has the lowest (38.3 ± 0.4 µg/mL). Between two hours and 24 hours, 
there was a steep decline in the concentration of FH. This continued and by 96 hours the 
concentration of the recombinant glycoforms of FH was close to or below the detection 
limit. Conversely, there is still a measurable concentration of hFH at 96 hours post-injection 












Figure 6.9: A) Concentration of four glycoforms of FH in samples of mouse plasma before, at two hours, 
and every 24 hours after, a single intraperitoneal injection of 1 mg of FH. Standard curves generated by 
plotting absorbance at wavelength of 450 nm against concentration of FH, using purified plasma derived 
human FH (B), DeGly-rFH (C), Gal-rFH (D) and Sia-rFH (E). PBS is phosphate buffered saline. Error bars in A) 






Measurements of half-life in blood plasma (table 6.4) allow for a comparison of the rate of 
clearance of each glycoform from mouse blood circulation and are independent of any 
potential differences in concentration of injected FH. hFH has the longest half-life in mouse 
blood plasma. In comparison, the half-life of the recombinant glycoforms of FH are similar 
and approximately half that of hFH. This suggests that the recombinant glycoforms are 
cleared more rapidly than hFH from mouse blood circulation.  
 
Enzymatic deglycosylation with Endo Hf leaves behind a GlcNAc at each N-linked 
glycosylation site. Therefore, there are potentially three ways in which the clearance of 
DeGly-rFH, might be accelerated compared to hFH in mice. First, the remaining GlcNAc 
residue is a ligand of the mannose-binding receptor (Taylor and Drickamer, 1992). Second, 
the glycans mask putative protease recognition sites (Russell et al., 2009) therefore 
removal of the glycan exposes these sites for proteolysis.  Third, removal of the glycans 
could expose novel antigenic sites for binding by antibodies and T-cell receptors (Szabó et 
al., 2009). Gal-rFH and Sia-rFH show a similar half-life to DeGly-rFH. Gal-rFH and Sia-rFH 
had been enzymatically deglycosylated with Endo Hf to remove yeast and hybrid-type 
glycans. Therefore, these glycoforms will have some GlcNAc residues and be at risk of 
accelerated blood plasma clearance by the same three mechanisms that applied to 
clearance of DeGly-rFH. In addition, terminally exposed galactose on Gal-rFH and on the 
monosialylated complex-type glycans on Sia-rFH present ligands for the asialoglycoprotein 
receptor (Ashwell and Harford, 1982 and, Schwartz, 1984). 
 
6.3.7 in vivo functional characterisation of sialylated and non-sialylated recombinant 
factor H: Plasma C3 levels in cfh-/- mice  
 
Next, the ability of the four glycoforms of FH to restore plasma C3 levels was investigated in 
cfh-/- deficient mice. A dose of 1 milligram of each glycoform of FH was administered to 
mice every 48 hours. A total of three injections were administered in a 144 hour period and 
Table 6.4: Calculated half-life (hours) for decrease of concentration of four glycoforms of FH in mouse blood 
plasma between 24 and 96 hours (hours) post-injection. 
Sample
Mean Concentation at 24 
hours (µg/mL)
SEM
Mean Concentation at 
96 hours (µg/mL)
SEM Time (hrs) Mean Half-life (hrs) SEM
hFH 71.227800 7.03295 10.119330 1.529989 34.096 3.947
DeGly-rFH 46.849170 0.542914 1.230804 0.018902 17.903 0.031
Gal-rFH 38.306270 0.366129 1.269851 0.007739 19.126 0.041




blood plasma samples were taken 0, 48, 96 and 144 hrs pre-injection. Each glycoform was 
administered to three mice and triplicate blood plasma samples were analysed at each 
time point for C3 concentration by sandwich ELISA. A standard curve of C3 absorbance at 
450 nm wavelength against concentration of purified C3 was generated (fig. 6.10 inset) and 













Figure 6.10 shows that plasma C3 levels remain low for the first 48 hours after the first 
injection of FH for all glycoforms of FH. After 48 hours, however, there is an increase in 
plasma C3 for hFH administered mice, but no change in C3 levels for the rFH administered 
mice. Pickering et al. (2002) observed that the normal C3 plasma concentration of wild-
type mice is approximately 450 – 500 µg/mL and Paixão-Cavalcante et al. (2009) measured 
normal C3 plasma levels to be 387 µg/mL. Additionally, the plasma C3 levels in cfh-/- were 
measured to be 30 µg/mL. The peak C3 concentration observed, in this study, at 96 hours 
for hFH, 203.5 ± 70.5 µg/mL, is lower than previously observed (Pickering et al., 2002 and, 
Paixão-Cavalcante et al., 2009) but well above the low level of C3, 25 – 60 µg/mL, observed 
for all recombinant glycoforms of FH, PBS and hFH between 0 – 24 hours and at 144 hours.  
 
The C3 plasma concentrations (fig. 6.10) were statistically evaluated using two-way analysis 
of variance (ANOVA) with Bonferroni multiple comparison test (table 6.5). 
Figure 6.10: Concentration of C3 in mouse blood circulation after repeated intraperitoneal injections of 1 milligram 
of four different glycoforms of FH. Blood samples were taken before each FH injection at 0, 48, 96 and 144 hours. A 
standard curve, inset, of absorbance at 450 nm wavelength against concentration of purified C3 was used to 














Although the plasma C3 levels at 96 hours for hFH are lower than observed in the 
literature, statistical analysis (table 7.4) of C3 concentration variance shows that the 
elevated C3 concentration at 96 hours is statistically significant. Statistical analysis also 
shows that there is no significant difference in plasma C3 concentration for any glycoform 
of rFH at any time point, relative to PBS administered mice. These data suggest that only 
hFH is elevating C3 plasma levels and that none of the rFH glycoforms have a measurable 
effect.  
 
6.3.8 in vivo functional characterisation of sialylated and non-sialylated recombinant 
factor H: Plasma factor H levels in cfh-/- mice  
 
The lack of response observed for plasma C3 levels in mice administered with the 
recombinant glycoforms of FH could be due to their low half-life resulting in accelerated 
clearance. In addition, Fakhouri et al., (2010) have observed the spontaneous development 
of anti-FH antibodies in mice administered with FH, therefore the lack of response seen for 
the recombinant glycoforms may be due also in part to the development of an anti-FH 
antibody. Thus, the FH concentration in blood plasma samples taken from cfh-/- mice was 
measured (fig 6.11) using the same sandwich ELISA assay employed previously for 












hFH 7.56 -34.97 to 50.09 >0.9999 No
DeGly-rFH 2.278 -40.25 to 44.81 >0.9999 No
Gal-rFH 4.489 -38.04 to 47.02 >0.9999 No
Sia-rFH 13.54 -28.99 to 56.07 >0.9999 No
hFH -10.99 -58.53 to 36.56 >0.9999 No
DeGly-rFH 15.78 -26.75 to 58.31 >0.9999 No
Gal-rFH 21.64 -20.89 to 65.17 0.7600 No
Sia-rFH 8.874 -33.66 to 51.4 >0.9999 No
hFH -152.6 -200.2 to -105.1 <0.0001 Yes
DeGly-rFH 8.161 -34.37 to 50.69 >0.9999 No
Gal-rFH 24.76 -17.77 to 67.28 0.5408 No
Sia-rFH 5.175 -37.35 to 47.7 >0.9999 No
hFH 4.26 -38.27 to 46.79 >0.9999 No
DeGly-rFH 7.983 -34.55 to 50.51 >0.9999 No
Gal-rFH 16.28 -26.25 to 58.8 >0.9999 No





Table 6.5: Two-way analysis of variance (ANOVA) with Bonferroni multiple comparison test. The C3 
concentration for each glycoform at each time point was analysed relative to the C3 concentration for PBS 




















The blood plasma concentration of hFH increases steadily to a maximum of 33.16 ± 0.99 
µg/mL at 96 hours. The concentration of hFH decreases rapidly after 96 hours to 0.88 ± 
0.01 µg/mL at 144 hours. The observed steady increase in concentration of hFH for 96 
hours followed by a rapid decline between 96 to 144 hours is consistent with the findings 
of Fakhouri et al. (2010). Therefore, the observed rapid decline in plasma hFH 
concentration may indeed be due to the production in mice of an anti-hFH antibody. 
In comparison, mice administered with Gal-rFH show no detectable Gal-rFH in blood 
plasma and mice administered with Sia-rFH and DeGly-rFH show a slight increase in plasma 
concentration at 48 hours, which is maintained at 96 hours in Sia-rFH administered mice. 
Statistical analysis by two-way ANOVA with Bonferroni multiple comparison test (table 6.6) 
was carried out to assess whether the differences seen in plasma concentrations of FH 












Figure 6.11: A) Concentration of FH in mouse blood circulation after repeated injection of 1 milligram of four 
different glycoforms of FH. Blood samples were taken before each FH injection at 0, 48, 96 and 144 hours. Standard 
curves of absorbance at 450 nm wavelength against concentration of purified hFH B), DeGly-rFH C), Gal-rFH D) and 
Sia-rFH E) were used to estimate blood plasma concentration of each of the four glycoforms of FH. Error bars are 















Statistical analysis (table 6.6) shows that the observed differences in plasma concentrations 
of DeGly-rFH (48 hours) and Sia-rFH (48 and 96 hours), relative to background, are 
significant. The analysis also shows that there is no detectable protein observed in plasma 
of all mice by the 144 hour time point. This would suggest that all glycoforms are 
essentially cleared by 144 hours. 
 
The fact that DeGly- and Sia-rFH plasma were detectable in the plasma of FH knockout mice 
at significant concentrations for at least 48 hours is consistent with the half-life data for FH 
obtained in wild-type mice (fig. 6.9). The concentration of DeGly-rFH was measured to be 
3.15 ± 0.29 µg/mL in wild-type mice and 4.98 ± 1.37 µg/mL in cfh-/- mice. Likewise, in wild-
type mice the concentration of Sia-rFH was measured to be 4.49 ± 0.44 µg/mL and in cfh-/- 
mice 4.99 ± 0.76 µg/mL. Importantly, a measurable increase in C3 plasma concentration 
was observed in the case of hFH administration only after 96 hours when, compared to 
DeGly-rFH and Sia-rFH, the concentration of hFH in blood plasma was much higher. 
Therefore, although DeGly-rFH and Sia-rFH were present in blood plasma for up to 48 hours 
(or longer in the case of Sia-rFH), these glycoforms may not persist long enough or at high 














hFH -0.06999 -3.676 to 3.536 No >0.9999
DeGly-rFH -0.2519 -3.858 to 3.354 No >0.9999
Gal-rFH -0.1883 -3.794 to 3.417 No >0.9999
Sia-rFH -0.1149 -3.721 to 3.491 No >0.9999
hFH -26.2 -30.14 to -22.25 <0.0001 Yes
DeGly-rFH -4.136 -7.742 to -0.5302 0.019 Yes
Gal-rFH -0.7103 -4.316 to 2.895 >0.9999 No
Sia-rFH -4.142 -8.092 to -0.192 0.0366 Yes
hFH -32.32 -36.27 to -28.37 <0.0001 Yes
DeGly-rFH -1.18 -4.786 to 2.426 >0.9999 No
Gal-rFH -0.6885 -4.294 to 2.917 >0.9999 No
Sia-rFH -5.569 -9.519 to -1.619 0.003 Yes
hFH 0.003153 -4.558 to 4.564 >0.9999 No
DeGly-rFH -0.1228 -4.684 to 4.438 >0.9999 No
Gal-rFH -0.09057 -4.652 to 4.47 >0.9999 No





Table 6.6: Two-way analysis of variance (ANOVA) with Bonferroni multiple comparison test. The FH 
concentration for each glycoform at each time point was analysed relative to the FH concentration for PBS 





The binding affinities of hFH and DeGly-rFH have been assessed previously in this study 
(Chapter 2 section 2.3.5 table 2.2) and in the literature (Schmidt et al., 2008, Schmidt et al., 
2011, Herbert et al., 2015 and, Kerr et al., 2017), where it was consistently shown that 
DeGly-rFH binds to C3b with greater affinity compared to hFH, and that DeGly-rFH binds to 
C3d with measurable affinity whereas hFH does not. But, previous studies (Kerr et al., 
2017) also noted lower responses for hFH compared to DeGly-rFH. In particular, the low 
responses for C3d binding by hFH probably explain why this binding was, in previous work, 
considered too weak to measure KD. 
In addition, in earlier findings (Chapter 2 section 2.3.5 table 2.2) and those of Kerr et al. 
(2017) the Rmax for DeGly-rFH binding to 150 RUs C3b was approximately 50% higher than 
for hFH whereas, in this study the Rmax for DeGly-rFH is approximately four-times higher 
than hFH. This could be due to subtle batch-to-batch variations in the Biacore chip surface 
and reflect a general “stickiness” of the proteins that is very sensitive to such variations. 
 
The different recombinant glycoforms of FH bound C3b and C3d with similar KDs and Rmax 
values. Nonetheless, the data appears to show that there may be a relationship between the 
size of the glycans carried by rFH and binding affinity and estimated Rmax for C3b and C3d. 
For example, Sia-rFH has a lower affinity and estimated Rmax for binding C3b and C3d 
compared to Gal-rFH and DeGly-rFH, and Gal-rFH is intermediate between the other two. 
But, the experiment must be repeated several times to clarify if the slight observed 
differences are statistically significant.  
However, this trend, that glycan size inversely correlates with FH affinity for C3b and C3d, 
was observed previously in Chapter 2 (section 2.3.5 table 2.2) for different glycoforms of 
hFH. In addition, Michelfelder et al. (2017) expressed and purified rFH with diantennary di-
N-acetylglucosamine terminal complex-type glycans, GlcNAc2Man3GlcNAc2, (GlcNAc-rFH) (as 
well as terminal mannose glycans) in glycoengineered moss. Michelfelder et al. (2017) 
showed that more GlcNAc-rFH bound immobilised C3b than hFH. Although a direct 
comparison cannot be drawn between the Biacore based C3b binding assay, reported here 
(table 6.2), and the ELISA conducted by Michelfelder et al. (2017), it is interesting to note 
that an independent study has demonstrated a link between reduced glycan length and 




DAA assays comparing the four glycoforms of FH show that all recombinant glycoforms 
outperform hFH in DAA. However, the in-solution CA assays, conducted in this study, show 
that there is no difference in CA between Gal-, Sia-rFH and hFH and, possibly, DeGly-rFH. In 
regard to hFH and DeGly-rFH, the findings are consistent with the literature in which 
Schmidt et al. (2011) and Kerr et al. (2017) report that DeGly-rFH has enhanced DAA 
compared to hFH. In addition, Kerr et al. (2017) also show that there is no detectable 
difference in CA between DeGly-rFH and hFH. 
Given that the DAA assay is carried out on a sensor-chip surface and C3b is randomly 
orientated on the chip surface, molecules of FH that can bind to both FH binding sites on 
C3b would be able to engage a larger proportion of C3bBb, resulting in a greater rate of 
turnover of the C3-convertase complex. 
In comparison, CA is carried out in solution and therefore there is not the same ligand 
orientation constraint. Thus, in the DAA assay the ability of FH to bind C3bBb may be a 
limiting factor but, this may not be the case in the CA. 
 
The glycoprofile of glycans released from Gal-rFH expressed in SuperGal CFH before and 
after enzymatic removal of yeast and hybrid-type glycosylation show that there is a 
significant contribution from these glycans to the overall glycoprofile of rFH expressed in 
SuperGal CFH and, that removal of these glycan species will leave some N-linked 
glycosylation sites unoccupied. Therefore, the main difference between hFH and Sia-rFH, 
which both have glycoprofiles composed of predominantly mono- and disialylated 
complex-type glycans, Sia1Gal2GlcNAc2Man3GlcNAc2 and Sia2Gal2GlcNAc2Man3GlcNAc2 
respectively, is that some of the N-linked glycosylation sites on Sia-rFH are unoccupied, 
whilst hFH potentially has all N-linked glycosylation sites occupied. In comparison to hFH, 
Sia- and Gal-rFH therefore have less glycans and may have higher conformational freedom 
allowing for a greater proportion of molecules to adopt the active, open conformation in 
the absence of self-surface markers. This would account for the higher C3b, C3d affinities 
and DAA of Sia- and Gal-rFH compared to hFH. If conformational freedom is the main factor 
influencing the difference in C3b, C3d binding affinities and DAA of the rFH glycoforms and 
hFH then it would be interesting to see how non-deglycosylated rFH functions in a 
comparative study. Non-deglycosylated rFH would have all glycosylation sites occupied, 
albeit with five mannose glycans, and, therefore, would presumably be under a similar 
conformational constraint as hFH. As both non-deglycosylated rFH and hFH would both 
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have fully occupied N-linked glycosylation sites, any differences observed between these 
two glycoforms would be due to the specific glycans the two proteins carry. 
 
This study (fig. 6.9) showed that hFH has a longer circulatory half-life in plasma of wild-type 
mice compared to the recombinant glycoforms of FH. Additionally, there does not appear 
to be a difference in plasma concentrations of hFH, Sia-rFH and DeGly-rFH between wild-
type and cfh-/- mice, as FH concentrations at 48 hours post-injection are consistent in the 
two strains of mice (compare figs. 6.9 and 6.11).  
 
Potentially therapeutic FH or FH-like molecules have been developed and analysed in vivo 
in the literature (Nichols et al., 2015 and, Michelfelder et al., 2017). Nichols et al. (2015) 
developed a “mini-FH” which consisted of the complement regulatory domains CCPs 1-5 
joined to the self-surface recognition domains CCPs 18-20. Although displaying CA and DAA 
comparable to hFH in vitro, in vivo this “mini-FH” was cleared rapidly from plasma of cfh-/- 
mice. Animals that were given a 0.5 milligram intraperitoneal injection of this “mini-FH” 
had a plasma concentration of 200 µg/mL at a time point two hours post-injection which 
then fell dramatically to become almost undetectable six hours post-injection. 
Intraperitoneal injections of 0.5 milligram glycoengineered moss-produced GlcNAc-rFH into 
cfh-/- mice (Michelfelder et al., 2017) had an equally rapid clearance rate – ~420 µg/mL 
GlcNAc-rFH was measured in plasma at ten minutes post-injection but, was not detectable 
6 hours post-injection. Therefore, although the recombinant glycoforms studied here (fig 
6.9 and 6.11) appear to be cleared more rapidly than hFH, they do appear to persist longer 
in circulation than comparative amounts of potentially therapeutic FH and FH-like 
molecules developed by others. 
 
As discussed in Chapter 1 section 1.1.3, glycoproteins carrying sialylated glycans have 
prolonged circulatory half-life (Morell et al., 1971) because sialic acids mask glycoproteins 
preventing clearance by the asialoglycoprotein receptor (Ashwell and Harford, 1982, 
Schwartz, 1984 and, Fukuda et al., 1989). It is intriguing, therefore, that Sia-rFH does not 
have an extended half-life compared to Gal- and DeGly-rFH (table 6.4). As previously 
discussed, the unoccupied glycosylation sites present on Sia-rFH, because of hybrid- and 
yeast-type glycan enzymatic removal by Endo Hf, may present sites for binding by 




Normal plasma C3 levels in CFH+/+ mice are ~450 – 500 µg/mL and cfh -/- mice have plasma 
C3 levels ≤ 30 µg/mL (Pickering et al., 2002). Intraperitoneal injections of hFH to cfh-/- mice 
(fig. 6.10) result in a rise in plasma C3 levels, reaching a high of ~200 µg/mL at 96 hours 
after a second intraperitoneal injection of hFH at 48 hours. Although this is not a full 
restoration of wild-type plasma C3 levels, the rise in C3 levels in hFH injected cfh-/- mice is 
consistent with findings in the literature for mice administered with murine FH (Paixão-
Cavalcante et al., 2009) and hFH (Fakhouri et al., 2010, Nichols et al., 2015 and, 
Michelfelder et al., 2017). It is significantly different from the responses of the three 
recombinant glycoforms of FH, which yielded no change in measurable plasma C3 levels in 
cfh-/- mice. 
In contrast to the possible inability of the rFH glycoforms to increase plasma C3 levels 
observed here (fig. 6.10), the potentially therapeutic GlcNAc-rFH expressed in 
glycoengineered moss showed an increase in plasma C3 levels, in mice administered with a 
single 0.5 milligram intraperitoneal injection of GlcNAc-rFH. This peaked six hours post-
injection (~200 µg/mL GlcNAc-rFH compared to ~450 µg/mL hFH) and fell slightly, but 
remained higher than PBS-treated mice, by 24 hours post-injection (Michelfelder et al., 
2017). Additionally, potentially therapeutic “mini-FH”, composed of CCPs 1-5 linked to 18-
20, also showed an increase in plasma C3 levels six hours after a single injection of 0.5 
milligram of “mini-FH” (~75 µg/mL compared to ~100 µg/mL hFH) however, the assay was 
not continued past six hours (Nichols et al., 2015). Both studies (Nichols et al., 2015 and, 
Michelfelder et al., 2017) assessed plasma C3 levels within a shorter time frame than 
studied here (fig. 6.10) (6-24 hours post-injection compared to 48 hours post-injection). 
Considering this, and knowing that the rFH glycoforms have a reduced half-life compared to 
hFH, it cannot be excluded that the rFH glycoforms may influence plasma C3 levels within 
the 48 hours post-injection. 
 
All literature studies referenced here (Paixão-Cavalcante et al., 2009, Fakhouri et al., 2010, 
Nichols et al., 2015 and, Michelfelder et al., 2017), in addition to measuring the change in 
plasma C3 levels, also evaluated kidney sections for C3 staining of the glomerular basement 
membrane (GBM). However, GBM C3 staining was not measured in this study.  
The opsonin C3b binds to surfaces via an exposed thioester in the TED domain. FI mediated 
cleavage of C3b converts surface-associated C3b to iC3b, further cleavage events produce 




It was observed here, and elsewhere (Herbert et al., 2015 and, Kerr et al., 2017), that the 
recombinant glycoforms of FH have a measurable affinity for C3d (table 6.2) but hFH binds 
C3d poorly. Considering this, and the fact that C3d persists on surfaces, a possible reason 
for the reduced plasma FH concentrations of rFH glycoforms observed here (figs. 6.9 and 
6.11), compared to hFH, is that the rFH glycoforms are pulled out of solution by binding to 
surface associated C3d. Analysis of FH staining of kidney sections, coupled with C3 and C3d 
staining, would clarify this hypothesis.  
 
Ultimately, the data presented here shows that glycoengineered Sia-rFH has an enhanced 
ability to bind C3b, a measurable affinity for C3d and enhanced DAA compared to hFH. 
However, glycoengineering and sialylating the glycans carried by rFH does not appear to 
improve the in vivo half-life or function compared to DeGly-rFH and this may be due to 
unoccupied glycosylation sites on Gal-rFH and Sia-rFH. Future work would seek to improve 


























7.1 Glycosidic linkage characterisation 
 
Although the characterisation of the glycosylation of hFH has been reported in several 
publications (Ritchie et al., 2002, Fenaille et al., 2007a, Benicky et al., 2014, and, Pompach 
et al., 2014), the work of Fenaille et al. (2007a) remains the most detailed assessment to 
date. Fenaille et al. (2007a) use a multiplex approach to quantify the glycoprofile of hFH 
and characterise the glycans at each N-linked glycosylation site. However, the types of 
glycosidic bonds that link the glycan monosaccharide constituents are not currently known. 
  
The glycosidic bond that links two monosaccharides is known to influence conformational 
entropy (Striegel and Boone, 2011), viscosity (Kath et al., 1999) and solubility (Best et al. 
2001). The different biophysical properties of glycosidic linkages affect glycoconjugate 
function. For example, differential infectivity and species discrimination of human and 
animal influenza viruses is mediated by the type of sialic acid glycosidic linkage present on 
glycoconjugates in the epithelia of the upper respiratory tract (Rogers and Paulson, 1983 
and, Shinya et al., 2006). Another example is that α(2,6)-linked sialic acid, but not α(2,3)-
linked sialic acid, protects T-cells from galectin-1 induced cell death (Toscano et al., 2007). 
 
Different tissues are known to carry different proportions of α(2,3)- and α(2,6)-linked sialic 
acid. For example, Baum and Paulson (1990) were able to show that human ciliated 
tracheal epithelial cells carry α(2,6)-sialic acid whereas goblet cell secreted mucus carries 
exclusively α(2,3)-sialic acid.  
Differential sialic acid glycosidic linkages have even been observed on the level of 
glycoproteins. By exploiting the glycosidic linkage specificity of sialic acid binding lectins 
SNA – which has specificity for α(2,6)-sialic acid – and Maakia amurensis lectin – which has 
specificity for α(2,3)sialic acid –  Heerze and Armstrong (1990) have shown that human 
fibrinogen, haptoglobin and transferrin is exclusively sialylated with α(2,6)-sialic acid whilst 




Glycosidic linkage analysis can be achieved by gas chromatography-mass spectrometry (Lv, 
et al., 2015) as well as by exploiting the glycosidic-linkage specificities of different lectins. 
Applying these methodologies to hFH could elucidate the terminal sialic acid glycosidic 
linkage. Given that the sialic acid linkages on hFH are not known, this raises some 
interesting questions: are the sialic acid linkages all one type, e.g. α(2,6) or α(2,3), and if so, 
why? Or are they a mixture of both? Answers to these questions have practical relevance 
for the use of recombinant hFH as a potential molecular replacement therapeutic and 
would better inform the choice of sialyltransferase used to cap rFH. 
 
7.2 Quantification and site-specific glycan functional characterisation 
 
Absent in this study was glycan quantification and site-specific glycan characterisation.  
Glycan quantification can be achieved by high-performance capillary electrophoresis with 
laser-induced fluorescence detection, as used by Fenaille et al. (2007a) to quantify the 
glycosylation of hFH, or by high-performance liquid chromatography (HPLC) (Roth et al., 
2012). In Chapter 3 of this study, the glycoprofile of rFH expressed in glycoengineered 
strain SuperGal was shown to be heterogenous and included hybrid- and yeast-type glycans 
as well as the target humanised complex-type glycan, Gal2GlcNAc2Man3GlcNAc2. 
Anticipating that the yeast- and hybrid-glycans would affect in vivo half-life, these glycan-
types were removed enzymatically with the yeast- and hybrid-glycan specific 
endoglycosidase Endo Hf. The removal of yeast- and hybrid-type glycans was qualified by 
MALDI-TOF mass spectrometry but not quantified. Therefore, it is not known exactly what 
proportion of the glycan content of FH is missing and how many glycosylation sites are 
unoccupied. 
 
Site-specific glycan characterisation has been carried out in the literature by tryptic digest 
coupled with liquid-chromatography electrospray ionisation tandem mass spectrometry 
(MS/MS) and MALDI-TOF MS/MS (Fenaille, et al., 2007a and Pompach et al., 2014). Fenaille 
et al. (2007a) found that the complexity of the glycans on hFH decreases toward the C-
terminus. The glycosylation site closest to the N-terminus, located on CCP9, had 40% 
triantennary trisialylated species occupancy and no monosialylated diantennary species. In 
comparison, the glycosylation site closest to the C-terminus had just 3% occupancy by 
triantennary trisialylated species whilst the diantennary monosialylated species accounted 
for 20% of the glycan occupancy at this site. In addition, the glycosylation site on CCP13 
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had the highest site occupancy (50%) of the diantennary disialylated species. Fenaille et al. 
(2007a) hypothesised that the folded back, compact structure predicted for FH (Aslam and 
Perkins, 2001 and, Oppermann et al., 2006) reduces accessibility of glycosyltransferases to 
the central, compact region of FH. Thus, there is clear site-specific glycan variance on hFH 
that is potentially caused by differential glycosyltransferase accessibility. If this is the case 
with hFH, is it also the case with rFH expressed in glycoengineered strain SuperGal? Do 
certain N-linked glycosylation sites on rFH expressed in SuperGal have a higher site 
occupancy by the target complex-type glycan, Gal2GlcNAc2Man3GlcNAc2, and do others 
have a higher occupancy by yeast-type and hybrid-type glycans? Site-specific glycan 
characterisation of rFH expressed in SuperGal would help answer these questions. 
 
7.3 Exposed N-linked glycosylation sites  
 
We observed an accelerated clearance of Sia- and Gal-rFH compared to hFH in mice. This 
likely contributed to the lack of recovery of plasma C3 levels. However, what was not 
tested in vivo was SuperGal-expressed rFH that had not been treated with glycosidase to 
selectively remove "unwanted" hybrid- and yeast-type glycans. As discussed in chapter 6, 
the accelerated clearance of Sia-rFH and, in part, Gal-rFH is likely due to the single GlcNAc 
left on each glycosylation site, due to Endo Hf cleavage of hybrid- and yeast-type glycans, 
and exposure of potentially immunogenic sites that would otherwise be masked by the 
presence of a glycan at that site (Skehel et al., 1984 and, Sun et al., 2012). Therefore, there 
are two parallel clearance pathways to consider: on the one hand the mannose-binding 
lectin clearance mechanism will be at work and, on the other hand, an antibody based 
clearance mechanism is likely to operate. Both of these mechanisms are likely to be 
responsible for the accelerated clearance observed for Sia-rFH and Gal-rFH. However, in 
theory, SuperGal-expressed and sialylated rFH not deglycosylated with Endo Hf should have 
all N-linked glycosylation sites occupied and, therefore, will not be cleared by the second 
antibody-based clearance mechanism. It would be interesting to test what effect this has 
on clearance rate?  
 
7.4 Optimisation of glycoengineered P. pastoris strain SuperGal 
 
As discussed, the yeast- and hybrid-type glycans thought to be present on rFH expressed in 
SuperGal would accelerate clearance and reduce in vivo half-life due to interaction with the 
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asialoglycoprotein receptor and mannose-binding lectins. It was shown in chapter 6 of this 
study that enzymatic removal of yeast- and hybrid-type glycans does not significantly 
improve in vivo half-life and, as speculated in the previous section, might even reduce it. 
Therefore, an alternative strategy to improve in vivo half-life is to increase complex-type N-
linked glycan glycosylation site occupancy.  
 
Different clones of P. pastoris can have markedly different heterologous protein expression 
yields (Hu et al., 2011) and therefore it is necessary to characterise the expression of a 
large number of clones to identify those with highest expression. This variation is due in 
part to the ability of P. pastoris to undergo random gene duplication, creating multiple 
copies of the heterologous gene (Higgins and Cregg, 1998). Variation could be assessed by 
taking advantage of advances in flow cytometry, in combination with glycan motif lectin 
recognition, which has allowed for cell surface (Batisse et al., 2004) and site-specific cell 
surface glycoprotein (Jayakumar et al., 2009) glycoprofiles to be monitored. Mannoproteins 
are heavily glycosylated components of the outer cell wall of yeasts with the glycan 
component extending out into the culture media (Klis et al., 2006). Cell wall mannoproteins 
of P. pastoris glycoengineered with the GlycoSwitch technology were used to characterise 
clones that had undergone a modification to the glycan biosynthetic pathway (Jacobs et al., 
2009). 
Considering that cell wall mannoproteins can be used as a marker for successfully 
glycoengineered clones of SuperGal, it may be possible, using cell sorting flow cytometry 
with the galactose binding lectin ECL, to exploit the natural clonal variation in expression 
levels of heterologous proteins to select for clones of SuperGal that are more efficient at 
complex-type diantennary digalactosylated glycan, Gal2GlcNAc2Man3GlcNAc2, biosynthesis. 
In this way, it may be possible to express rFH in SuperGal that has a much higher complex-
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Appendix 
Och1 
Gctatattcgccgtttctgtcatttgcgttttgtacggaccctcacaacaattatcatctccaaaaatagactatgatccattgacgct
ccgatcacttgatttgaagactttggaagctccttcacagttgagtccaggcaccgtagaagataatcttcgaagacaattggagtt
tcattttccttaccgcagttacgaaccttttccccaacatatttggcaaacgtggaaagtttctccctctgatagttcctttccgaaaa
acttcaaagacttaggtgaaagttggctgcaaaggtccccaaattatgatcattttgtgatacccgatgatgcagcatgggaactta
ttcaccatgaatacgaacgtgtaccagaagtcttggaagcttt 
 
ManI 
atgagatttccttctagttccgtcttggcacttggattgattggaccagccttggcataccctaaaccaggagcaacaaagagaggt
tctccaaaccctactagagctgctgctgttaaggctgcttttcaaacttcttggaatgcttaccatcactttgctttccctcatgatgat
ttgcacccagtttctaactctttcgatgatgaaagaaatggttggggttcttctgctattgatggtttggatactgctattttgatggga
gatgctgatatcgttaacactatcttgcaatacgttcctcaaattaacttcactactactgctgttgctaatcaaggttcttctgttttcg
agactaacatcagatacttgggtggtttgttgtctgcttatgatttgttgagaggtccattttcttctttggctactaaccaaactttggt
taactctttgttgagacaagctcaaactttggctaacggtttgaaagttgctttcactactccttctggtgttccagatcctactgttttc
tttaatccaactgttagaagatctggtgcttcttctaacaatgttgctgaaattggttctttggttttggagtggactagattgtctgat
ttgactggtaaccctcaatacgctcagttggctcaaaagggtgaatcttatttgttgaatccaaaaggttctcctgaggcttggccag
gtttgatcggtactttcgtttctacttctaacggtactttccaagattcttctggttcttggtctggtttgatggattctttctacgaatatt
tgattaagatgtacttgtatgatccagttgctttcgctcattacaaagatagatgggttttgggtgctgattctactattggtcatttgg
gttctcacccttctactagaaaggatttgactttcttgtcttcttacaacggtcaatctacttctccaaattctggtcacttggcttctttt
ggtggtggtaacttcattttgggtggtatcttgttgaacgaacaaaagtacatcgatttcggtattaaattggcttcttcttacttcggt
acttatactcaaactgcttctggtattggtcctgagggtttcgcttgggttgattctgttactggtgctggtggttctccaccttcttctc
aatctggtttttattcttctgctggtttctgggttactgctccttactatattttgagaccagaaactttggagtctttgtactatgcttat
agagttactggagattctaaatggcaagatttggcttgggaagctttgtctgctattgaggatgcttgtagagctggttctgcttattc
ttctattaacgatgttactcaagctaacggtggtggtgcttctgatgatatggaatctttttggttcgctgaggctttgaagtacgctta
tttgatcttcgctgaagaatctgatgttcaagttcaagctactggtggtaacaaatttgttttcaatactgaagctcatccattttcaat
cagaagtagtagtagaaggggaggacatttggctcacgacgagttgtaa 
 
Ph-6ST 
atgaaaaactttttattattaactttaatattacttactgcttgtaataattcagaagaaaatacacaatctattattaaaaatgatat
taataaaactattattgatgaggagtatgttaatttagagccaattaatcaatcaaacatctcttttacaaaacactcttgggtacaa
acttgtggtacgcaacaactattaacagaacaaaataaagagtcaatatcattatctgtagtggcgccacgattagatgacgatga
aaagtactgctttgattttaatggtgttagtaataaaggtgaaaaatatataacaaaagtaacattaaacgtagtggctccatcttt
agaggtttatgttgatcatgcatctcttccaactcttcagcagctaatggatattattaaatcggaagaagaaaatcctacagcaca
aagatatatagcttgggggagaatagttccgactgatgagcaaatgaaagagttaaatattacatcgtttgcattgataaataacc
atacaccagctgacttagtacaagaaattgttaagcaagcacaaacaaagcatagattgaatgttaaacttagctctaacactgct
cattcatttgataatttagtgccaatactaaaagaattaaattcgtttaataacgttacggtaacaaatatagatttatatgatgatg
gttcagcagaatatgtaaatttatataactggagagatacattaaataaaacagataatttaaaaattggtaaagattatcttgag
gatgtcattaatggtatcaatgaagacacttcaaatacaggaacatcatctgtttataactggcaaaaactatatccagctaactac
cattttttaagaaaagattatttaactttagaaccatcattacatgagttacgagactatattggtgatagtttaaagcaaatgcaat
gggatggtttcaaaaaattcaatagcaaacaacaagaattattcttatcgattgttaattttgacaaacaaaaattacaaaatgaa
tataattcatctaatttaccaaactttgtgtttacaggtacgactgtatgggctggtaaccatgaaagagagtattatgcgaaacaa
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caaattaatgtcattaataatgcaattaatgaatcgagcccacattatttaggcaatagttatgatttgttcttcaaaggtcaccctg
gtggcggtatcattaatacattaataatgcaaaactatccttcaatggttgatattccatcaaaaatatcatttgaagttttgatgatg
acagatatgcttcctgatgcagttgctggtatagcgagctctttatatttcacgataccagctgaaaaaattaaatttatagtttttac
atcgacagaaactataactgatcgtgaaactgctttgagaagtcctttagttcaagtaatgataaaactaggtattgtaaaagaag
agaatgtacttttttgggctgatctgccaaattgtgaaacaggtgtttgtattgcagtctag 
 
 
 
